10-Q

Date: May 7, 2021

/s/ FRANK H. LAUKIEN, PH.D.

Frank H. Laukien, Ph.D.

President, Chief Executive Officer and Chairman

(Principal Executive Officer)

0001193125-21-155172.txt : 20210510 0001193125-21-155172.hdr.sgml : 20210510 20210507183157 ACCESSION NUMBER: 0001193125-21-155172 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210510 DATE AS OF CHANGE: 20210507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRUKER CORP CENTRAL INDEX KEY: 0001109354 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043110160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30833 FILM NUMBER: 21904493 BUSINESS ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 978663-3660 MAIL ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER BIOSCIENCES CORP DATE OF NAME CHANGE: 20030721 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER DALTONICS INC DATE OF NAME CHANGE: 20000315 10-Q 1 d112071d10q.htm 10-Q 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the transition period from

Commission File Number

000-30833

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)


Delaware		04-3110160
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

40 Manning Road, Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area

code: (978) 663-3660

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbols(s)	Name of each exchange on which registered
Common Stock	BRKR	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class		Outstanding at May 3, 2021
Common Stock, $0.01 par value per share		151,521,114 shares

Table of Contents

BRUKER CORPORATION

Index


		Page
Part I	FINANCIAL INFORMATION		1
Item 1:	Unaudited Condensed Consolidated Financial Statements		1
	Unaudited Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020		1
	Unaudited Condensed Consolidated Statements of Income and Comprehensive Income (Loss) for the three months ended March 31, 2021 and 2020		2
	Unaudited Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Shareholders’ Equity for the three months ended March 31, 2021 and 2020		3
	Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020		4
	Notes to Unaudited Condensed Consolidated Financial Statements		5
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations		19
Item 3:	Quantitative and Qualitative Disclosures About Market Risk		28
Item 4:	Controls and Procedures		29
Part II	OTHER INFORMATION		30
Item 1:	Legal Proceedings		30
Item 1A:	Risk Factors		30
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds		31
Item 6:	Exhibits		32
	Signatures		33

Table of Contents

PART I FINANCIAL INFORMATION

ITEM 1.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share and per share data)


	March 31, 2021			December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	$	696.8		$	681.8
Short-term investments		50.0			50.0
Accounts receivable, net		326.0			335.3
Inventories		700.7			692.3
Other current assets		172.7			165.6

Total current assets		1,946.2			1,925.0
Property, plant and equipment, net		384.1			395.5
Goodwill		313.3			320.4
Intangible assets, net		213.4			229.1
Other long-term assets		177.9			179.0

Total assets	$	3,034.9		$	3,049.0

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	108.4		$	2.2
Accounts payable		152.3			134.6
Customer advances		182.2			189.2
Other current liabilities		500.6			465.9

Total current liabilities		943.5			791.9
Long-term debt		715.8			842.3
Other long-term liabilities		393.9			440.5
Commitments and contingencies (Note 14)
Shareholders’ equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding		—			—
Common stock, $0.01 par value 260,000,000 shares authorized, 174,132,743 and 174,045,610 shares issued and 151,543,485 and 151,987,081 shares outstanding at March 31, 2021 and December 31, 2020, respectively		1.7			1.7
Treasury stock, at cost, 22,589,258 and 22,058,529 shares at March 31, 2021 and December 31, 2020		(699.8	)		(667.0	)
Accumulated other comprehensive (loss) income		(12.1	)		3.7
Other shareholders’ equity		1,677.9			1,622.8

Total shareholders’ equity attributable to Bruker Corporation		967.7			961.2
Noncontrolling interest in consolidated subsidiaries		14.0			13.1

Total shareholders’ equity		981.7			974.3

Total liabilities and shareholders’ equity	$	3,034.9		$	3,049.0

The accompanying notes are an integral part of these financial statements.

Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)

(in millions, except per share data)


	Three Months Ended March 31,
	2021			2020
Product revenue	$	458.6		$	345.0
Service revenue		94.1			78.2
Other revenue		2.0			0.8

Total revenue		554.7			424.0
Cost of product revenue		220.9			180.5
Cost of service revenue		54.8			51.1
Cost of other revenue		0.3			0.1

Total cost of revenue		276.0			231.7

Gross profit		278.7			192.3
Operating expenses:
Selling, general and administrative		131.8			121.2
Research and development		54.8			48.5
Other charges, net		3.0			6.2

Total operating expenses		189.6			175.9

Operating income		89.1			16.4
Interest and other income (expense), net		(3.8	)		(2.9	)

Income before income taxes and noncontrolling interest in consolidated subsidiaries		85.3			13.5
Income tax provision		27.5			2.9

Consolidated net income		57.8			10.6
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries		1.1			0.1

Net income attributable to Bruker Corporation	$	56.7		$	10.5

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.37		$	0.07

Diluted	$	0.37		$	0.07

Weighted average common shares outstanding:
Basic		151.8			154.2
Diluted		153.2			155.4
Comprehensive income	$	41.6		$	12.1
Less: Comprehensive income (loss) attributable to noncontrolling interests		0.9			(0.1	)
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		—			(0.5	)

Comprehensive income attributable to Bruker Corporation	$	40.7		$	12.7

The accompanying notes are an integral part of these financial statements.

Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS’ EQUITY

(in millions, except per share data)


	Redeemable Noncontrolling Interest			Common Shares			Common Stock Amount		Treasury Shares		Treasury Stock Amount			Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Shareholders’ Equity Attributable to Bruker Corporation			Noncontrolling Interests in Consolidated Subsidiaries			Total Shareholders’ Equity

Balance at December 31, 2019	$	21.1			154,155,798		$	1.7		19,346,577	$	(543.8	)	$	199.7		$	1,274.7		$	(25.5	)	$	906.8		$	10.3		$	917.1
Stock options exercised					30,182			—							0.7									0.7						0.7
Restricted stock units vested					40,516			—							(0.1	)								(0.1	)					(0.1	)
Stock-based compensation															3.0									3.0						3.0
Dividends declared to common stockholders ($0.04 per share)		—																(6.2	)					(6.2	)		(1.2	)		(7.4	)
Acquired remaining 20% interest in Hain LifeScience GmbH		(20.6	)															(1.3	)					(1.3	)					(1.3	)
Consolidated net income																		10.5						10.5			0.1			10.6
Other comprehensive income (loss)		(0.5	)																		2.2			2.2			(0.2	)		2.0

Balance at March 31, 2020	$	—			154,226,496		$	1.7		19,346,577	$	(543.8	)	$	203.3		$	1,277.7		$	(23.3	)	$	915.6		$	9.0		$	924.6

Balance at December 31, 2020					151,987,081		$	1.7		22,058,529	$	(667.0	)	$	216.3		$	1,406.5		$	3.7		$	961.2		$	13.1		$	974.3
Stock options exercised					65,312			—							1.2									1.2						1.2
Restricted stock units vested					21,821			—							(0.1	)								(0.1	)					(0.1	)
Stock based compensation															3.4									3.4						3.4
Shares purchased					(530,729	)				530,729		(32.8	)											(32.8	)					(32.8	)
Dividends declared to common stockholders ($0.04 per share)																		(6.1	)					(6.1	)					(6.1	)
Consolidated net income																		56.7						56.7			1.1			57.8
Other comprehensive income (loss)																					(15.8	)		(15.8	)		(0.2	)		(16.0	)

Balance at March 31, 2021					151,543,485		$	1.7		22,589,258	$	(699.8	)	$	220.8		$	1,457.1		$	(12.1	)	$	967.7		$	14.0		$	981.7

The accompanying notes are an integral part of these financial statements

Table of Contents

BRUKER CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)


	Three Months Ended March 31,
	2021			2020
Cash flows from operating activities:
Consolidated net income	$	57.8		$	10.6
Adjustments to reconcile consolidated net income to cash flows from operating activities:
Depreciation and amortization		22.3			19.0
Stock-based compensation expense		3.8			3.3
Deferred income taxes		4.9			1.1
Other non-cash expenses, net		4.9			11.7
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable		0.8			29.5
Inventories		(41.6	)		(61.0	)
Accounts payable and accrued expenses		35.5			19.1
Income taxes payable		10.1			(15.0	)
Deferred revenue		14.1			20.6
Customer advances		2.5			16.5
Other changes in operating assets and liabilities, net		(17.1	)		(20.4	)

Net cash provided by operating activities		98.0			35.0

Cash flows from investing activities:
Purchases of short-term investments		—			(50.0	)
Cash paid for acquisitions, net of cash acquired		(4.0	)		(22.0	)
Purchases of property, plant and equipment		(24.7	)		(30.5	)
Proceeds from sales of property, plant and equipment		1.2			—
Net proceeds from cross-currency swap agreements		3.5			1.9

Net cash used in investing activities		(24.0	)		(100.6	)

Cash flows from financing activities:
Proceeds from revolving lines of credit		—			197.5
Repayment of other debt		(0.4	)		(0.3	)
Proceeds from other debt		0.3			1.2
Proceeds from issuance of common stock, net		1.1			0.6
Payment of contingent consideration		(0.4	)		(0.3	)
Payment of dividends to common stockholders		(6.1	)		(6.2	)
Purchases of common stock		(32.6	)		—
Cash payments to noncontrolling interest		—			(1.2	)

Net cash (used in) provided by financing activities		(38.1	)		191.3

Effect of exchange rate changes on cash, cash equivalents and restricted cash		(21.0	)		(8.7	)

Net change in cash, cash equivalents and restricted cash		14.9			117.0
Cash, cash equivalents and restricted cash at beginning of period		685.5			681.9

Cash, cash equivalents and restricted cash at end of period	$	700.4		$	798.9

Supplemental disclosure of cash flow information:
Restricted cash period beginning balance	$	3.7		$	3.6

Restricted cash period ending balance	$	3.6		$	3.4

The accompanying notes are an integral part of these financial statements.

Table of Contents

BRUKER CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021

1.	Description of Business

Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology,

in-vitro

diagnostics, nanotechnology and materials science research.

The Company has four operating segments,

Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) Nano Segment

and

Bruker Energy

& Supercon Technologies (BEST)

. The Company has three reportable segments,

BSI Life Science Segment, BSI NANO Segment

and

BEST

For financial reporting purposes, the Bruker BioSpin Group and Bruker CALID Group operating segments are aggregated into the reportable BSI Life Science Segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.

Bruker BioSpin

— The Bruker BioSpin Group designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. Bruker BioSpin Group’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.

Bruker CALID (Chemicals, Applied Markets, Life Science,

In-Vitro

Diagnostics, Detection)

- The Bruker CALID Group designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the Bruker CALID Group include: academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and

for-profit

forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.

The BSI NANO Segment designs, manufactures and distributes advanced

X-ray

instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and

X-ray

metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile

X-ray

fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chip cytometry products and services for targeted spatial proteomics, multi-omic services, and products and services for spatial genomics research. Customers of the BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.

The BEST reportable segment develops and manufactures superconducting and

non-superconducting

materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.

The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of March 31, 2021 and December 31, 2020, and for the three months ended March 31, 2021 and 2020, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for Quarterly Reports on Form

10-Q

and Article 10 of Regulation

S-X.

Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.

At March 31, 2021, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form

10-K

for the year ended December 31, 2020, have not changed.

Table of Contents

Risks and Uncertainties

The Company is subject to risks common to its industry including, but not limited to, global economic conditions, rapid technological change, government and academic funding levels, the impact of the

COVID-19

coronavirus, changes in commodity prices, spending patterns of its customers, protection of its intellectual property, availability of key raw materials and components, compliance with existing and future regulation by government agencies and fluctuations in foreign currency exchange rates and interest rates.

The impact of the

COVID-19

worldwide pandemic has been and will likely continue to be extensive in certain geographies and aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to the global economy, global supply chains, as well as businesses and capital markets around the world.

Impacts to the Company’s business included temporary closures in 2020 of many of the Company’s government and university customers and suppliers, disruptions or restrictions on employees’ and customers’ ability to travel, and delays in product installations or shipments to and from affected countries. In an effort to halt the outbreak of

COVID-19,

a number of countries, including the United States, have implemented and continue to implement significant restrictions on travel, shelter in place or stay at home orders, and business closures. While some of these restrictions are loosening in certain jurisdictions, some markets have returned to restrictions in the face of increases in new

COVID-19

cases or new strains of the virus. A number of states, including California, Massachusetts and New Jersey where the Company has significant operations have implemented phased

re-opening

policies as vaccines to protect against the virus continue to be administered. However, many of the Company’s employees in these areas continue to work remotely, and any

re-openings

may be delayed or pulled back if the virus continues to spread or as new strains of the virus emerge, in particular if existing vaccines are determined to be less effective against these new strains than against earlier strains. In addition, a number of the Company’s production facilities had to either temporarily close or operate on a reduced capacity in 2020. Much of the commercial activity in sales and marketing, and customer demonstrations and applications training, is still either being conducted remotely or postponed. Many customer purchasing departments are still operating at reduced capacity, and many customers could delay or cut capital expenditures and operating budgets due to pandemic-related concerns. Even where customers have

re-opened

their sites, many still operate at productivity levels that are below

pre-pandemic

levels in an effort to accommodate safety protocols. Any resurgence of the virus or the emergence of new strains of the virus, particularly any new strains which are resistant to existing vaccines, may require the Company or its customers to close or partially close operations once again. These travel restrictions, business closures and operating reductions at Bruker, customers, distributors, and/or suppliers have and may continue to adversely impact the Company’s operations worldwide, including the ability to manufacture, sell or distribute products, as well as cause temporary closures of foreign distributors, or the facilities of suppliers or customers. Global supply chains, including for semiconductor chips and other component products, have been disrupted causing shortages, which could impact the Company’s ability to manufacture or supply its products. This disruption of the Company’s employees, distributors, suppliers and customers has impacted and may continue to impact the Company’s global sales and operating results.

The Company is continuing to monitor and assess the effects of the

COVID-19

pandemic on commercial operations, including its impact on revenue in 2021. However, the Company cannot at this time accurately predict what effects these conditions will ultimately have on future operations due to uncertainties relating to the severity of the disease, the duration of the outbreak, including the impact of any resurgence of the virus or the continued emergence of new strains of the virus, the effectiveness and availability of vaccines, (including to protect against any new strains of the virus), the willingness of individuals to receive vaccines, and the length or severity of the travel restrictions, business closures, and other safety and precautionary measures imposed by the governments of impacted countries. The pandemic has also adversely affected the economies and financial markets of many countries, which has affected and likely will continue to affect demand for the Company’s products and its operating results.

The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the

COVID-19

pandemic will directly or indirectly impact the future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, including as a result of new information that may emerge concerning

COVID-19,

the effectiveness and availability of

COVID-19

vaccines or individuals’ willingness to receive vaccines, and the actions taken to contain or treat the virus, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of

COVID-19

within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.

Table of Contents

2.	Recent Accounting Pronouncements

In March 2020, the FASB issued Accounting Standards Updates (“ASU”)

No. 2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

(“ASU

2020-04”),

which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The guidance provides optional expedients and exceptions for applying generally accepted accounting principles to transactions affected by reference rate reform if certain criteria are met. These transactions include: contract modifications, hedging relationships, and sale or transfer of debt securities classified as

held-to-maturity.

In January 2021, the FASB issued ASU

2021-01,

Reference Rate Reform (Topic 848)

: Scope, to clarify that certain optional expedients and exceptions under the reference rate reform guidance for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. Specifically, certain provisions in the reference rate reform guidance, if elected by an entity, apply to derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. This temporary guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company may elect to apply this guidance for all contract modifications or eligible hedging relationships during that time period subject to certain criteria. The Company is still evaluating the impact of reference rate reform and whether this guidance will be adopted.

In January 2020, the FASB issued ASU

2020-01-

Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force)

, which clarifies the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. The guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The Company adopted this guidance using a prospective method. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

In December 2019, the FASB issued ASU

2019-12

- Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

. The guidance simplifies the accounting for income taxes by removing certain exceptions within the current guidance; including the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The amendment also improves consistent application by clarifying and amending existing guidance related to aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step up in the tax basis of goodwill. This guidance is effective for annual and interim periods beginning after December 15, 2020 and early adoption was permitted. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

Revenue

The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Revenue by Group:
Bruker BioSpin	$	159.4		$	120.9
Bruker CALID		192.4			140.5
Bruker Nano		154.4			120.1
BEST		52.4			46.2
Eliminations		(3.9	)		(3.7	)

Total revenue	$	554.7		$	424.0

Table of Contents


	Three Months Ended March 31,
	2021		2020
Revenue by End Customer Geography:
United States	$	119.0	$	109.4
Germany		70.1		40.9
Rest of Europe		149.8		104.0
Asia Pacific		180.5		137.2
Other		35.3		32.5

Total revenue	$	554.7	$	424.0

Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Revenue recognized at a point in time	$	480.0	$	367.7
Revenue recognized over time		74.7		56.3

Total revenue	$	554.7	$	424.0

Remaining Performance Obligations

Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of March 31, 2021, remaining performance obligations were approximately $1,940.3 million. The Company expects to recognize revenue on approximately 65.7% of the remaining performance obligations over the next twelve months and the remaining performance obligations primarily within one to three years.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets.

Contract assets—

Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Billing often occurs subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as other current assets in the unaudited condensed consolidated balance sheets. The balance of contract assets as of March 31, 2021 and December 31, 2020 was $48.8 million and $41.8 million, respectively

Contract liabilities—

The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the unaudited condensed consolidated balance sheet based on the timing of when revenue recognition is expected. As of March 31, 2021 and December 31, 2020, the contract liabilities were $407.5 million and $399.4 million, respectively. The increase in the contract liability balance during the three months ended March 31, 2021 is primarily the result of a delay in installations due to the impact of

COVID-19

on the global economy. Approximately $121.4 million of the contract liability balance on December 31, 2020 was recognized as revenue during the three months ended March 31, 2021.

4.	Acquisitions

The impact of all acquisitions and investments in other entities during the three months ended March 31, 2021, individually and collectively, on revenues, net income and total assets was not material and accordingly, pro forma financial information reflecting all acquisitions has not been presented.

Table of Contents

2021

In the three months ended March 31, 2021, the Company made investments in businesses complementary to its own portfolio

. The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions):


Name	Acquisition / Investment		Date Acquired		Segment		Consideration		Cash Consideration
Glycopath Inc.		Investment		February 18, 2021		BSI Life Science	$	2.0	$	2.0
IonPath Inc		Investment		March 18, 2021		BSI Life Science		2.0		2.0
Acuity Spatial Genomics, Inc.		Investment		February 24, 2021		BSI Nano		4.5		4.5

							$	8.5	$	8.5

5.	Inventories

Inventories consisted of the following (dollars in millions):


	March 31, 2021		December 31, 2020
Raw materials	$	197.1	$	198.8
Work-in-process		253.2		245.7
Finished goods		157.0		152.1
Demonstration units		93.4		95.7

Inventories	$	700.7	$	692.3

Finished goods include

in-transit

systems that have been shipped to the Company’s customers for which control has not passed to the customers as the systems were not installed and accepted by the customer. As of March 31, 2021, and December 31, 2020, the value of

inventory-in-transit

was $59.6 million and $67.8 million, respectively.

6.	Goodwill and Intangible Assets

Goodwill

The following table sets forth the changes in the carrying amount of goodwill (dollars in millions):


	Total
Balance at December 31, 2020	$	320.4
Current period additions/adjustments		(0.3	)
Foreign currency impact		(6.8	)

Balance at March 31, 2021	$	313.3

Table of Contents

Intangible Assets

The following is a summary of intangible assets, excluding goodwill (dollars in millions):


	March 31, 2021							December 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Existing technology and related patents	$	299.0	$	(192.3	)	$	106.7	$	309.8	$	(194.6	)	$	115.2
Customer relationships		144.4		(48.0	)		96.4		148.3		(45.4	)		102.9
Trade names		14.8		(4.7	)		10.1		15.2		(4.4	)		10.8
Other		0.3		(0.1	)		0.2		0.3		(0.1	)		0.2

Intangible assets	$	458.5	$	(245.1	)	$	213.4	$	473.6	$	(244.5	)	$	229.1

For the three months ended March 31, 2021 and 2020, the Company recorded amortization expense of $8.9 million and $8.7 million, respectively, related to intangible assets subject to amortization.

Debt

The Company’s debt obligations consisted of the following (dollars in millions):


	March 31, 2021			December 31, 2020
US Dollar notes under the 2012 Note Purchase Agreement	$	205.0		$	205.0
CHF notes (in dollars) under the 2019 Note Purchase Agreement		314.8			335.5
US Dollar notes under the 2019 Term Loan		300.0			300.0
Unamortized debt issuance costs		(2.3	)		(2.4	)
Capital lease obligations and other loans		6.7			6.4

Total debt		824.2			844.5
Current portion of long-term debt		(108.4	)		(2.2	)

Total long-term debt, less current portion	$	715.8		$	842.3

The following is a summary of the maximum commitments and the net amounts available to the Company under its credit agreements and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at March 31, 2021 (in millions):


	Weighted Average Interest Rate			Total Amount Committed by Lenders		Outstanding Borrowings		Outstanding Letters of Credit		Total Committed Amounts Available
2019 Credit Agreement		1.3	%	$	600.0	$	—	$	0.2	$	599.8
Bank guarantees and working capital line		0.0	%		120.2		—		120.2		—

Total revolving lines of credit				$	720.2	$	—	$	120.4	$	599.8

As of March 31, 2021, the Company was in compliance with the financial covenants of all debt agreements.

As of March 31, 2021, the Company ha

several cross-currency and interest rate swap agreements with a notional value of $150.0 million of U.S. to Swiss Franc and a notional value of $355.0 million of U.S. to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. These agreements qualify for hedge accounting and accordingly the change

in fair value of the derivative are recorded in other comprehensive income as part of foreign currency translation adjustments and remain in accumulated comprehensive income (loss) attributable to Bruker Corporation in shareholders’ equity until the sale or substantial liquidation of the foreign operation. The difference between the interest rate received and paid under the interest rate and cross-currency swap agreements is recorded in interest and other income (expenses) in the unaudited consolidated statements of income and comprehensive income. As a result of entering into these agreements, the Company has lowered net interest expense by $1.4 million and $2.6 million during the three months ended March 31, 2021 and 2020, respectively. The gains (losses) related to hedges of net asset investments in international operations that were recorded within the cumulative translation adjustment section of other comprehensive income were

gains of

$27.7 million and $10.9 million for the three months ended March 31, 2021 and 2020, respectively. The Company presents the cross-currency swap periodic settlements in investing activities and the interest rate swap periodic settlements in operating activities in the statement of cash flows.

Table of Contents

8.	Fair Value of Financial Instruments

following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (dollars in millions):


March 31, 2021	Total		Quoted Prices in Active Markets Available (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Time deposits and money market funds	$	151.1	$	—	$	151.1	$	—
Short-term investments		50.0		—		50.0		—
Interest rate and cross currency swap agreements		7.1		—		7.1		—
Forward currency contracts		0.1		—		0.1		—
Fixed price commodity contracts		3.8		—		3.8		—
Debt securities available for sale		1.2		—		—		1.2

Total assets recorded at fair value	$	213.3	$	—	$	212.1	$	1.2

Liabilities:
Contingent consideration	$	3.3	$	—	$	—	$	3.3
Hybrid instrument liability		13.8		—		—		13.8
Interest rate and cross currency swap agreements		33.3		—		33.3		—
Embedded derivatives in purchase and delivery contracts		0.3		—		0.3		—
Forward currency contracts		1.3		—		1.3		—

Total liabilities recorded at fair value	$	52.0	$	—	$	34.9	$	17.1


December 31, 2020	Total		Quoted Prices in Active Markets Available (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Time deposits and money market funds	$	183.2	$	—	$	183.2	$	—
Short-term investments		50.0		—		50.0		—
Interest rate and cross currency swap agreements		7.6		—		7.6		—
Forward currency contracts		2.1		—		2.1		—
Embedded derivatives in purchase and delivery contracts		0.1		—		0.1		—
Fixed price commodity contracts		3.1		—		3.1		—
Debt securities available for sale		1.2		—		—		1.2

Total assets recorded at fair value	$	247.3	$	—	$	246.1	$	1.2

Liabilities:
Contingent consideration	$	4.3	$	—	$	—	$	4.3
Hybrid instrument liability		13.9		—		—		13.9
Interest rate and cross currency swap agreements		61.5		—		61.5		—
Forward currency contracts		0.4		—		0.4		—

Total liabilities recorded at fair value	$	80.1	$	—	$	61.9	$	18.2

The Company’s financial instruments consist primarily of cash equivalents, short-term investments, restricted cash, derivative instruments consisting of forward currency contracts, cross-currency interest rate swap agreements, commodity contracts, derivatives embedded in certain purchase and sale contracts, derivatives embedded within noncontrolling interests, accounts receivable, accounts payable, contingent consideration and long-term debt. The carrying amounts of the Company’s cash equivalents, short-term investments and restricted cash, accounts receivable, borrowings under a revolving credit agreement and accounts payable approximate fair value because of their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company’s long-term debt consists principally of a note purchase agreement entered into in 2012 and a revolving credit agreement, long term loan agreement and note purchase agreement entered into in 2019.

Table of Contents

The Company has evaluated the estimated fair value of financial instruments using available market information and management’s estimates. The use of different market assumptions and/or estimation methodologies could have a significant effect on the estimated fair value amounts.

The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the three months ended March 31, 2021 or 2020.

The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was $527.7 million and $549.8 million at March 31, 2021 and December 31, 2020, respectively, based on market and observable sources with similar maturity

dates. The carrying value of our variable rate debt approximates its fair value at March 31, 2021 and December 31, 2020.

On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could create an impairment. None were noted for the three months ended March 31, 2021 or 2020.

Contingent consideration recorded within other current liabilities represents the estimated fair value of future payments to the former shareholders as part of certain acquisitions. The contingent consideration is primarily based on the applicable acquired company achieving annual revenue and gross margin targets in certain years as specified in the relevant purchase and sale agreement. The Company initially values the contingent consideration on acquisition date by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term.

The following table sets forth the changes in contingent consideration liabilities (dollars in millions):


Balance at December 31, 2020	$	4.3
Current period adjustments		(0.5	)
Current period settlements		(0.4	)
Foreign currency effect		(0.1	)

Balance at March 31, 2021	$	3.3

As part of the Mestrelab acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 49% of Mestrelab for cash at a contractually defined redemption value. These rights (an embedded derivative) are exercisable beginning in 2022 and can be accelerated, at a discounted redemption value, upon certain events related to post combination services. As the option is tied to continued employment, the Company classified the hybrid instrument (noncontrolling interest with an embedded derivative) as a long-term liability on the consolidated balance sheet. Subsequent to the acquisition, the carrying value of the hybrid instrument is remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the requisite service period vested. The hybrid instrument is classified as Level 3 in the fair value hierarchy.

The following table sets forth the changes in hybrid instrument liability (dollars in millions):


Balance at December 31, 2020	$	13.9
Current period adjustments		0.4
Foreign currency effect		(0.5	)

Balance at March 31, 2021	$	13.8

Table of Contents

9.	Derivative Instruments and Hedging Activities

Commodity Price Risk Management

At March 31, 2021 and December 31, 2020, the Company had fixed price commodity contracts with notional amounts aggregating $5.8 million and $8.8 million, respectively. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues.

Foreign Exchange Rate Risk Management

The Company had the following notional amounts outstanding under foreign exchange contracts and cross-currency interest rate swap agreements (in millions):


	March 31, 2021					December 31, 2020
	Notional Amount in U.S. Dollars		Fair Value			Notional Amount in U.S. Dollars		Fair Value
Forward Currency Contracts (1):
Assets	$	10.0	$	0.1		$	175.8	$	2.1
Liabilities		121.3		(1.3	)		102.5		(0.4	)
Cross-Currency and Interest Rate Swap Agreements (2):
Liabilities		505.0		(26.2	)		505.0		(53.9	)

	$	636.3	$	(27.4	)	$	783.3	$	(52.2	)

(1)	Derivatives not designated as accounting hedges.

(2)	Derivatives designated as accounting hedges.

In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The

contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $6.1 million for the delivery of products and $4.3 million for the purchase of products at March 31, 2021 and $7.5 million for the delivery of products and $4.8 million for the purchase of products at December 31, 2020. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income (loss).

Table of Contents

The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets as follows (dollars in millions):


	March 31, 2021			December 31, 2020
Derivatives designated as hedging instruments
Interest rate cross-currency swap agreements
Other current assets	$	7.1		$	7.6
Other current liabilities		(9.3	)		(4.3	)
Other long-term liabilities		(24.0	)		(57.2	)

Total derivatives designated as hedging instruments		(26.2	)		(53.9	)

Derivatives not designated as hedging instruments
Forward currency contracts
Other current assets	$	0.1		$	2.1
Other current liabilities		(1.3	)		(0.4	)
Embedded derivatives in purchase and delivery contracts
Other current assets		—			0.1
Other current liabilities		(0.3	)		—
Fixed price commodity contracts
Other current assets		3.8			3.1

Total derivatives not designated as hedging instruments		2.3			4.9

Total derivatives	$	(23.9	)	$	(49.0	)


		Three Months Ended March 31,
	Financial Statement Classification	2021			2020
Derivatives not designated as hedging instruments
Forward currency contracts	Interest and other income (expense), net	$	(5.0	)	$	(0.5	)
Embedded derivatives in purchase and delivery contracts	Interest and other income (expense), net		(0.4	)		0.6

		$	(5.4	)	$	0.1

Derivatives designated as Cash Flow hedging instruments
Interest rate cross-currency swap agreements
Interest incurred	Interest and other income (expense), net	$	(1.1	)	$	—
Unrealized gains (losses) on contracts	Accumulated other comprehensive income		9.9			(19.0	)

		$	8.8		$	(19.0	)

Derivatives designated as Net Investment hedging instruments
Interest rate cross-currency swap agreements
Interest earned	Interest and other income (expense), net	$	2.5		$	2.6
Unrealized gains on contracts	Accumulated other comprehensive income		17.8			29.9

		$	20.3		$	32.5

10.	Provision for Income Taxes

The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold.

Table of Contents

The income tax provision for the three months ended March 31, 2021 and 2020 was $27.5 million and $2.9 million, respectively, representing effective tax rates of 32.2% and 21.5%, respectively. The Company’s effective tax rate may change over time as the amount or mix of income and taxes changes among the jurisdictions in which the Company is subject to

tax. The increase in our effective tax rate was primarily due to the jurisdictional mix and the impact of unfavorable discrete items in the period.

As of March 31, 2021 and December 31, 2020, the Company had gross unrecognized tax benefits, excluding penalties and interest, of approximately $24.3 million and $22.7 million, respectively, which, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of March 31, 2021 and December 31, 2020, approximately $1.9 million and $1.8 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other long-term liabilities on the Company’s unaudited condensed consolidated balance sheets.

The Company files tax returns in the United States, which includes federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The majority of the Company’s earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 2021 are approximately 30.0% and 20.0% for Germany and Switzerland, respectively. The mix of earnings in those two jurisdictions resulted in an increase of 5.1% from the U.S. statutory rate of 21.0% in the three months ended March 31, 2021.

On March 27, 2020 the House passed the Coronavirus Aid, Relief, and Economic Security Act (The

CARES Act

), also known as the Third

COVID-19

Supplemental Relief bill, and the president of the United States signed the legislation into law. The Company does not expect the provisions of the legislation to have a significant impact on the effective tax rate or the income tax payable and deferred income tax positions of the Company.

11.	Earnings Per Share

The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker shareholders (dollars in millions, except per share amounts):


	Three Months Ended March 31,
	2021		2020
Net income attributable to Bruker Corporation, as reported	$	56.7	$	10.5
Weighted average shares outstanding:
Weighted average shares outstanding-basic		151.8		154.2
Effect of dilutive securities:
Stock options and restricted stock awards and units		1.4		1.2

		153.2		155.4

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.37	$	0.07

Diluted	$	0.37	$	0.07

The following common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares):


	Three Months Ended March 31,
	2021		2020
Stock options		—		0.1
Unvested restricted stock units		—		—

Table of Contents

12.	Shareholders’ Equity

Share Repurchase Program

In May 2019, the Company’s Board of Directors approved a stock repurchase plan authorizing the purchase of common stock in the amount of up to $300.0 million from time to time, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements and other considerations. During the quarter ended March 31, 2021, the Company purchased a total of 530,729 shares at an aggregate cost of $32.8 million under the share repurchase plan. There were no purchases under the plan in the three months ended March 31, 2020. At March 31, 2021, $1.7

million remained available for future purchases under the plan. We completed the share purchase program in April 2021, after reaching the maximum cumulative spend. This share repurchase plan was set to expire on May 13, 2021.

Accumulated Other Comprehensive Income (Loss)

The following is a summary of comprehensive income (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Consolidated net income	$	57.8		$	10.6
Foreign currency translation adjustments		(19.5	)		(13.0	)
Pension liability adjustments, net of tax		3.3			14.5

Net comprehensive income		41.6			12.1
Less: Comprehensive income (loss) attributable to noncontrolling interests		0.9			(0.1	)
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		—			(0.5	)

Comprehensive income attributable to Bruker Corporation	$	40.7		$	12.7

The following is a summary of the components of accumulated other comprehensive income (loss), net of tax (dollars in millions):


	Foreign Currency Translation			Pension Liability Adjustment			Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2020	$	49.4		$	(45.7	)	$	3.7
Other comprehensive income (loss) before reclassifications		(19.1	)		2.6			(16.5	)
Realized loss on amounts reclassified from other comprehensive income (loss), net of tax		—			0.7			0.7

Net current period other comprehensive income (loss)		(19.1	)		3.3			(15.8	)

Balance at March 31, 2021	$	30.3		$	(42.4	)	$	(12.1	)

Stock-Based Compensation

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Costs of product revenue	$	0.5	$	0.5
Selling, general and administrative		2.4		2.0
Research and development		0.5		0.5

Total stock-based compensation	$	3.4	$	3.0

In addition to the awards above, the Company recorded stock-based compensation expense within other charges, net of $0.4 million and $0.3 million in the three months ended March 31, 2021 and 2020, respectively, related to the 2018 acquisition of Mestrelab Research, S.L. (Mestrelab).

At March 31, 2021, the Company had $23.4 million of unrecognized compensation expense related to employees and directors’ unvested stock units and stock options that are expected to be recognized over a weighted average period of 2.3 years.

Table of Contents

13.	Other Charges, Net

Other Charges, Net

The components of other charges, net were as follows (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Information technology transformation costs	$	0.7	$	0.9
Professional fees incurred in connection with investigation matters		0.1		3.4
Restructuring charges		1.3		1.5
Acquisition-related charges		0.9		(1.1	)
Long-lived asset impairments		—		1.2
Other		—		0.3

Other charges, net	$	3.0	$	6.2

Restructuring Initiatives

Restructuring charges include charges for various programs that were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The following table sets forth the restructuring charges (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Cost of revenues	$	1.1	$	0.8
Other charges, net		1.3		1.5

	$	2.4	$	2.3

The following table sets forth the changes in restructuring reserves (dollars in millions):


	Total			Severance			Exit Costs			Provisions for Excess Inventory
Balance at December 31, 2020	$	9.8		$	7.6		$	0.8		$	1.4
Restructuring charges		2.4			2.2			0.2			—
Cash payments		(5.2	)		(4.7	)		(0.5	)		—
Other, non-cash adjustments and foreign currency effect		(0.1	)		—			—			(0.1	)

Balance at March 31, 2021	$	6.9		$	5.1		$	0.5		$	1.3

14.	Commitments and Contingencies

In accordance with ASC Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages or other costs to the extent specific losses are probable and estimable.

Litigation and Related Contingencies

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure is also provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. The Company believes the outcome of pending proceedings, individually and in the aggregate, will not have a material impact on the Company’s financial statements.

On September 25, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (Zeiss), sued Luxendo GmbH (Luxendo), a subsidiary of Bruker Corporation, for infringement of a recently registered German utility model patent licensed to Zeiss pertaining to one specific Luxendo product category. The Company is vigorously defending against this claim

Table of Contents

4.0

million payment in the second quarter of 2021 and agreed

to pay royalties, subject to a quarterly minimum, on certain Tims TOF systems commencing March 1, 2022. In addition, pursuant to the Patent License Agreement, all claims between the parties in connection with this and other pending infringement matters were settled and dismissed with prejudice. The settlement of this matter did not and is not expected to materially impact the Company’s results of operations

As of March 31, 2021 and December 31, 2020, no material accruals have been recorded for potential contingencies.

15.	Business Segment Information

The Company has three reportable segments, BSI Life Science, BSI NANO and BEST, as discussed in Note 1 to the consolidated financial statements.

Revenue and operating income by reportable segment are presented below (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Revenue:
BSI Life Science	$	351.8		$	261.4
BSI NANO		154.4			120.1
BEST		52.4			46.2
Eliminations (a)		(3.9	)		(3.7	)

Total revenue	$	554.7		$	424.0

Operating Income (loss)
BSI Life Science	$	88.9		$	39.5
BSI NANO		12.3			(8.0	)
BEST		4.1			1.7
Corporate, eliminations and other (b)		(16.2	)		(16.8	)

Total operating income	$	89.1		$	16.4

(a)	Represents product and service revenue between reportable segments.

(b)	Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by reportable segment are as follows (dollars in millions):


	March 31, 2021			December 31, 2020
Assets:
BSI Life Science, BSI NANO & Corporate	$	2,947.8		$	2,964.5
BEST		92.3			88.7
Eliminations and other (a)		(5.2	)		(4.2	)

Total assets	$	3,034.9		$	3,049.0

(a)	Assets not allocated to the reportable segments and eliminations of intercompany transactions.

The Company is unable, without unreasonable effort or expense, to disclose the amount of total assets by BSI Life Science and BSI NANO Segments as well as the Corporate function and further, the Company’s chief operating decision maker does not receive any asset information by operating segment.

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on

Form 10-Q,

and in conjunction with the consolidated financial statements contained in our Annual Report on

Form 10-K

for the year ended December 31, 2020.

Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form

10-Q,

which express that we “believe,” “anticipate,” “plan,” “expect,” “seek,” “may,” “will,” “intend,” “estimate,” “should” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward looking statements include, but are not limited to, statements regarding the impact of

COVID-19

on our business, operations, and supply chain, including our implementation of certain cost cutting measures and their impact, expectations regarding the global economy, our intentions regarding our intellectual property, the impact of government contracts and government regulation, our working capital requirements and sufficiency of cash, our competition, the seasonality of our business, the sufficiency of our facilities, our employee relations, the impact of legal or intellectual property proceedings, the impact of changes to tax and accounting rules and changes in law, our anticipated tax rate, our expectations regarding cash dividends, share repurchases, interest expense, interest rate swap agreements, expenses and capital expenditures, the impact of foreign currency exchange rates and changes in commodity prices, the impact of our restructuring initiatives, our expectations regarding backlog and revenue and other risk factors discussed herein and from time to time in our other filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form

10-K

for the year ended December 31, 2020 and subsequent filings. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Non-GAAP

Measures

Although our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), we believe describing revenue and expenses, excluding the effects of foreign currency, acquisitions and divestitures, as well as certain other charges, net, provides meaningful supplemental information regarding our performance. We rely internally on certain measures that are not calculated according to GAAP. These measures are organic revenue, free cash flow,

non-GAAP

gross profit margin and

non-GAAP

operating margin. Our management believes that these financial measures provide relevant and useful information that is widely used by equity analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. We define the term organic revenue as GAAP revenue excluding the effect of foreign currency translation changes and the effect of acquisitions and divestitures. We define the term

non-GAAP

gross profit margin as GAAP gross profit margin with certain

non-GAAP

measures excluded and

non-GAAP

operating margin as GAAP operating margin with certain

non-GAAP

measures excluded. These

non-GAAP

measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiative, and other

non-operational

costs and we believe these are useful measures to evaluate our continuing business.

We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends and repayment of debt. We regularly use these

non-GAAP

financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such

non-GAAP

measures and use this information for our planning and forecasting activities. These measures may also be useful to investors in evaluating the underlying operating performance of our business. The presentation of these

non-GAAP

financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from

non-GAAP

financial measures used by other companies, and therefore, may not be comparable among companies.

OVERVIEW

We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, Asia and North America and we have sales offices located throughout the world. Bruker is organized into three reportable segments: the BSI Life Science Segment (comprised of the Bruker BioSpin Group and the Bruker CALID Group), the BSI NANO Segment and the Bruker Energy & Supercon Technologies (BEST) Segment.

Table of Contents

Revenue for the three months ended March 31, 2021 increased by $130.7 million, or 30.8%, to $554.7 million, compared to $424.0 million for the comparable period in 2020. Included in revenue was an increase of approximately $26.8 million from foreign currency translation and an increase of $3.2 million from acquisitions. Excluding the effects of foreign currency translation and our recent acquisitions, our organic revenue, a

non-GAAP

measure, increased $100.7 million. Revenue increases were driven by strong demand for our high performance life science tools, scientific instruments and diagnostic solutions.

Our gross profit margin increased to 50.2% during the three months ended March 31, 2021 compared to 45.4% for the three months ended March 31, 2020. Our operating margin increased to 16.1% for the three months ended March 31, 2021 compared to 3.9% during the three months ended March 31, 2020. The increase in gross and operating margin was a result of higher revenue, volume, operating leverage and contributions from higher margin products.

Our income tax provision in the three months ended March 31, 2021 and 2020 was $27.5 million and $2.9 million, respectively, representing effective tax rates of 32.2% and 21.5%, respectively. The increase in our effective tax rate was primarily due to the jurisdictional mix and the impact of unfavorable discrete items in the period.

Diluted earnings per share for the three months ended March 31, 2021 were $0.37, an increase of $0.30 compared to $0.07 per share in the three months ended March 31, 2020. The increase in net income and earnings per diluted share was primarily driven by higher revenue, gross profit and operating profit in the three months ended March 31, 2021.

The following table presents a reconciliation from net cash provided by operating activities, which is the most directly comparable GAAP operating financial measure, to free cash flow as used by management (in millions):


	Three Months Ended March 31,
	2021			2020
Net cash provided by operating activities	$	98.0		$	35.0
Less: purchases of property, plant and equipment		(24.7	)		(30.5	)

Free Cash Flow	$	73.3		$	4.5

The following table presents a reconciliation from gross profit, which is the most directly comparable GAAP operating performance measure, to

non-GAAP

gross profit margin as used by management (in millions):


	Three Months Ended March 31,
	2021		2020
Gross profit	$	278.7	$	192.3
Restructuring costs		1.1		0.8
Purchased intangible amortization		4.5		4.9
Other costs		—		0.1

Non-GAAP gross profit	$	284.3	$	198.1

Our

non-GAAP

gross profit was 51.3% and 46.7% in the three months ended March 31, 2021 and 2020, respectively. Our

non-GAAP

gross profit margin increased due to volume leverage and contributions from higher margin products in 2021, as compared to 2020 which was negatively impacted by the

COVID-19

pandemic.

Table of Contents

The following table presents a reconciliation from operating income, which is the most directly comparable GAAP operating performance measure, to

non-GAAP

operating income as used by management (in millions):


	Three Months Ended March 31,
	2021		2020
Operating income	$	89.1	$	16.4
Restructuring costs		2.4		2.3
Acquisition-related costs		0.9		(1.1	)
Purchased intangible amortization		9.0		8.7
Other costs		0.8		5.9

Non-GAAP operating income	$	102.2	$	32.2

Our

non-GAAP

operating margin was 18.4% and 7.6% in the three months ended March 31, 2021 and 2020, respectively. Our

non-GAAP

operating margin increased in 2021, as compared to 2020 due to higher revenue, gross margins and operating leverage in 2021, as compared to 2020 which was negatively impacted by the

COVID-19

pandemic.

We can experience

quarter-to-quarter

fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

•

the impact of the

COVID-19

global pandemic on our customers, supply chain or manufacturing capabilities;

•

the timing of governmental stimulus programs and academic research budgets;

•

the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received;

•

foreign currency exchange rates;

•

the time it takes for us to receive critical materials to manufacture our products;

•

general economic conditions, including the impact of

COVID-19

on the global economy;

•

the time it takes to satisfy local customs requirements and other export/import requirements;

•

the time it takes for customers to construct or prepare their facilities for our products; and

•

the time required to obtain governmental licenses.

Several of these factors have in the past affected the amount and timing of revenue recognized on sales of our products and receipt of related payments and will likely continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance. The

COVID-19

pandemic continues to present a challenging operating environment and we remain focused on four key priorities: the health and safety of our employees, customers and partners; maintaining business continuity and service levels for our customers; executing prudent temporary cost reductions; and delivering enabling research and diagnostic products to help fight the pandemic, and to support other essential priorities of our society.

Health and safety of our valued employees, customers and partners

We have implemented strict social distancing, enhanced cleaning protocols and other preventative measures, such as temperature scanners and company-issued face coverings, in our major facilities. While many of our office colleagues are working remotely, we are placing enhanced focus on our service organization and factory employees for whom work from home is not feasible. Where customer sites are accessible and open, our field service organizations operate under social distancing protocols with proper face coverings to ensure the safety of customer sites, when our employees need to be on site. Many of our facilities have begun to plan for employees who have been working remotely during the pandemic to gradually return to the office. Employee and visitor health and safety will remain our paramount concern.

Table of Contents

Maintaining business continuity and service levels to our customers

Ensuring our ability to supply our enabling technologies and solutions and maintaining high service levels for our customers is another top priority for Bruker. In late March and during parts of April 2020, several of our manufacturing sites underwent temporary controlled shutdowns or were operating at reduced capacity to implement new safety protocols, comply with local rules, and manage cost and inventory levels. These sites thereafter ramped back up with expanding capacity and productivity levels. However, with any resurgence of the virus or the emergence of additional strains of the virus, particularly any new strains of the virus that are more resistant to existing vaccines, we may need to consider further temporary controlled shutdowns or reduced capacity measures. In addition, we are continuing capital investments in production facilities for efficiencies and expansion. We continue to manage supply chain risks, more recently associated with the economic recovery from the pandemic, like the worldwide shortage of semiconductor chips and components.

Executing prudent temporary cost reductions

In an effort to mitigate the negative impacts on our business of

COVID-19

and the related slowdown in the global economy, we implemented temporary cost control and cost reduction measures in 2020. These temporary measures included short-time work for many of our European operations, temporary tiered salary reductions for our board of directors, global leadership team and workforce,

one-to

two-week

closures of select manufacturing locations, selective product manufacturing reductions, a hiring freeze, and curtailment of

non-strategic

discretionary spending. At the same time, we looked to minimize the disruption for our employees and preserve our ability to ramp up again with our highly trained and loyal work force. While pursuing cost savings throughout the business, we have maintained our important investments in key strategic initiatives. Many of these cost reduction measures have now been relaxed and our revenue is experiencing a recovery.

Delivering enabling research and diagnostic products to help fight the pandemic and to support other essential priorities of our society

Bruker is providing critical technologies and solutions to help combat the

COVID-19

crisis, most notably our Microbiology and infectious disease diagnostics portfolio, to which we have added

SARS-COV-2

PCR tests, and our nuclear magnetic resonance and mass spectrometry systems which are used in critical disease, therapeutic and vaccine research.

The

COVID-19

global pandemic has driven volatility and uncertainty in global markets and has in the past affected our operations significantly. We continue to work to manage the impact of

COVID-19

on our operations; however, the full extent to which any resurgence of the virus, the emergence of any new strains of the virus, or the availability and effectiveness of

COVID-19

vaccines will impact our business, directly or indirectly, cannot accurately be predicted at this time. In 2020, the

COVID-19

pandemic affected productivity at our manufacturing facilities and caused disruptions and delays in certain of our shipments to customers who closed facilities during the pandemic. We continue to monitor the impact of

COVID-19

on our business and our supply chain and respond accordingly. For additional information on the various risks posed by the

COVID-19

pandemic, refer to Item 1A. Risk Factors included in this report.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to: revenue recognition; stock-based compensation expense; restructuring and other related charges; income taxes, including the recoverability of deferred tax assets; allowances for doubtful accounts; inventory reductions for excess and obsolete inventories; estimated fair values of long-lived assets used to measure the recoverability of long-lived assets; intangible assets and goodwill; expected future cash flows used to measure the recoverability of intangible assets and long-lived assets; warranty costs; derivative financial instruments; and contingent liabilities. We base our estimates and judgments on our historical experience, current market and economic conditions, industry trends, and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

We believe the following critical accounting policies and estimates to be both those most important to the portrayal of our financial position and results of operations and those that require the most estimation and subjective judgment.

•

Revenue recognition;

•

Income taxes;

•

Inventories;

•

Goodwill, other intangible assets and other long-lived assets; and

•

Business combinations.

Table of Contents

For a further discussion of our critical accounting policies, please refer to our Annual Report on Form

10-K

for the year ended December 31, 2020.

RESULTS OF OPERATIONS

Three Months Ended March 31, 2021 compared to the Three Months Ended March 31, 2020

Consolidated Results

The following table presents our results (dollars in millions, except per share data):


	Three Months Ended March 31,
	2021			2020			Dollar Change			Percentage Change
Product revenue	$	458.6		$	345.0		$	113.6			32.9	%
Service revenue		94.1			78.2			15.9			20.3	%
Other revenue		2.0			0.8			1.2			150.0	%

Total revenue		554.7			424.0			130.7			30.8	%
Cost of product revenue		220.9			180.5			40.4			22.4	%
Cost of service revenue		54.8			51.1			3.7			7.2	%
Cost of other revenue		0.3			0.1			0.2			200.0	%

Total cost of revenue		276.0			231.7			44.3			19.1	%

Gross profit		278.7			192.3			86.4			44.9	%
Operating expenses:
Selling, general and administrative		131.8			121.2			10.6			8.7	%
Research and development		54.8			48.5			6.3			13.0	%
Other charges, net		3.0			6.2			(3.2	)		(51.6	)%

Total operating expenses		189.6			175.9			13.7			7.8	%

Operating income		89.1			16.4			72.7			443.3	%
Interest and other income (expense), net		(3.8	)		(2.9	)		(0.9	)		31.0	%

Income before income taxes and noncontrolling interest in consolidated subsidiaries		85.3			13.5			71.8			531.9	%
Income tax provision		27.5			2.9			24.6			848.3	%

Consolidated net income		57.8			10.6			47.2			445.3	%
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries		1.1			0.1			1.0			1,000.0	%

Net income attributable to Bruker Corporation	$	56.7		$	10.5		$	46.2			440.0	%

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.37		$	0.07		$	0.30			428.6	%

Diluted	$	0.37		$	0.07		$	0.30			428.6	%

Weighted average common shares outstanding:
Basic		151.8			154.2
Diluted		153.2			155.4

Revenue

Revenue increases were driven by strong demand for our high performance life science tools, scientific instruments and diagnostic solutions.

Gross Profit

The increase in gross profit in the three months ended March 31, 2021, as compared to the same period in 2020, was a result of higher revenue, volume, operating leverage and contributions from higher margin products.

Table of Contents

Selling, General and Administrative

Our selling, general and administrative expenses for the three months ended March 31, 2021 decreased to 23.8% of total revenue, from 28.6% of total revenue for the comparable period in 2020. The decrease as a percentage of revenue was a result of the increase in revenue period over period.

Research and Development

Our research and development expenses for the three months ended March 31, 2021 decreased to 9.9% of total revenue from 11.4% of total revenue for the comparable period in 2020. The decrease as a percentage of revenue was a result of the increase in revenue period over period.

Other Charges, Net

Other charges, net was $3.0 million for the three months ended March 31, 2021. The charges consisted primarily of $1.3 million in restructuring costs, $0.9 million in acquisition-related charges related to acquisitions completed in 2021 and 2020, $0.7 million of costs associated with our global information technology (IT) transformation initiative and $0.1 million of professional fees incurred in connection with investigation matters. The IT transformation initiative is a multi-year project aimed at updating and integrating our global enterprise resource planning and human resource information systems.

Other charges, net was $6.2 million for the three months ended March 31, 2020. The charges consisted primarily of $3.4 million of professional fees incurred in connection with investigation matters, $1.5 million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives, $1.2 million related to long-lived asset impairments, $0.9 million of costs associated with our global information technology transformation initiative and a benefit of $1.1 million of acquisition-related charges related to acquisitions completed in 2020 and 2019.

Operating Income

The increase in operating income was due to higher revenue and gross profit in the three months ended March 31, 2021 as our business and end markets began to rebound, as compared to the same period in 2020 which was negatively impacted by the

COVID-19

pandemic and related economic slowdown.

Interest and Other Income (Expense), Net

The increase in net interest expense in the three months ended March 31, 2021, as compared to the same period in 2020, was primarily attributable to an increase in realized losses on foreign currency denominated transactions of $2.0 million.

Income Tax Provision

In the three months ended March 31, 2021 and 2020 effective tax rates were estimated using projected annual

pre-tax

income on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances and the effect of jurisdictional differences in statutory tax rates were also considered in the calculation.

The income tax provision for the three months ended March 31, 2021 and 2020 was $27.5 million and $2.9 million, respectively, representing effective tax rates of 32.2% and 21.5%, respectively. The increase in our effective tax rate was primarily due to the jurisdictional mix and the impact of unfavorable discrete items in the period.

Net Income (Loss) Attributable to Noncontrolling Interests

The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.

Net Income Attributable to Bruker Corporation

The increase in net income and earnings per diluted share in the three months ended March 31, 2021, as compared to the same period in 2020, was primarily driven by the increase in revenue, gross profit and operating profit as a result of the rebounding in our business and end markets.

Table of Contents

Segment Results

Revenue

The following table presents revenue, change in revenue and revenue growth by reportable segment (dollars in millions):


	Three Months Ended March 31,									Percentage
	2021			2020			Dollar Change			Change
BSI Life Science	$	351.8		$	261.4		$	90.4			34.6	%
BSI NANO		154.4			120.1			34.3			28.6	%
BEST		52.4			46.2			6.2			13.4	%
Eliminations (a)		(3.9	)		(3.7	)		(0.2	)

	$	554.7		$	424.0		$	130.7			30.8	%

(a)	Represents product and service revenue between reportable segments.

For financial reporting purposes, we aggregate the Bruker BioSpin Group and Bruker CALID Group as the BSI Life Science Segment. This aggregation reflects the similar economic characteristics, production processes, customer services provided, types and classes of customers, methods of distribution and regulatory environments.

The increase in revenue for the BSI Life Science Segment in the three months ended March 31, 2021 was due to strong demand for mass spectrometry, infrared and Raman products, a recovery in customer demand and deliveries for Nuclear Magnetic Resonance (NMR) systems and included customer acceptance of two GHz-class NMR systems. The increase in revenue for the BSI NANO segment was driven by a recovery in industrial research and academic market demand and continued strong demand from semiconductor and microelectronics customers. BEST segment revenue was higher resulting from certain project completions in the three months ended March 31, 2021.

Operating Income

The following table presents operating income and operating margins on revenue by reportable segment (dollars in millions):


	Three Months Ended March 31,
	2021						2020
				Percentage of						Percentage of
	Operating			Segment			Operating			Segment
	Income			Revenue			Income			Revenue
BSI Life Science	$	88.9			25.3	%	$	39.5			15.1	%
BSI NANO		12.3			8.0	%		(8.0	)		(6.7	%)
BEST		4.1			7.8	%		1.7			3.7	%
Corporate, eliminations and other (a)		(16.2	)					(16.8	)

Total operating income	$	89.1			16.1	%	$	16.4			3.9	%

(a)	Represents corporate costs and eliminations not allocated to the reportable segments.

The operating margin increases in the BSI Life Science and BSI NANO Segments resulted from higher revenue, volume and operating leverage, and contributions from higher margin products. The operating margin increase in the BEST segment resulted from higher revenue, favorable mix.

LIQUIDITY AND CAPITAL RESOURCES

We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may complete, repurchases of our common stock, or the payment of dividends in the future. Historically, we have financed our growth and liquidity needs through cash flow generation and a combination of debt financings and issuances of common stock. In the future, there are no assurances that we will continue to generate cash flow from operations or that additional financing alternatives will be available to us, if required, or if available, will be obtained on terms favorable to us.

Cash, cash equivalents and short-term investments at March 31, 2021 and December 31, 2020 totaled $746.8 million and $731.8 million, respectively, of which $570.0 million and $514.9 million, respectively, related to cash, cash equivalents and short-term investments held outside of the U.S. in our foreign subsidiaries, most significantly in the Netherlands, Switzerland and Hong Kong.

Table of Contents

The following table presents our cash flows from operating activities, investing activities and financing activities for the periods presented (in millions):


	Three Months Ended March 31,
	2021			2020
Net cash provided by operating activities	$	98.0		$	35.0
Net cash used in investing activities		(24.0	)		(100.6	)
Net cash (used in) provided by financing activities		(38.1	)		191.3
Effect of exchange rates on cash and cash equivalents		(21.0	)		(8.7	)

Total increase (decrease) in cash and cash equivalents	$	14.9		$	117.0

Cash provided by operating activities during the first quarter of 2021 resulted primarily from consolidated net income adjusted for

non-cash

items of $93.7 million, in addition to a change in operating assets and liabilities, net of acquisitions and divestitures of $4.3 million. The increase in operating assets and liabilities, net of acquisitions and divestitures for the three months ended March 31, 2021 was primarily due to higher payables and accrued liabilities as well as timing of income tax payables offset by improved inventory turnover within the same period of the prior year.

During the three months ended March 31, 2020, net cash provided by operating activities resulted primarily from consolidated net income adjusted for

non-cash

items of $45.7 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $10.7 million.

During the three months ended March 31, 2021, cash used in investing activities was primarily for net purchases of property, plant and equipment of $24.7 million, cash paid for acquisitions, net of cash acquired of $4.0 million, offset by $3.5 million from proceeds of cross currency swap agreements.

Cash used in investing activities during the three months ended March 31, 2020 was primarily attributed to cash paid for purchases of short-term investments of $50.0 million, purchases of property, plant and equipment of $30.5 million and acquisitions of $22.0 million.

Cash used in financing activities during the first quarter of 2021 was primarily due to the $32.6 million in purchases of common stock associated with our ongoing Repurchase Program (as defined below), $6.1 million for the payment of dividends, partially offset by proceeds of $1.1 million from the exercise of stock options. Net cash provided by financing activities during the three months ended March 31, 2020 was primarily attributable to $197.5 million in proceeds from borrowings under the 2019 Revolving Credit Agreement offset in part by $6.2 million for the payment of dividends.

Share Repurchase Program

In May 2019, our Board of Directors approved our share repurchase program (the “Repurchase Program”) under which repurchases of common stock in the amount of up to $300.0 million were authorized to occur from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. During the three months ended March 31, 2021, we purchased 530,729 shares of common stock with an aggregate cost of approximately $32.8 million under the Repurchase Program. There were no purchases under the Repurchase Program in the three months ended March 31, 2020. At March 31, 2021, $1.7 million remained for future purchase under the share repurchase plan. We completed the Repurchase Program in April 2021, after reaching the maximum cumulative spend. The Repurchase Program would have expired on May 13, 2021. The purchased shares are reflected within Treasury stock in the accompanying unaudited condensed consolidated balance sheet at March 31, 2021.

Income Taxes

At December 31, 2020 and in accordance with the tax reform legislation signed by the president of the United States on December 22, 2017, or the 2017 Tax Act, we recorded state and foreign withholding taxes, as well as subsequent foreign currency translations on these withholding taxes as they are an obligation of the parent company, on the cash and liquid assets portion of the unremitted earnings and profits (E&P) of foreign subsidiaries expected to be repatriated from our foreign subsidiaries to the United States. We continue to be indefinitely reinvested in the amount of $435.6 million of

non-cash

E&P that is subject to the 2017 Tax Act deemed repatriation. If this E&P is ultimately distributed to the United States in the form of dividends or otherwise we would likely be subject to additional withholding tax. We will continue to evaluate our assertions on the cumulative historical outside basis differences in our foreign subsidiaries as of December 31, 2020. The amount of unrecognized deferred withholding taxes on the undistributed E&P was $62.9 million at December 31, 2020.

Table of Contents

As of March 31, 2021, we had approximately $65.2 million of net operating loss carryforwards available to reduce state taxable income that are expected to expire at various times beginning in 2021; approximately $104.0 million of net operating losses available to reduce German federal income and trade taxes that are carried forward indefinitely and $13.1 million of other foreign net operating losses that are expected to expire at various times beginning in 2021. We also had U.S. state research and development tax credits of $7.1 million. Utilization of these credits and state net operating losses may be subject to annual limitations due to the ownership percentage change limitations provided by the Internal Revenue Code Section 382 of 1986, as amended (the “Code”), and similar state provisions. In the event of a deemed change in control under Code Section 382, an annual limitation on the utilization of net operating losses and credits may result in the expiration of all or a portion of the net operating loss and credit carryforwards.

Uncertain tax contingencies are positions taken or expected to be taken on an income tax return that may result in additional payments to tax authorities. If a tax authority agrees with the tax position taken or expected to be taken or the applicable statute of limitations expires, then additional payments will not be necessary.

Credit Facilities

On December 11, 2019, we entered into (1) a new revolving credit agreement to establish a new revolving credit facility in the aggregate principal amount of $600 million; (2) a term loan agreement to establish a new term loan facility in the aggregate principal amount of $300 million; and (3) a note purchase agreement to issue and sell CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. Floating interest rates under the term loan were simultaneously fixed through cross-currency and interest rate swap agreements into Euro ($150 million) and Swiss Franc ($150 million) rates carrying average effective interest rates of 0.94% and hedge our net investment in our Euro and Swiss Franc denominated net assets. The new revolving credit agreement replaced our $500 million five-year revolving credit agreement established on October 27, 2015, that was terminated on December 11, 2019. In addition, we designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Proceeds from this financing were used to repay the outstanding borrowings under our prior 2015 revolving credit facility and we intend to use the remaining proceeds for general corporate purposes and to support corporate strategic objectives. During December 2019, we entered into U.S. Dollar to Euro cross-currency swaps on our existing 2012 private placement notes of $105 million of 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022, and the existing $100 million of 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024, resulting in an average effective interest rate of 2.25% on these instruments. The cross-currency swaps hedge our net investment in our Euro denominated net assets. As a result of entering into these interest rate and cross currency swap agreements, we reduced our interest expense by $1.4 million during the three months ended March 31, 2021. We anticipate these swap agreements will lower net interest expense in future years.

We had the following debt outstanding (dollars in millions):


	March 31, 2021			December 31, 2020
US Dollar notes under the 2012 Note Purchase Agreement	$	205.0		$	205.0
CHF notes (in dollars) under the 2019 Note Purchase Agreement		314.8			335.5
US Dollar notes under the 2019 Term Loan		300.0			300.0
Unamortized debt issuance costs		(2.3	)		(2.4	)
Capital lease obligations and other loans		6.7			6.4

Total debt		824.2			844.5
Current portion of long-term debt		(108.4	)		(2.2	)

Total long-term debt, less current portion	$	715.8		$	842.3

As of March 31, 2021, there are no material changes to our contractual obligations from those disclosed in our Annual Report on Form

10-K

for the fiscal year ended December 31, 2020.

As of March 31, 2021, we had no

off-balance

sheet arrangements.

Table of Contents

The following is a summary of the maximum commitments and the net amounts available to us under the 2019 Credit Agreement and other banking working capital lines and guarantees of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand at March 31, 2021 (dollars in millions):


	Weighted Average Interest Rate			Total Amount Committed by Lenders		Outstanding Borrowings		Outstanding Letters of Credit		Total Committed Amounts Available
2019 Credit Agreement		1.3	%	$	600.0	$	—	$	0.2	$	599.8
Bank guarantees and working capital line		0.0	%		120.2		—		120.2		—

Total revolving lines of credit				$	720.2	$	—	$	120.4	$	599.8

As of March 31, 2021, we were in compliance with the financial covenants of these debt agreements.

RECENT ACCOUNTING PRONOUNCEMENTS

Information regarding recent accounting standard changes and developments is incorporated by reference from Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this document and should be considered an integral part of this Item 2. See Note 2 in the Notes to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form

10-Q

for recently adopted and issued accounting standards.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are potentially exposed to market risks associated with changes in foreign currency translation rates, interest rates and commodity prices. We selectively use financial instruments to reduce these risks. All transactions related to risk management techniques are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign currency translation and interest rate risk include market valuations and sensitivity analyses.

Foreign Currency Risk

We generate a substantial portion of our revenues in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which exposes our operations to the risk of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. Our costs related to sales in foreign currencies are largely denominated in the same respective currencies, reducing our transaction risk exposure. However, for foreign currency denominated sales in certain regions, such as Japan, where we do not incur significant costs denominated in Japanese Yen, we are more exposed to the impact of foreign currency fluctuations.

For sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we would have received before the rate increase went into effect. If we price our products in U.S. dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency. For example, if the U.S. dollar strengthened against the Japanese Yen, our Japanese-based competitors would have a greater pricing advantage over us.

Changes in foreign currency translation rates increased our revenue by 6.2% and decreased our revenue by 1.2% for the three months ended March 31, 2021 and 2020, respectively.

Assets and liabilities of our foreign subsidiaries, where the functional currency is the local currency, are translated into U.S. dollars using

period-end

exchange rates. Revenues and expenses of foreign subsidiaries are translated at the average exchange rates in effect during the year. Adjustments resulting from financial statement translations are included as a separate component of shareholders’ equity. For the three months ended March 31, 2021 and 2020, we recorded net losses from currency translation adjustments of $19.5 million and $13.0 million, respectively. Gains and losses resulting from foreign currency transactions are reported in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income.

The impact of currency exchange rate movement can be positive or negative in any period. We periodically enter into foreign currency contracts in order to minimize the volatility that fluctuations in currency translation have on our monetary transactions. Under these arrangements, we typically agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates with maturities of less than twelve months, with some agreements extending to longer periods. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the unaudited condensed consolidated statements of income and comprehensive income.

Table of Contents

As of March 31, 2021, we have several cross-currency and interest rate swap agreements with a notional value of $150.0 million of U.S. Dollar to Swiss Franc and a notional value of $355.0 million of U.S. dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. Under the GAAP hedge accounting guidance, changes in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in comprehensive income (loss) and remain in accumulated comprehensive income (loss) in shareholders’ equity until the sale or substantial liquidation of the foreign operation. The difference between the interest rate received and paid under the interest rate cross-currency swap derivative agreement is recorded in interest income in the unaudited condensed consolidated statements of income and comprehensive income.

From time to time, we have entered into forward currency contracts designed to minimize the volatility that fluctuations in foreign currency have on our cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, we agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates typically with maturities of less than twelve months with some agreements extending to longer periods. These transactions are recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. At March 31, 2021 and December 31, 2020, we had forward currency contracts with notional amounts aggregating $131.3 million and $278.3 million, respectively. We will continue to evaluate our currency risks, and in the future may utilize foreign currency contracts more frequently.

Interest Rate Risk

We regularly invest excess cash in short-term investments that are subject to changes in interest rates. We believe that the market risk arising from holding these financial instruments is minimal because of our policy of investing in short-term financial instruments issued by highly rated financial institutions.

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates. We currently have a higher level of fixed rate debt than variable rate debt, which limits the exposure to adverse movements in interest rates.

Commodity Price Risk

We are exposed to certain commodity risks associated with prices for various raw materials. The prices of copper and certain other raw materials, particularly

niobium-tin,

used to manufacture superconductors have increased significantly over the last decade. Copper and

niobium-tin

are the main components of low temperature superconductors and continued commodity price increases for copper and niobium, as well as other raw materials, may negatively affect our profitability. Periodically, we enter into commodity forward purchase contracts to minimize the volatility that fluctuations in the price of copper have on our sales of these products. At March 31, 2021 and December 31, 2020, we had fixed price commodity contracts with notional amounts aggregating $5.8 million and $8.8 million, respectively. The fair value of the fixed price commodity contracts at March 31, 2021 and December 31, 2020 was $3.8 million and $3.1 million, respectively. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues. We will continue to evaluate our commodity risks and may utilize commodity forward purchase contracts more frequently in the future.

Inflation Risk

We do not believe inflation had a material impact on our business or operating results during any of the periods presented.

ITEM 4.

CONTROLS AND PROCEDURES

We have established disclosure controls and procedures (as defined in Rules

13a-15(e)

and

15d-15(e)

under the Securities Exchange Act of 1934, as amended (Exchange Act) that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2021. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2021.

Table of Contents

Management concluded that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form

10-Q

fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.

Changes in Internal Controls over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent and commercial matters, which arise in the ordinary course of business. There are no such matters pending that we currently believe are reasonably likely to have a material impact on our business or to our consolidated financial statements.

On September 23, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Micromass UK Limited (Micromass), a subsidiary of Waters Corporation, sued Bruker Corporation, as well as its affiliate, Bruker Daltonik GmbH, for infringement of a European patent pertaining to our timsTOF product line. Bruker was later notified that Micromass had expanded its complaint in Düsseldorf to assert another recently granted European patent in Germany. On March 5, 2021, the parties entered into a Patent License Agreement pursuant to which Bruker licensed certain patents from Micromass and agreed to pay a one-time, upfront $4.0 million payment in the second quarter of 2021 and agreed to pay royalties, subject to a quarterly minimum, on certain TimsTOF systems commencing March 1, 2022. In addition, pursuant to the Patent License Agreement, all claims between the parties in connection with this and other pending infringement matters were settled and dismissed with prejudice. The settlement of this matter did not and is not expected to materially impact the Company’s results of operations.

In addition, we are subject to regulation by national, state and local government agencies in the United States and other countries in which we operate. From time to time, we are the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on our financial position, results of operations and/or liquidity.

ITEM IA.

RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form

10-K

for the year ended December 31, 2020, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form

10-K

are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Our financial condition and results of operations for fiscal 2021 may be adversely affected by the

COVID-19

pandemic.

The impact of the worldwide

COVID-19

pandemic has been and will likely continue to be extensive in many geographies and aspects of society. The pandemic has resulted in and will likely continue to result in disruptions to the global economy, as well as businesses, supply chains and capital markets around the world.

Impacts to our business included temporary closures in 2020 of many of our government and university customers and our suppliers, disruptions or restrictions on our employees’ and customers’ ability to travel, and delays in product installations or shipments to and from affected countries. In an effort to halt the outbreak of

COVID-19,

COVID-19

cases or new strains of the virus. A number of states, including California, Massachusetts and New Jersey where we have significant operations, have implemented phased

re-opening

policies as vaccines to protect against the virus continue to be administered. However, many of our employees in these areas continue to work remotely, and any

re-openings

may be delayed or pulled back if the virus continues to spread or as new strains of the virus emerge, in particular if existing vaccines are determined to be less effective against these new strains than against earlier strains. In addition, a number of our production facilities had to either temporarily close or operate on a reduced capacity in 2020. Much of the commercial activity in sales and marketing, and customer demonstrations and applications training, is still either being conducted remotely or postponed. Many customer purchasing departments are still operating at reduced capacity, and many customers could delay or cut capital expenditures and operating budgets due to ongoing pandemic-related concerns. Even where customers have

re-opened

their sites, many still operate at productivity levels that are below

pre-pandemic

levels in an effort to accommodate safety

Table of Contents

protocols. Any resurgence of the virus or the emergence of new strains of the virus, particularly any new strains which are resistant to existing vaccines, may require us or our customers to close or partially close operations once again. These travel restrictions, business closures and operating reductions at Bruker, our customers, our distributors, and/or our suppliers have and may continue to adversely impact our operations worldwide, including our ability to manufacture, sell or distribute our products, as well as cause temporary closures of our foreign distributors, or the facilities of suppliers or customers. Global supply chains, including for semiconductor chips and other component products, have been disrupted causing shortages, which could impact our ability to manufacture or supply our products. This disruption of our employees, distributors, suppliers or customers has and may continue to impact our global sales and future operating results. We anticipate that the

COVID-19

pandemic and challenges to our customers’ and our own operations may continue to have a negative impact on our second quarter 2021 financial results.

We are continuing to monitor and assess the effects of the

COVID-19

pandemic on our commercial operations, including its continued impact on our revenue in 2021. However, we cannot at this time accurately predict what effects these conditions will ultimately have on our operations due to uncertainties relating to the severity of the disease, including the impact of any resurgence of the virus, the continued emergence of new strains of the virus, the effectiveness and availability of vaccines, the willingness of individuals to receive vaccines, (including to protect against any new strains of the virus), and the length or severity of the travel restrictions, business closures, and other safety and precautionary measures imposed by the governments of impacted countries. The pandemic has also adversely affected the economies and financial markets of many countries, which has affected and likely may continue to affect demand for the Company’s products and its operating results.

There have been no other material changes to the risk factors previously disclosed in our Annual Report on Form

10-K

for the fiscal year ended December 31, 2020.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table provides information about purchases made by or on behalf of the Company or any “affiliated purchaser,” as defined in Rule

10b-18(a)(3)

under the Exchange Act, during the quarter ended March 1, 2021 of shares of our common stock.


Period	Total Number of Shares Purchased (1)		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (2)
January 1 - January 31, 2021		85,773	$	58.29		85,773	$	29,453,135
February 1 - February 28, 2021		390,783	$	62.55		390,783	$	5,009,816
March 1 - March 31, 2021		54,173	$	59.76		54,173	$	1,691,717

		530,729	$	61.73		530,729	$	1,691,717

(1)	The Company purchased shares of common stock in accordance with its share repurchase program approved by the Board of Directors and announced on May 10, 2019. The shares were purchased on the open market at prevailing prices.

(2)	The Repurchase Program authorized the Company to purchase up to $300.0 million of its common stock over a two-year period. We completed the share purchase program in April 2021, after reaching the maximum cumulative spend. The Repurchase Program was set to expire May 13, 2021.

Table of Contents

ITEM 6.

EXHIBITS


Exhibit No.		Description

31.1*		Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		Inline XBRL Instance Document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*		The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 has been formatted in Inline XBRL (included in Exhibit 101)

*	Filed or furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	BRUKER CORPORATION

Date: May 7, 2021	By:	/s/ FRANK H. LAUKIEN, PH.D.
		Frank H. Laukien, Ph.D.
		President, Chief Executive Officer and Chairman
		(Principal Executive Officer)

Date: May 7, 2021	By:	/s/ GERALD N. HERMAN
		Gerald N. Herman
		Chief Financial Officer and Executive Vice President
		(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 d112071dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Frank H. Laukien, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Bruker Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d112071dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Gerald N. Herman, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Bruker Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d112071dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bruker Corporation (Company) on Form 10-Q for the three months ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (Report), each of the undersigned, Frank H. Laukien, President, Chief Executive Officer and Chairman of the Board of Directors of the Company, and Gerald N. Herman, Chief Financial Officer and Vice President of the Company, certifies, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 7, 2021	By:	/s/ FRANK H. LAUKIEN, PH.D.
		Frank H. Laukien, Ph.D.
		President, Chief Executive Officer and Chairman
		(Principal Executive Officer)

Date: May 7, 2021	By:	/s/ GERALD N. HERMAN
		Gerald N. Herman
		Chief Financial Officer and Executive Vice President
		(Principal Financial Officer and Principal Accounting Officer)

EX-101.SCH 5 brkr-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Description of Business link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Acquisitions link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Provision for Income Taxes link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Other Charges, Net link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Business Segment Information link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Acquisitions (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Other Charges, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Business Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Revenue - Disaggregation (Details) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Revenue - Remaining Performance Obligations (Details) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Revenue - Contract Balances (Details) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Acquisitions - Consideration transferred and reportable segment (Details) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Debt - Components (Details) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Debt - Revolving Loan Arrangements (Details) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Debt - Currency Swaps (Details) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Fair Value of Financial Instruments - Hierarchy (Details) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Derivative Instruments and Hedging Activities - Risk Management (Details) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet (Details) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Derivative Instruments and Hedging Activities - Income Statement (Details) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Provision for Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Earnings Per Share - Computation (Details) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Earnings Per Share - Anti-dilutive Stock Options (Details) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Shareholders' Equity - Share Repurchase and Dividends (Details) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Shareholders' Equity - Comprehensive Income (Loss) (Details) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Shareholders' Equity - Expense (Details) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Other Charges, Net - Components of other charges (Details) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Other Charges, Net - Restructuring Plans (Details) link:presentationLink link:definitionLink link:calculationLink 1059 - Disclosure - Other Charges, Net - Restructuring Reserves (Details) link:presentationLink link:definitionLink link:calculationLink 1060 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 1061 - Disclosure - Business Segment Information (Details) link:presentationLink link:definitionLink link:calculationLink 1062 - Disclosure - Revenue - Remaining Performance Obligations (Details) Alternate link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 brkr-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 brkr-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 brkr-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province City Area Code Local Phone Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Trading Symbol Security Exchange Name Title of 12(b) Security Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Entity Tax Identification Number Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Short-term Investments Short-term investments Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable, net Inventory, Net Inventories Inventories Other Assets, Current Other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net Goodwill Goodwill Balance at the beginning of the period Balance at the end of the period Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Other Assets, Noncurrent Other long-term assets Assets Total assets Assets Liabilities and Equity [Abstract] LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Long-term Debt and Lease Obligation, Current, Total Current portion of long-term debt Current portion of long-term debt Accounts Payable, Current Accounts payable Contract with Customer, Liability, Current Customer advances Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Total long-term debt, less current portion Other Liabilities, Noncurrent Other long-term liabilities Commitments and Contingencies Commitments and contingencies (Note 14) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Shareholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding Common Stock, Value, Outstanding Common stock, $0.01 par value 260,000,000 shares authorized, 174,132,743 and 174,045,610 shares issued and 151,543,485 and 151,987,081 shares outstanding at March 31, 2021 and December 31, 2020, respectively Treasury Stock, Value Treasury stock, at cost, 22,589,258 and 22,058,529 shares at March 31, 2021 and December 31, 2020 Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) income Stockholders' Equity Attributable to Parent Total shareholders' equity attributable to Bruker Corporation Stockholders' Equity Attributable to Noncontrolling Interest Noncontrolling interest in consolidated subsidiaries Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total shareholders' equity Balance at beginning of period Balance at end of period Other Shareholders Equity Other shareholders' equity The aggregate amount of all other stockholder's equity not separately identified, including additional paid-in capital and the cumulative amount of the reporting entity's undistributed earnings or deficit. Liabilities and Equity Total liabilities and shareholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Shares Treasury stock, shares Income Statement [Abstract] Statement [Table] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product [Member] Product Service [Member] Service Product and Service, Other [Member] Other Statement [Line Items] Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Cost of Revenue Total cost of revenue Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: Selling, General and Administrative Expense Selling, general and administrative Research and Development Expense Research and development Other Nonrecurring Expense Other charges, net Operating Expenses Total operating expenses Operating Income (Loss) Operating income Operating Income (loss) Nonoperating Income (Expense) Interest and other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes and noncontrolling interest in consolidated subsidiaries Income Tax Expense (Benefit) Income tax provision Income tax expense (benefit) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Consolidated net income Consolidated net income Net Income (Loss) Attributable to Noncontrolling Interest Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries Net Income (Loss) Attributable to Parent Net income attributable to Bruker Corporation Earnings Per Share Net income per common share attributable to Bruker Corporation shareholders: Earnings Per Share, Basic Basic (in dollars per share) Earnings Per Share, Diluted Diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average common shares outstanding: Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted average shares outstanding-basic Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Weighted-average number of common shares used in computing diluted net income per common share Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Nonredeemable Less: Comprehensive income (loss) attributable to noncontrolling interests Less: Comprehensive income (loss) attributable to noncontrolling interests Comprehensive Income Loss Net Of Tax Attributable To Non redeemable Non controlling Interest Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to redeemable noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income attributable to Bruker Corporation Comprehensive income attributable to Bruker Corporation CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Parent [Member] Total Shareholders' Equity Attributable to Bruker Corporation Common Stock [Member] Common Stock Treasury Stock [Member] Treasury Stock Additional Paid-in Capital [Member] Additional Paid-In Capital Retained Earnings [Member] Retained Earnings AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Noncontrolling Interest [Member] Noncontrolling Interests in Consolidated Subsidiaries Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest Representing information pertaining to Redeemable Noncontrolling Interest. Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, Stock Options Exercised Stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Stock options exercised (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures RSU vested Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures RSU vested (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock based compensation Dividends, Common Stock, Cash Dividends declared to common stockholders Interest Acquired In Subsidiary Acquired 80% interest in Hain LifeScience GmbH The amount of interest acquired in Hain LifeScience GmbH. Net Income (Loss), Including Portion Attributable to Redeemable Noncontrolling Interest Consolidated net income Net Income (Loss) including Attributable to Redeemable Noncontrolling Interest, Total Stock Repurchased During Period, Value Shares purchased Stock Repurchased During Period, Shares Shares purchased (in shares) Other Comprehensive Income (Loss), Net of Tax, Excluding Redeemable Noncontrolling Interest Other comprehensive income (loss) Amount after tax and reclassification adjustments of other comprehensive income (loss), excluding redeemable noncontrolling interest. Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Hain Lifescience Gmbh [Member] Hain Represents the information pertaining to Hain lifescience gmbh. Common Stock, Dividends, Per Share, Cash Paid Dividends declared (per share) Business Acquisition, Percentage of Voting Interests Acquired Interest acquired CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile consolidated net income to cash flows from operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Deferred Income Tax Expense (Benefit) Deferred income taxes Other Noncash Income (Expense) Other non-cash expenses, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventories Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Income Taxes Payable Income taxes payable Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Contract with Customer, Liability Customer advances Increase (Decrease) in Other Operating Assets and Liabilities, Net Other changes in operating assets and liabilities, net Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Short-term Investments Purchases of short-term investments Payments to Acquire Businesses, Net of Cash Acquired Cash paid for acquisitions, net of cash acquired Cash Consideration Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from sales of property, plant and equipment Payments for (Proceeds from) Hedge, Investing Activities Net proceeds from cross-currency swap agreements Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Lines of Credit Proceeds from revolving lines of credit Repayments of Other Debt Repayment of other debt Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net Payment for Contingent Consideration Liability, Financing Activities Payment of contingent consideration Payments of Ordinary Dividends, Common Stock Payment of dividends to common stockholders Payments to Noncontrolling Interests Cash payments to noncontrolling interest Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Proceeds from Other Debt Proceeds from other debt Payments for Repurchase of Common Stock Purchases of common stock Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of exchange rate changes on cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Restricted Cash and Cash Equivalents Restricted cash period beginning balance Restricted cash period ending balance Description of Business Nature of Operations [Text Block] Description of Business Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements Revenue Revenue from Contract with Customer [Text Block] Revenue Acquisitions Business Combination Disclosure [Text Block] Acquisitions Inventories Inventory Disclosure [Text Block] Inventories Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Debt Debt Disclosure [Text Block] Debt Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments EX-101.PRE 9 brkr-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 d112071d10q_htm.xml IDEA: XBRL DOCUMENT 0001109354 2021-03-31 0001109354 2020-12-31 0001109354 2021-01-01 2021-03-31 0001109354 2020-01-01 2020-03-31 0001109354 2021-05-03 0001109354 2021-03-05 2021-03-05 0001109354 2019-12-31 0001109354 2020-03-31 0001109354 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0001109354 us-gaap:CustomerRelationshipsMember 2020-12-31 0001109354 us-gaap:TradeNamesMember 2020-12-31 0001109354 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001109354 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001109354 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001109354 brkr:NotePurchaseAgreement2012Member 2020-12-31 0001109354 brkr:NotePurchaseAgreement2019Member 2020-12-31 0001109354 brkr:TermLoanAgreementMember 2020-12-31 0001109354 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001109354 us-gaap:ForeignExchangeForwardMember 2020-12-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-12-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-12-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-12-31 0001109354 us-gaap:CurrencySwapMember 2020-12-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2020-12-31 0001109354 us-gaap:OtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001109354 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-12-31 0001109354 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001109354 brkr:CapitalLeaseObligationsAndOtherLoanMember 2020-12-31 0001109354 us-gaap:ForeignExchangeContractMember 2020-12-31 0001109354 us-gaap:CommodityContractMember 2020-12-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-12-31 0001109354 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2020-12-31 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2020-12-31 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2020-12-31 0001109354 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-03-31 0001109354 us-gaap:CustomerRelationshipsMember 2021-03-31 0001109354 us-gaap:TradeNamesMember 2021-03-31 0001109354 us-gaap:OtherIntangibleAssetsMember 2021-03-31 0001109354 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001109354 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001109354 brkr:NotePurchaseAgreement2012Member 2021-03-31 0001109354 brkr:NotePurchaseAgreement2019Member 2021-03-31 0001109354 brkr:TermLoanAgreementMember 2021-03-31 0001109354 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001109354 us-gaap:DomesticLineOfCreditMember brkr:RevolvingCreditAgreement2019Member 2021-03-31 0001109354 brkr:BankGuaranteesAndWorkingCapitalLineMember 2021-03-31 0001109354 us-gaap:ForeignExchangeForwardMember 2021-03-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-03-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2021-03-31 0001109354 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2021-03-31 0001109354 us-gaap:CurrencySwapMember 2021-03-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2021-03-31 0001109354 us-gaap:OtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-03-31 0001109354 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2021-03-31 0001109354 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2021-03-31 0001109354 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-03-31 0001109354

2020-01-01

2021-03-31 0001109354 srt:MaximumMember

2020-01-01

2021-03-31 0001109354 srt:MinimumMember

2020-01-01

2021-03-31 0001109354 brkr:CapitalLeaseObligationsAndOtherLoanMember 2021-03-31 0001109354 us-gaap:ForeignExchangeContractMember 2021-03-31 0001109354 us-gaap:CommodityContractMember 2021-03-31 0001109354 us-gaap:DesignatedAsHedgingInstrumentMember 2021-03-31 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2021-03-31 0001109354 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2021-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2021-03-31 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2021-03-31 0001109354 brkr:CrossCurrencyInterestRateContractUSDollarsToSwissFrancMember 2021-03-31 0001109354 brkr:CrossCurrencyInterestRateContractUsDollarsToEuroMember 2021-03-31 0001109354 us-gaap:ProductMember 2020-01-01 2020-03-31 0001109354 us-gaap:ServiceMember 2020-01-01 2020-03-31 0001109354 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0001109354 brkr:BrukerBioSpinGroupMember 2020-01-01 2020-03-31 0001109354 brkr:BrukerCalidGroupMember 2020-01-01 2020-03-31 0001109354 brkr:BrukerNanoGroupMember 2020-01-01 2020-03-31 0001109354 brkr:EnergyAndSuperconTechnologiesMember 2020-01-01 2020-03-31 0001109354 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-03-31 0001109354 country:US 2020-01-01 2020-03-31 0001109354 country:DE 2020-01-01 2020-03-31 0001109354 brkr:RestOfEuropeMember 2020-01-01 2020-03-31 0001109354 srt:AsiaPacificMember 2020-01-01 2020-03-31 0001109354 brkr:OtherCountryMember 2020-01-01 2020-03-31 0001109354 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-03-31 0001109354 us-gaap:TransferredOverTimeMember 2020-01-01 2020-03-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember 2020-01-01 2020-03-31 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-01-01 2020-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001109354 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-01-01 2020-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001109354 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001109354 us-gaap:ForeignExchangeForwardMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember 2020-01-01 2020-03-31 0001109354 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001109354 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001109354 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001109354 brkr:MestrelabResearchS.lMember 2020-01-01 2020-03-31 0001109354 us-gaap:OtherExpenseMember 2020-01-01 2020-03-31 0001109354 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2020-01-01 2020-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiNanoMember 2020-01-01 2020-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2020-01-01 2020-03-31 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2020-01-01 2020-03-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001109354 us-gaap:ParentMember 2020-01-01 2020-03-31 0001109354 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001109354 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001109354 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001109354 brkr:RedeemableNoncontrollingInterestMember 2020-01-01 2020-03-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001109354 us-gaap:ProductMember 2021-01-01 2021-03-31 0001109354 us-gaap:ServiceMember 2021-01-01 2021-03-31 0001109354 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-03-31 0001109354 brkr:BrukerBioSpinGroupMember 2021-01-01 2021-03-31 0001109354 brkr:BrukerCalidGroupMember 2021-01-01 2021-03-31 0001109354 brkr:BrukerNanoGroupMember 2021-01-01 2021-03-31 0001109354 brkr:EnergyAndSuperconTechnologiesMember 2021-01-01 2021-03-31 0001109354 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-03-31 0001109354 country:US 2021-01-01 2021-03-31 0001109354 country:DE 2021-01-01 2021-03-31 0001109354 brkr:RestOfEuropeMember 2021-01-01 2021-03-31 0001109354 srt:AsiaPacificMember 2021-01-01 2021-03-31 0001109354 brkr:OtherCountryMember 2021-01-01 2021-03-31 0001109354 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0001109354 us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0001109354 brkr:MestrelabResearchS.lMember 2021-01-01 2021-03-31 0001109354 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember 2021-01-01 2021-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001109354 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2021-01-01 2021-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001109354 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-03-31 0001109354 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2021-01-01 2021-03-31 0001109354 us-gaap:ForeignExchangeForwardMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember us-gaap:InterestIncomeMember 2021-01-01 2021-03-31 0001109354 brkr:CrossCurrencyAndInterestRateSwapAgreementsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2021-01-01 2021-03-31 0001109354 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001109354 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001109354 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001109354 us-gaap:OtherExpenseMember 2021-01-01 2021-03-31 0001109354 brkr:May2019RepurchaseProgramMember 2021-01-01 2021-03-31 0001109354 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0001109354 us-gaap:FacilityClosingMember 2021-01-01 2021-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:ScientificInstrumentsMember 2021-01-01 2021-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:BsiNanoMember 2021-01-01 2021-03-31 0001109354 us-gaap:OperatingSegmentsMember brkr:EnergyAndSuperconTechnologiesMember 2021-01-01 2021-03-31 0001109354 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001109354 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001109354 brkr:AcquisitionsIn2021Member 2021-01-01 2021-03-31 0001109354 brkr:ContingentConsiderationMember 2021-01-01 2021-03-31 0001109354 us-gaap:HybridInstrumentMember 2021-01-01 2021-03-31 0001109354 brkr:CorporateReconcilingItemsAndEliminationsMember 2021-01-01 2021-03-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001109354 us-gaap:ParentMember 2021-01-01 2021-03-31 0001109354 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001109354 brkr:ProvisionsForExcessInventoryMember 2021-01-01 2021-03-31 0001109354 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001109354 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001109354 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001109354 country:CH 2021-01-01 2021-03-31 0001109354 brkr:GlycopathIncMember brkr:ScientificInstrumentsMember 2021-01-01 2021-03-31 0001109354 brkr:IonPathIncMember brkr:ScientificInstrumentsMember 2021-01-01 2021-03-31 0001109354 brkr:AcuitySpatialGenomicsIncMember brkr:BsiNanoMember 2021-01-01 2021-03-31 0001109354 brkr:HainLifescienceGmbhMember 2020-03-31 0001109354 brkr:May2019RepurchaseProgramMember 2019-05-31 0001109354 brkr:May2019RepurchaseProgramMember us-gaap:SubsequentEventMember 2021-05-03 0001109354 brkr:RedeemableNoncontrollingInterestMember 2019-12-31 0001109354 us-gaap:CommonStockMember 2019-12-31 0001109354 us-gaap:TreasuryStockMember 2019-12-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001109354 us-gaap:RetainedEarningsMember 2019-12-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001109354 us-gaap:ParentMember 2019-12-31 0001109354 us-gaap:NoncontrollingInterestMember 2019-12-31 0001109354 us-gaap:CommonStockMember 2020-03-31 0001109354 us-gaap:TreasuryStockMember 2020-03-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001109354 us-gaap:RetainedEarningsMember 2020-03-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001109354 us-gaap:ParentMember 2020-03-31 0001109354 us-gaap:NoncontrollingInterestMember 2020-03-31 0001109354 us-gaap:CommonStockMember 2020-12-31 0001109354 us-gaap:TreasuryStockMember 2020-12-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001109354 us-gaap:RetainedEarningsMember 2020-12-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001109354 us-gaap:ParentMember 2020-12-31 0001109354 us-gaap:NoncontrollingInterestMember 2020-12-31 0001109354 brkr:ContingentConsiderationMember 2020-12-31 0001109354 us-gaap:HybridInstrumentMember 2020-12-31 0001109354 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001109354 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001109354 us-gaap:EmployeeSeveranceMember 2020-12-31 0001109354 us-gaap:FacilityClosingMember 2020-12-31 0001109354 brkr:ProvisionsForExcessInventoryMember 2020-12-31 0001109354 brkr:ContingentConsiderationMember 2021-03-31 0001109354 us-gaap:HybridInstrumentMember 2021-03-31 0001109354 us-gaap:CommonStockMember 2021-03-31 0001109354 us-gaap:TreasuryStockMember 2021-03-31 0001109354 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001109354 us-gaap:RetainedEarningsMember 2021-03-31 0001109354 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001109354 us-gaap:ParentMember 2021-03-31 0001109354 us-gaap:NoncontrollingInterestMember 2021-03-31 0001109354 us-gaap:EmployeeSeveranceMember 2021-03-31 0001109354 brkr:ProvisionsForExcessInventoryMember 2021-03-31 0001109354 us-gaap:FacilityClosingMember 2021-03-31 0001109354 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001109354 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 iso4217:USD shares pure utr:Year utr:Month iso4217:USD shares brkr:segment

P1Y

MA 0001109354 --12-31 2021 Q1 false 10-Q true 2021-03-31 false 000-30833 BRUKER CORPORATION DE 04-3110160 40 Manning Road Billerica 01821 978 663-3660 Common Stock BRKR NASDAQ Yes Yes Large Accelerated Filer false false false 151521114

696800000

681800000

50000000.0

326000000.0

335300000

700700000

692300000

172700000

165600000

1946200000

1925000000.0

384100000

395500000

313300000

320400000

213400000

229100000

177900000

179000000.0

3034900000

3049000000.0

108400000

2200000

152300000

134600000

182200000

189200000

500600000

465900000

943500000

791900000

715800000

842300000

393900000

440500000

0.01

5000000

0.01

260000000

174132743

174045610

151543485

151987081

1700000

22589258

22058529

699800000

667000000.0

-12100000

3700000

1677900000 1622800000

967700000

961200000

14000000.0

13100000

981700000

974300000

3034900000

3049000000.0

458600000

345000000.0

94100000

78200000

2000000.0

800000

554700000

424000000.0

220900000

180500000

54800000

51100000

300000

100000

276000000.0

231700000

278700000

192300000

131800000

121200000

54800000

48500000

3000000.0

6200000

189600000

175900000

89100000

16400000

-3800000

-2900000

85300000

13500000

27500000

2900000

57800000

10600000

1100000

100000

56700000

10500000

0.37

0.07

0.37

0.07

151800000

154200000

153200000

155400000

41600000

12100000

900000

-100000

-500000

40700000

12700000

21100000

154155798

1700000

19346577

-543800000

199700000

1274700000

-25500000

906800000

10300000

917100000

30182

700000

40516

-100000

3000000.0

0.04

6200000

1200000

7400000

0.20

-20600000 -1300000 -1300000 -1300000 -10500000 -10500000 -100000 -10600000 -500000 2200000 2200000 -200000 2000000.0

154226496

1700000

19346577

-543800000

203300000

1277700000

-23300000

915600000

9000000.0

924600000

151987081

1700000

22058529

-667000000.0

216300000

1406500000

3700000

961200000

13100000

974300000

65312

1200000

21821

-100000

3400000

-530729

530729

32800000

0.04

6100000

-56700000 -56700000 -1100000 -57800000 -15800000 -15800000 -200000 -16000000.0

151543485

1700000

22589258

-699800000

220800000

1457100000

-12100000

967700000

14000000.0

981700000

57800000

10600000

22300000

19000000.0

3800000

3300000

4900000

1100000

-4900000

-11700000

-800000

-29500000

41600000

61000000.0

35500000

19100000

10100000

-15000000.0

14100000

20600000

2500000

16500000

17100000

20400000

98000000.0

35000000.0

50000000.0

4000000.0

22000000.0

24700000

30500000

1200000

-3500000

-1900000

-24000000.0

-100600000

197500000

400000

300000

1200000

1100000

600000

400000

300000

6100000

6200000

32600000

1200000

-38100000

191300000

-21000000.0

-8700000

14900000

117000000.0

685500000

681900000

700400000

798900000

3700000

3600000

3400000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue by Group:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bruker BioSpin</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bruker CALID</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bruker Nano</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BEST</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliminations</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.7</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">554.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue by End Customer Geography:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Germany</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rest of Europe</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">149.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia Pacific</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">554.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognized at a point in time</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">367.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognized over time</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">554.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

159400000

120900000

192400000

140500000

154400000

120100000

52400000

46200000

-3900000

-3700000

554700000

424000000.0

119000000.0

109400000

70100000

40900000

149800000

104000000.0

180500000

137200000

35300000

32500000

554700000

424000000.0

480000000.0

367700000

74700000

56300000

554700000

424000000.0

1940300000

0.657

P12M

P3Y

48800000

41800000

407500000

399400000

121400000

The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 41%; font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acquisition /<br/> Investment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date Acquired</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consideration</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Consideration</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Glycopath Inc.</div></div> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Investment</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">February 18, 2021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">BSI Life Science</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IonPath Inc</div></div> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Investment</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">March 18, 2021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">BSI Life Science</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 41%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acuity Spatial Genomics, Inc.</div></div> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> Investment </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">February 24, 2021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">BSI Nano</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 41%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman"; width: 41%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 41%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

2000000.0

4500000

8500000

197100000

198800000

253200000

245700000

157000000.0

152100000

93400000

95700000

700700000

692300000

59600000

67800000

320400000

300000

-6800000

313300000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of intangible assets, excluding goodwill (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 50%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing technology and related patents</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">299.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(192.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">309.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(194.6</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">144.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(45.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.7</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">458.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(245.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">213.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">473.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(244.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">229.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

299000000.0

192300000

106700000

309800000

194600000

115200000

144400000

48000000.0

96400000

148300000

45400000

102900000

14800000

4700000

10100000

15200000

4400000

10800000

300000

100000

200000

300000

100000

200000

458500000

245100000

213400000

473600000

244500000

229100000

8900000

8700000

205000000.0

314800000

335500000

300000000.0

2300000

2400000

6700000

6400000

824200000

844500000

108400000

2200000

715800000

842300000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of the maximum commitments and the net amounts available to the Company under its credit agreements and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at March 31, 2021 (in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest Rate</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Amount</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Committed by</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lenders</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Borrowings</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Letters of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Committed</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amounts<br/> Available</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 Credit Agreement</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">600.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> — </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">599.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bank guarantees and working capital line</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revolving lines of credit</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> 720.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> — </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> 120.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"> 599.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

0.013

600000000.0

200000

599800000

0.000

120200000

720200000

120400000

599800000

150000000.0

355000000.0

1400000 2600000

27700000

10900000

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (dollars in millions): </div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%; font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March 31, 2021</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets<br/> Available<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time deposits and money market funds</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed price commodity contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities available for sale</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">213.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hybrid instrument liability</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%; font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2020</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets<br/> Available<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time deposits and money market funds</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed price commodity contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities available for sale</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hybrid instrument liability</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s financial instruments consist primarily of cash equivalents, short-term investments, restricted cash, derivative instruments consisting of forward currency contracts, cross-currency interest rate swap agreements, commodity contracts, derivatives embedded in certain purchase and sale contracts, derivatives embedded within noncontrolling interests, accounts receivable, accounts payable, contingent consideration and long-term debt. The carrying amounts of the Company’s cash equivalents, short-term investments and restricted cash, accounts receivable, borrowings under a revolving credit agreement and accounts payable approximate fair value because of their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company’s long-term debt consists principally of a note purchase agreement entered into in 2012 and a revolving credit agreement, long term loan agreement and note purchase agreement entered into in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated the estimated fair value of financial instruments using available market information and management’s estimates. The use of different market assumptions and/or estimation methodologies could have a significant effect on the estimated fair value amounts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the three months ended March 31, 2021 or 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was $527.7 million and $549.8 million at March 31, 2021 and December 31, 2020, respectively, based on market and observable sources with similar maturity <div style="letter-spacing: 0px; top: 0px;;display:inline;">dates. The carrying value of our variable rate debt approximates its fair value at March 31, 2021 and December 31, 2020.</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could create an impairment. None were noted for the three months ended March 31, 2021 or 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration recorded within other current liabilities represents the estimated fair value of future payments to the former shareholders as part of certain acquisitions. The contingent consideration is primarily based on the applicable acquired company achieving annual revenue and gross margin targets in certain years as specified in the relevant purchase and sale agreement. The Company initially values the contingent consideration on acquisition date by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the changes in contingent consideration liabilities (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 92%; font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December 31, 2020</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current period adjustments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current period settlements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency effect</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March 31, 2021</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the Mestrelab acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 49% of Mestrelab for cash at a contractually defined redemption value. These rights (an embedded derivative) are exercisable beginning in 2022 and can be accelerated, at a discounted redemption value, upon certain events related to post combination services. As the option is tied to continued employment, the Company classified the hybrid instrument (noncontrolling interest with an embedded derivative) as a long-term liability on the consolidated balance sheet. Subsequent to the acquisition, the carrying value of the hybrid instrument is remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the requisite service period vested. The hybrid instrument is classified as Level 3 in the fair value hierarchy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the changes in hybrid instrument liability (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December 31, 2020</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current period adjustments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency effect</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March 31, 2021</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Th<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div> following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (dollars in millions): </div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%; font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March 31, 2021</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets<br/> Available<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time deposits and money market funds</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed price commodity contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities available for sale</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">213.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hybrid instrument liability</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%; font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2020</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets<br/> Available<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time deposits and money market funds</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">183.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed price commodity contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities available for sale</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hybrid instrument liability</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate and cross currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities recorded at fair value</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

151100000

50000000.0 50000000.0

7100000

100000

3800000

1200000

213300000

212100000

1200000

3300000

13800000 13800000

33300000

300000

1300000

52000000.0

34900000

17100000

183200000

50000000.0 50000000.0

7600000

2100000

100000

3100000

1200000

247300000

246100000

1200000

4300000

13900000 13900000

61500000

400000

80100000

61900000

18200000

527700000

549800000

4300000

-500000

400000

-100000

3300000

0.49

13900000

400000

-500000

13800000

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Instruments and Hedging Activities </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commodity Price Risk Management </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March 31, 2021 and December 31, 2020, the Company had fixed price commodity contracts with notional amounts aggregating $5.8 million and $8.8 million, respectively. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues. </div></div> <div style="text-indent: 4%; font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Exchange Rate Risk Management </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following notional amounts outstanding under foreign exchange contracts and cross-currency interest rate swap agreements (in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional<br/> Amount in U.S.<br/> Dollars</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional<br/> Amount in U.S.<br/> Dollars</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward Currency Contracts (1):</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-Currency and Interest Rate Swap Agreements (2):</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">636.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(52.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives not designated as accounting hedges. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as accounting hedges. </div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The<div style="letter-spacing: 0px; top: 0px;;display:inline;">se</div> contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $6.1 million for the delivery of products and $4.3 million for the purchase of products at March 31, 2021 and $7.5 million for the delivery of products and $4.8 million for the purchase of products at December 31, 2020. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income (loss). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate cross-currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total derivatives designated as hedging instruments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives not designated as hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed price commodity contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total derivatives not designated as hedging instruments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total derivatives</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of the activity included in the unaudited condensed consolidated statements of income and comprehensive income loss related to the derivative instruments described above (in millions): </div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 41%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td style="width: 36%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statement Classification</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives not designated as hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(5.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(0.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">0.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as Cash Flow hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate cross-currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest<div style="letter-spacing: 0px; top: 0px;;display:inline;"> incurred</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(1.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains (losses) on contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">9.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(19.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as Net Investment hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate cross-currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Unrealized gains on contracts</div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29.9</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.5</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

5800000

8800000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following notional amounts outstanding under foreign exchange contracts and cross-currency interest rate swap agreements (in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional<br/> Amount in U.S.<br/> Dollars</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional<br/> Amount in U.S.<br/> Dollars</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward Currency Contracts (1):</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-Currency and Interest Rate Swap Agreements (2):</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">636.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(52.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives not designated as accounting hedges. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as accounting hedges. </div></div> </td> </tr> </table>

10000000.0

100000

175800000

2100000

121300000

1300000

102500000

400000

505000000.0

26200000

505000000.0

53900000

636300000

-27400000

783300000

-52200000

6100000 4300000 7500000 4800000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate cross-currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total derivatives designated as hedging instruments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives not designated as hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed price commodity contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total derivatives not designated as hedging instruments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total derivatives</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

7100000

7600000

-9300000

-4300000

-24000000.0

-57200000

-26200000

-53900000

100000

2100000

-1300000

-400000

100000

-300000

3800000

3100000

2300000

4900000

-23900000

-49000000.0

The following is a summary of the activity included in the unaudited condensed consolidated statements of income and comprehensive income loss related to the derivative instruments described above (in millions): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 41%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td style="width: 36%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statement Classification</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives not designated as hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward currency contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(5.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(0.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivatives in purchase and delivery contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(0.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">0.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as Cash Flow hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate cross-currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest<div style="letter-spacing: 0px; top: 0px;;display:inline;"> incurred</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(1.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains (losses) on contracts</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">9.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(19.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives designated as Net Investment hedging instruments</div></div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate cross-currency swap agreements</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and other income (expense), net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Unrealized gains on contracts</div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29.9</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.5</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman";"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

-5000000.0

-500000

-400000

600000

-5400000

100000

-1100000

9900000

-19000000.0

8800000

-19000000.0

2500000

2600000

17800000

29900000

20300000

32500000

27500000

2900000

0.322

0.215

24300000

22700000

1900000

1800000

0.300

0.200

0.051

0.210

<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable to Bruker Corporation, as reported</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding-basic</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive securities:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options and restricted stock awards and units</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">153.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income per common share attributable to Bruker Corporation shareholders:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

56700000

10500000

151800000

154200000

1400000

1200000

153200000

155400000

0.37

0.07

0.37

0.07

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock units</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table>

100000

300000000.0

530729

32800000

1700000

<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 8%; padding: 0px;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding: 0px 0px 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding: 0px 0px 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated net income</div></div> </td> <td style="vertical-align: top; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments</div></div> </td> <td style="vertical-align: top; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pension liability adjustments, net of tax</div></div> </td> <td style="vertical-align: top; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 77%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net comprehensive income</div></div> </td> <td style="vertical-align: top; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Less: Comprehensive<div style="display:inline;"> income (loss) </div>attributable to noncontrolling interests</div> </td> <td style="vertical-align: bottom; width: 8%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Less: Comprehensive<div style="display:inline;"> income (loss) </div>attributable to redeemable noncontrolling interest</div> </td> <td style="vertical-align: top; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 77%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income attributable to Bruker Corporation</div></div> </td> <td style="vertical-align: top; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 77%;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; width: 8%; padding: 0px;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

57800000

10600000

-19500000

-13000000.0

3300000

14500000

41600000 12100000

900000

-100000

-500000

40700000

12700000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of the components of accumulated other comprehensive income (loss), net of tax (dollars in millions): </div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> Currency<br/> Translation</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension<br/> Liability<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> <div style="display:inline;">Income<br/> (Loss)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December 31, 2020</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(45.7</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) before reclassifications</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16.5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Realized loss on amounts reclassified from other comprehensive income (loss), net of tax</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net current period other comprehensive income (loss)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March 31, 2021</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(42.4</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

49400000

-45700000

3700000

-19100000

2600000

-16500000

-700000

-19100000

3300000

-15800000

30300000

-42400000

-12100000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%;"/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs of product revenue</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

500000

2400000

2000000.0

500000

3400000

3000000.0

400000

300000

23400000

P2Y3M18D

700000

900000

100000

3400000

1300000 1500000

900000

-1100000

1200000

300000

3000000.0

6200000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring charges include charges for various programs that were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The following table sets forth the restructuring charges (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%;"/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other charges, net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

1100000

800000

1300000

1500000

2400000

2300000

9800000

7600000

800000

1400000

2400000

2200000

200000

5200000

4700000

500000

-100000

6900000

5100000

500000

1300000

4000000.0

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue and operating income by reportable segment are presented below (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BSI Life Science</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BSI NANO</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BEST</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliminations (a)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.7</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">554.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income (loss)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BSI Life Science</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BSI NANO</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8.0</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BEST</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate, eliminations and other (b)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16.8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents product and service revenue between reportable segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents corporate costs and eliminations not allocated to the reportable segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets by reportable segment are as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BSI Life Science, BSI NANO & Corporate</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,947.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,964.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BEST</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliminations and other (a)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,034.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,049.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets not allocated to the reportable segments and eliminations of intercompany transactions. </div></div> </td> </tr> </table>

351800000

261400000

154400000

120100000

52400000

46200000

-3900000

-3700000

554700000

424000000.0

88900000

39500000

12300000

-8000000.0

4100000

1700000

-16200000

-16800000

89100000

16400000

2947800000

2964500000

92300000

88700000

-5200000

-4200000

3034900000

3049000000.0

XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2021	May 03, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	000-30833
Entity Registrant Name	BRUKER CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3110160
Entity Address, Address Line One	40 Manning Road
Entity Address, City or Town	Billerica
Entity Address, Postal Zip Code	01821
Entity Address, State or Province	MA
City Area Code	978
Local Phone Number	663-3660
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Trading Symbol	BRKR
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		151,521,114
Entity Central Index Key	0001109354
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 696.8	$ 681.8
Short-term investments	50.0	50.0
Accounts receivable, net	326.0	335.3
Inventories	700.7	692.3
Other current assets	172.7	165.6
Total current assets	1,946.2	1,925.0
Property, plant and equipment, net	384.1	395.5
Goodwill	313.3	320.4
Intangible assets, net	213.4	229.1
Other long-term assets	177.9	179.0
Total assets	3,034.9	3,049.0
Current liabilities:
Current portion of long-term debt	108.4	2.2
Accounts payable	152.3	134.6
Customer advances	182.2	189.2
Other current liabilities	500.6	465.9
Total current liabilities	943.5	791.9
Long-term debt	715.8	842.3
Other long-term liabilities	393.9	440.5
Commitments and contingencies (Note 14)
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 174,132,743 and 174,045,610 shares issued and 151,543,485 and 151,987,081 shares outstanding at March 31, 2021 and December 31, 2020, respectively	1.7	1.7
Treasury stock, at cost, 22,589,258 and 22,058,529 shares at March 31, 2021 and December 31, 2020	(699.8)	(667.0)
Accumulated other comprehensive (loss) income	(12.1)	3.7
Other shareholders' equity	1,677.9	1,622.8
Total shareholders' equity attributable to Bruker Corporation	967.7	961.2
Noncontrolling interest in consolidated subsidiaries	14.0	13.1
Total shareholders' equity	981.7	974.3
Total liabilities and shareholders' equity	$ 3,034.9	$ 3,049.0

XML 13 R3.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	260,000,000	260,000,000
Common stock, shares issued	174,132,743	174,045,610
Common stock, shares outstanding	151,543,485	151,987,081
Treasury stock, shares	22,589,258	22,058,529

XML 14 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total revenue	$ 554.7	$ 424.0
Total cost of revenue	276.0	231.7
Gross profit	278.7	192.3
Operating expenses:
Selling, general and administrative	131.8	121.2
Research and development	54.8	48.5
Other charges, net	3.0	6.2
Total operating expenses	189.6	175.9
Operating income	89.1	16.4
Interest and other income (expense), net	(3.8)	(2.9)
Income before income taxes and noncontrolling interest in consolidated subsidiaries	85.3	13.5
Income tax provision	27.5	2.9
Consolidated net income	57.8	10.6
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries	1.1	0.1
Net income attributable to Bruker Corporation	$ 56.7	$ 10.5
Net income per common share attributable to Bruker Corporation shareholders:
Basic (in dollars per share)	$ 0.37	$ 0.07
Diluted (in dollars per share)	$ 0.37	$ 0.07
Weighted average common shares outstanding:
Basic (in shares)	151.8	154.2
Diluted (in shares)	153.2	155.4
Comprehensive income	$ 41.6	$ 12.1
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.9	(0.1)
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		(0.5)
Comprehensive income attributable to Bruker Corporation	40.7	12.7
Product
Total revenue	458.6	345.0
Total cost of revenue	220.9	180.5
Service
Total revenue	94.1	78.2
Total cost of revenue	54.8	51.1
Other
Total revenue	2.0	0.8
Total cost of revenue	$ 0.3	$ 0.1

XML 15 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest
Balance at beginning of period at Dec. 31, 2019	$ 917.1	$ 906.8	$ 1.7	$ (543.8)	$ 199.7	$ 1,274.7	$ (25.5)	$ 10.3	$ 21.1
Balance (in shares) at Dec. 31, 2019			154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.7	0.7			0.7
Stock options exercised (in shares)			30,182
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			40,516
Stock based compensation	3.0	3.0			3.0
Dividends declared to common stockholders	(7.4)	(6.2)				(6.2)		(1.2)
Acquired 80% interest in Hain LifeScience GmbH	(1.3)	(1.3)				(1.3)			(20.6)
Consolidated net income	10.6	10.5				10.5		0.1
Other comprehensive income (loss)	2.0	2.2					2.2	(0.2)	$ (0.5)
Balance at end of period at Mar. 31, 2020	924.6	915.6	$ 1.7	$ (543.8)	203.3	1,277.7	(23.3)	9.0
Balance (in shares) at Mar. 31, 2020			154,226,496	19,346,577
Balance at beginning of period at Dec. 31, 2020	974.3	961.2	$ 1.7	$ (667.0)	216.3	1,406.5	3.7	13.1
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.2	1.2			1.2
Stock options exercised (in shares)			65,312
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			21,821
Stock based compensation	3.4	3.4			3.4
Shares purchased	(32.8)	(32.8)		$ (32.8)
Shares purchased (in shares)			(530,729)	530,729
Dividends declared to common stockholders	(6.1)	(6.1)				(6.1)
Consolidated net income	57.8	56.7				56.7		1.1
Other comprehensive income (loss)	(16.0)	(15.8)					(15.8)	(0.2)
Balance at end of period at Mar. 31, 2021	$ 981.7	$ 967.7	$ 1.7	$ (699.8)	$ 220.8	$ 1,457.1	$ (12.1)	$ 14.0
Balance (in shares) at Mar. 31, 2021			151,543,485	22,589,258

XML 16 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Dividends declared (per share)	$ 0.04	$ 0.04
Hain
Interest acquired		20.00%

XML 17 R7.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Consolidated net income	$ 57.8	$ 10.6
Adjustments to reconcile consolidated net income to cash flows from operating activities:
Depreciation and amortization	22.3	19.0
Stock-based compensation expense	3.8	3.3
Deferred income taxes	4.9	1.1
Other non-cash expenses, net	4.9	11.7
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable	0.8	29.5
Inventories	(41.6)	(61.0)
Accounts payable and accrued expenses	35.5	19.1
Income taxes payable	10.1	(15.0)
Deferred revenue	14.1	20.6
Customer advances	2.5	16.5
Other changes in operating assets and liabilities, net	(17.1)	(20.4)
Net cash provided by operating activities	98.0	35.0
Cash flows from investing activities:
Purchases of short-term investments		(50.0)
Cash paid for acquisitions, net of cash acquired	(4.0)	(22.0)
Purchases of property, plant and equipment	(24.7)	(30.5)
Proceeds from sales of property, plant and equipment	1.2
Net proceeds from cross-currency swap agreements	3.5	1.9
Net cash used in investing activities	(24.0)	(100.6)
Cash flows from financing activities:
Proceeds from revolving lines of credit		197.5
Repayment of other debt	(0.4)	(0.3)
Proceeds from other debt	0.3	1.2
Proceeds from issuance of common stock, net	1.1	0.6
Payment of contingent consideration	(0.4)	(0.3)
Payment of dividends to common stockholders	(6.1)	(6.2)
Purchases of common stock	(32.6)
Cash payments to noncontrolling interest		(1.2)
Net cash (used in) provided by financing activities	(38.1)	191.3
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(21.0)	(8.7)
Net change in cash, cash equivalents and restricted cash	14.9	117.0
Cash, cash equivalents and restricted cash at beginning of period	685.5	681.9
Cash, cash equivalents and restricted cash at end of period	700.4	798.9
Supplemental disclosure of cash flow information:
Restricted cash period beginning balance	3.7	3.6
Restricted cash period ending balance	$ 3.6	$ 3.4

XML 18 R8.htm IDEA: XBRL DOCUMENT

Description of Business

3 Months Ended

Mar. 31, 2021

Description of Business

Description of Business

1.	Description of Business

in-vitro

diagnostics, nanotechnology and materials science research.

The Company has four operating segments,

Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) Nano Segment

and

Bruker Energy

& Supercon Technologies (BEST)

. The Company has three reportable segments,

BSI Life Science Segment, BSI NANO Segment

and

BEST

Bruker BioSpin

Bruker CALID (Chemicals, Applied Markets, Life Science,

In-Vitro

Diagnostics, Detection)

for-profit

forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.

The BSI NANO Segment designs, manufactures and distributes advanced

X-ray

instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and

X-ray

metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile

X-ray

The BEST reportable segment develops and manufactures superconducting and

non-superconducting

10-Q

and Article 10 of Regulation

S-X.

At March 31, 2021, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form

10-K

for the year ended December 31, 2020, have not changed.

Risks and Uncertainties

The Company is subject to risks common to its industry including, but not limited to, global economic conditions, rapid technological change, government and academic funding levels, the impact of the

COVID-19

The impact of the

COVID-19

COVID-19,

COVID-19

cases or new strains of the virus. A number of states, including California, Massachusetts and New Jersey where the Company has significant operations have implemented phased

re-opening

policies as vaccines to protect against the virus continue to be administered. However, many of the Company’s employees in these areas continue to work remotely, and any

re-openings

re-opened

their sites, many still operate at productivity levels that are below

pre-pandemic

The Company is continuing to monitor and assess the effects of the

COVID-19

COVID-19,

the effectiveness and availability of

COVID-19

XML 19 R9.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

3 Months Ended

Mar. 31, 2021

Recent Accounting Pronouncements

Recent Accounting Pronouncements

2.	Recent Accounting Pronouncements

In March 2020, the FASB issued Accounting Standards Updates (“ASU”)

No. 2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

(“ASU

2020-04”),

held-to-maturity.

In January 2021, the FASB issued ASU

2021-01,

Reference Rate Reform (Topic 848)

In January 2020, the FASB issued ASU

2020-01-

In December 2019, the FASB issued ASU

2019-12

- Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Revenue

3 Months Ended

Mar. 31, 2021

Revenue

Revenue

The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Revenue by Group:
Bruker BioSpin	$	159.4		$	120.9
Bruker CALID		192.4			140.5
Bruker Nano		154.4			120.1
BEST		52.4			46.2
Eliminations		(3.9	)		(3.7	)

Total revenue	$	554.7		$	424.0


	Three Months Ended March 31,
	2021		2020
Revenue by End Customer Geography:
United States	$	119.0	$	109.4
Germany		70.1		40.9
Rest of Europe		149.8		104.0
Asia Pacific		180.5		137.2
Other		35.3		32.5

Total revenue	$	554.7	$	424.0

Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Revenue recognized at a point in time	$	480.0	$	367.7
Revenue recognized over time		74.7		56.3

Total revenue	$	554.7	$	424.0

Remaining Performance Obligations

Contract Balances

Contract assets—

Contract liabilities—

COVID-19

on the global economy. Approximately $121.4 million of the contract liability balance on December 31, 2020 was recognized as revenue during the three months ended March 31, 2021.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Acquisitions

3 Months Ended

Mar. 31, 2021

Acquisitions

Acquisitions

4.	Acquisitions

2021

In the three months ended March 31, 2021, the Company made investments in businesses complementary to its own portfolio

. The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions):


Name	Acquisition / Investment		Date Acquired		Segment		Consideration		Cash Consideration
Glycopath Inc.		Investment		February 18, 2021		BSI Life Science	$	2.0	$	2.0
IonPath Inc		Investment		March 18, 2021		BSI Life Science		2.0		2.0
Acuity Spatial Genomics, Inc.		Investment		February 24, 2021		BSI Nano		4.5		4.5

							$	8.5	$	8.5

XML 22 R12.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2021

Inventories

Inventories

5.	Inventories

Inventories consisted of the following (dollars in millions):


	March 31, 2021		December 31, 2020
Raw materials	$	197.1	$	198.8
Work-in-process		253.2		245.7
Finished goods		157.0		152.1
Demonstration units		93.4		95.7

Inventories	$	700.7	$	692.3

Finished goods include

in-transit

inventory-in-transit

was $59.6 million and $67.8 million, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets

Goodwill and Intangible Assets

6.	Goodwill and Intangible Assets

Goodwill

The following table sets forth the changes in the carrying amount of goodwill (dollars in millions):


	Total
Balance at December 31, 2020	$	320.4
Current period additions/adjustments		(0.3	)
Foreign currency impact		(6.8	)

Balance at March 31, 2021	$	313.3

Intangible Assets

The following is a summary of intangible assets, excluding goodwill (dollars in millions):


	March 31, 2021							December 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Existing technology and related patents	$	299.0	$	(192.3	)	$	106.7	$	309.8	$	(194.6	)	$	115.2
Customer relationships		144.4		(48.0	)		96.4		148.3		(45.4	)		102.9
Trade names		14.8		(4.7	)		10.1		15.2		(4.4	)		10.8
Other		0.3		(0.1	)		0.2		0.3		(0.1	)		0.2

Intangible assets	$	458.5	$	(245.1	)	$	213.4	$	473.6	$	(244.5	)	$	229.1

For the three months ended March 31, 2021 and 2020, the Company recorded amortization expense of $8.9 million and $8.7 million, respectively, related to intangible assets subject to amortization.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Debt

3 Months Ended

Mar. 31, 2021

Debt

Debt

The Company’s debt obligations consisted of the following (dollars in millions):


	March 31, 2021			December 31, 2020
US Dollar notes under the 2012 Note Purchase Agreement	$	205.0		$	205.0
CHF notes (in dollars) under the 2019 Note Purchase Agreement		314.8			335.5
US Dollar notes under the 2019 Term Loan		300.0			300.0
Unamortized debt issuance costs		(2.3	)		(2.4	)
Capital lease obligations and other loans		6.7			6.4

Total debt		824.2			844.5
Current portion of long-term debt		(108.4	)		(2.2	)

Total long-term debt, less current portion	$	715.8		$	842.3


	Weighted Average Interest Rate			Total Amount Committed by Lenders		Outstanding Borrowings		Outstanding Letters of Credit		Total Committed Amounts Available
2019 Credit Agreement		1.3	%	$	600.0	$	—	$	0.2	$	599.8
Bank guarantees and working capital line		0.0	%		120.2		—		120.2		—

Total revolving lines of credit				$	720.2	$	—	$	120.4	$	599.8

As of March 31, 2021, the Company was in compliance with the financial covenants of all debt agreements.

As of March 31, 2021, the Company ha

gains of

XML 25 R15.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2021

Fair Value of Financial Instruments

Fair Value of Financial Instruments

8.	Fair Value of Financial Instruments


March 31, 2021	Total		Quoted Prices in Active Markets Available (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Time deposits and money market funds	$	151.1	$	—	$	151.1	$	—
Short-term investments		50.0		—		50.0		—
Interest rate and cross currency swap agreements		7.1		—		7.1		—
Forward currency contracts		0.1		—		0.1		—
Fixed price commodity contracts		3.8		—		3.8		—
Debt securities available for sale		1.2		—		—		1.2

Total assets recorded at fair value	$	213.3	$	—	$	212.1	$	1.2

Liabilities:
Contingent consideration	$	3.3	$	—	$	—	$	3.3
Hybrid instrument liability		13.8		—		—		13.8
Interest rate and cross currency swap agreements		33.3		—		33.3		—
Embedded derivatives in purchase and delivery contracts		0.3		—		0.3		—
Forward currency contracts		1.3		—		1.3		—

Total liabilities recorded at fair value	$	52.0	$	—	$	34.9	$	17.1


December 31, 2020	Total		Quoted Prices in Active Markets Available (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Time deposits and money market funds	$	183.2	$	—	$	183.2	$	—
Short-term investments		50.0		—		50.0		—
Interest rate and cross currency swap agreements		7.6		—		7.6		—
Forward currency contracts		2.1		—		2.1		—
Embedded derivatives in purchase and delivery contracts		0.1		—		0.1		—
Fixed price commodity contracts		3.1		—		3.1		—
Debt securities available for sale		1.2		—		—		1.2

Total assets recorded at fair value	$	247.3	$	—	$	246.1	$	1.2

Liabilities:
Contingent consideration	$	4.3	$	—	$	—	$	4.3
Hybrid instrument liability		13.9		—		—		13.9
Interest rate and cross currency swap agreements		61.5		—		61.5		—
Forward currency contracts		0.4		—		0.4		—

Total liabilities recorded at fair value	$	80.1	$	—	$	61.9	$	18.2

dates. The carrying value of our variable rate debt approximates its fair value at March 31, 2021 and December 31, 2020.

The following table sets forth the changes in contingent consideration liabilities (dollars in millions):


Balance at December 31, 2020	$	4.3
Current period adjustments		(0.5	)
Current period settlements		(0.4	)
Foreign currency effect		(0.1	)

Balance at March 31, 2021	$	3.3

The following table sets forth the changes in hybrid instrument liability (dollars in millions):


Balance at December 31, 2020	$	13.9
Current period adjustments		0.4
Foreign currency effect		(0.5	)

Balance at March 31, 2021	$	13.8

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

9.	Derivative Instruments and Hedging Activities

Commodity Price Risk Management

Foreign Exchange Rate Risk Management

The Company had the following notional amounts outstanding under foreign exchange contracts and cross-currency interest rate swap agreements (in millions):


	March 31, 2021					December 31, 2020
	Notional Amount in U.S. Dollars		Fair Value			Notional Amount in U.S. Dollars		Fair Value
Forward Currency Contracts (1):
Assets	$	10.0	$	0.1		$	175.8	$	2.1
Liabilities		121.3		(1.3	)		102.5		(0.4	)
Cross-Currency and Interest Rate Swap Agreements (2):
Liabilities		505.0		(26.2	)		505.0		(53.9	)

	$	636.3	$	(27.4	)	$	783.3	$	(52.2	)

(1)	Derivatives not designated as accounting hedges.

(2)	Derivatives designated as accounting hedges.

The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets as follows (dollars in millions):


	March 31, 2021			December 31, 2020
Derivatives designated as hedging instruments
Interest rate cross-currency swap agreements
Other current assets	$	7.1		$	7.6
Other current liabilities		(9.3	)		(4.3	)
Other long-term liabilities		(24.0	)		(57.2	)

Total derivatives designated as hedging instruments		(26.2	)		(53.9	)

Derivatives not designated as hedging instruments
Forward currency contracts
Other current assets	$	0.1		$	2.1
Other current liabilities		(1.3	)		(0.4	)
Embedded derivatives in purchase and delivery contracts
Other current assets		—			0.1
Other current liabilities		(0.3	)		—
Fixed price commodity contracts
Other current assets		3.8			3.1

Total derivatives not designated as hedging instruments		2.3			4.9

Total derivatives	$	(23.9	)	$	(49.0	)


		Three Months Ended March 31,
	Financial Statement Classification	2021			2020
Derivatives not designated as hedging instruments
Forward currency contracts	Interest and other income (expense), net	$	(5.0	)	$	(0.5	)
Embedded derivatives in purchase and delivery contracts	Interest and other income (expense), net		(0.4	)		0.6

		$	(5.4	)	$	0.1

Derivatives designated as Cash Flow hedging instruments
Interest rate cross-currency swap agreements
Interest incurred	Interest and other income (expense), net	$	(1.1	)	$	—
Unrealized gains (losses) on contracts	Accumulated other comprehensive income		9.9			(19.0	)

		$	8.8		$	(19.0	)

Derivatives designated as Net Investment hedging instruments
Interest rate cross-currency swap agreements
Interest earned	Interest and other income (expense), net	$	2.5		$	2.6
Unrealized gains on contracts	Accumulated other comprehensive income		17.8			29.9

		$	20.3		$	32.5

XML 27 R17.htm IDEA: XBRL DOCUMENT

Provision for Income Taxes

3 Months Ended

Mar. 31, 2021

Income Taxes

Provision for Income Taxes

10.	Provision for Income Taxes

tax. The increase in our effective tax rate was primarily due to the jurisdictional mix and the impact of unfavorable discrete items in the period.

On March 27, 2020 the House passed the Coronavirus Aid, Relief, and Economic Security Act (The

CARES Act

), also known as the Third

COVID-19

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Earnings Per Share

3 Months Ended

Mar. 31, 2021

Earnings Per Share

Earnings Per Share

11.	Earnings Per Share


	Three Months Ended March 31,
	2021		2020
Net income attributable to Bruker Corporation, as reported	$	56.7	$	10.5
Weighted average shares outstanding:
Weighted average shares outstanding-basic		151.8		154.2
Effect of dilutive securities:
Stock options and restricted stock awards and units		1.4		1.2

		153.2		155.4

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.37	$	0.07

Diluted	$	0.37	$	0.07


	Three Months Ended March 31,
	2021		2020
Stock options		—		0.1
Unvested restricted stock units		—		—

XML 29 R19.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

3 Months Ended

Mar. 31, 2021

Shareholders' Equity

Shareholders' Equity

12.	Shareholders’ Equity

Share Repurchase Program

Accumulated Other Comprehensive Income (Loss)

The following is a summary of comprehensive income (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Consolidated net income	$	57.8		$	10.6
Foreign currency translation adjustments		(19.5	)		(13.0	)
Pension liability adjustments, net of tax		3.3			14.5

Net comprehensive income		41.6			12.1
Less: Comprehensive income (loss) attributable to noncontrolling interests		0.9			(0.1	)
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		—			(0.5	)

Comprehensive income attributable to Bruker Corporation	$	40.7		$	12.7

The following is a summary of the components of accumulated other comprehensive income (loss), net of tax (dollars in millions):


	Foreign Currency Translation			Pension Liability Adjustment			Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2020	$	49.4		$	(45.7	)	$	3.7
Other comprehensive income (loss) before reclassifications		(19.1	)		2.6			(16.5	)
Realized loss on amounts reclassified from other comprehensive income (loss), net of tax		—			0.7			0.7

Net current period other comprehensive income (loss)		(19.1	)		3.3			(15.8	)

Balance at March 31, 2021	$	30.3		$	(42.4	)	$	(12.1	)

Stock-Based Compensation

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Costs of product revenue	$	0.5	$	0.5
Selling, general and administrative		2.4		2.0
Research and development		0.5		0.5

Total stock-based compensation	$	3.4	$	3.0

XML 30 R20.htm IDEA: XBRL DOCUMENT

Other Charges, Net

3 Months Ended

Mar. 31, 2021

Other Charges (Gain), Net

Other Charges, Net

13.	Other Charges, Net

Other Charges, Net

The components of other charges, net were as follows (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Information technology transformation costs	$	0.7	$	0.9
Professional fees incurred in connection with investigation matters		0.1		3.4
Restructuring charges		1.3		1.5
Acquisition-related charges		0.9		(1.1	)
Long-lived asset impairments		—		1.2
Other		—		0.3

Other charges, net	$	3.0	$	6.2

Restructuring Initiatives


	Three Months Ended March 31,
	2021		2020
Cost of revenues	$	1.1	$	0.8
Other charges, net		1.3		1.5

	$	2.4	$	2.3

The following table sets forth the changes in restructuring reserves (dollars in millions):


	Total			Severance			Exit Costs			Provisions for Excess Inventory
Balance at December 31, 2020	$	9.8		$	7.6		$	0.8		$	1.4
Restructuring charges		2.4			2.2			0.2			—
Cash payments		(5.2	)		(4.7	)		(0.5	)		—
Other, non-cash adjustments and foreign currency effect		(0.1	)		—			—			(0.1	)

Balance at March 31, 2021	$	6.9		$	5.1		$	0.5		$	1.3

XML 31 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2021

Commitments And Contingencies

Commitments and Contingencies

14.	Commitments and Contingencies

In accordance with ASC Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages or other costs to the extent specific losses are probable and estimable.

Litigation and Related Contingencies

4.0

million payment in the second quarter of 2021 and agreed

As of March 31, 2021 and December 31, 2020, no material accruals have been recorded for potential contingencies.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Business Segment Information

3 Months Ended

Mar. 31, 2021

Business Segment Information

Business Segment Information

15.	Business Segment Information

The Company has three reportable segments, BSI Life Science, BSI NANO and BEST, as discussed in Note 1 to the consolidated financial statements.

Revenue and operating income by reportable segment are presented below (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Revenue:
BSI Life Science	$	351.8		$	261.4
BSI NANO		154.4			120.1
BEST		52.4			46.2
Eliminations (a)		(3.9	)		(3.7	)

Total revenue	$	554.7		$	424.0

Operating Income (loss)
BSI Life Science	$	88.9		$	39.5
BSI NANO		12.3			(8.0	)
BEST		4.1			1.7
Corporate, eliminations and other (b)		(16.2	)		(16.8	)

Total operating income	$	89.1		$	16.4

(a)	Represents product and service revenue between reportable segments.

(b)	Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by reportable segment are as follows (dollars in millions):


	March 31, 2021			December 31, 2020
Assets:
BSI Life Science, BSI NANO & Corporate	$	2,947.8		$	2,964.5
BEST		92.3			88.7
Eliminations and other (a)		(5.2	)		(4.2	)

Total assets	$	3,034.9		$	3,049.0

(a)	Assets not allocated to the reportable segments and eliminations of intercompany transactions.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

3 Months Ended

Mar. 31, 2021

Revenue

Schedule of revenues disaggregated by Group, end customer geographical location and timing of recognition

The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Revenue by Group:
Bruker BioSpin	$	159.4		$	120.9
Bruker CALID		192.4			140.5
Bruker Nano		154.4			120.1
BEST		52.4			46.2
Eliminations		(3.9	)		(3.7	)

Total revenue	$	554.7		$	424.0


	Three Months Ended March 31,
	2021		2020
Revenue by End Customer Geography:
United States	$	119.0	$	109.4
Germany		70.1		40.9
Rest of Europe		149.8		104.0
Asia Pacific		180.5		137.2
Other		35.3		32.5

Total revenue	$	554.7	$	424.0

Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Revenue recognized at a point in time	$	480.0	$	367.7
Revenue recognized over time		74.7		56.3

Total revenue	$	554.7	$	424.0

XML 34 R24.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2021

2021 Acquisitions

Acquisitions

Schedule of components and fair value allocation of the consideration transferred in connection with acquisitions

The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions):


Name	Acquisition / Investment		Date Acquired		Segment		Consideration		Cash Consideration
Glycopath Inc.		Investment		February 18, 2021		BSI Life Science	$	2.0	$	2.0
IonPath Inc		Investment		March 18, 2021		BSI Life Science		2.0		2.0
Acuity Spatial Genomics, Inc.		Investment		February 24, 2021		BSI Nano		4.5		4.5

							$	8.5	$	8.5

XML 35 R25.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2021

Inventories

Schedule of inventories

Inventories consisted of the following (dollars in millions):


	March 31, 2021		December 31, 2020
Raw materials	$	197.1	$	198.8
Work-in-process		253.2		245.7
Finished goods		157.0		152.1
Demonstration units		93.4		95.7

Inventories	$	700.7	$	692.3

XML 36 R26.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets

Schedule of changes in the carrying amount of goodwill

The following table sets forth the changes in the carrying amount of goodwill (dollars in millions):


	Total
Balance at December 31, 2020	$	320.4
Current period additions/adjustments		(0.3	)
Foreign currency impact		(6.8	)

Balance at March 31, 2021	$	313.3

Summary of intangible assets

The following is a summary of intangible assets, excluding goodwill (dollars in millions):


	March 31, 2021							December 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Existing technology and related patents	$	299.0	$	(192.3	)	$	106.7	$	309.8	$	(194.6	)	$	115.2
Customer relationships		144.4		(48.0	)		96.4		148.3		(45.4	)		102.9
Trade names		14.8		(4.7	)		10.1		15.2		(4.4	)		10.8
Other		0.3		(0.1	)		0.2		0.3		(0.1	)		0.2

Intangible assets	$	458.5	$	(245.1	)	$	213.4	$	473.6	$	(244.5	)	$	229.1

XML 37 R27.htm IDEA: XBRL DOCUMENT

Debt (Tables)

3 Months Ended

Mar. 31, 2021

Debt

Components of debt obligations

The Company’s debt obligations consisted of the following (dollars in millions):


	March 31, 2021			December 31, 2020
US Dollar notes under the 2012 Note Purchase Agreement	$	205.0		$	205.0
CHF notes (in dollars) under the 2019 Note Purchase Agreement		314.8			335.5
US Dollar notes under the 2019 Term Loan		300.0			300.0
Unamortized debt issuance costs		(2.3	)		(2.4	)
Capital lease obligations and other loans		6.7			6.4

Total debt		824.2			844.5
Current portion of long-term debt		(108.4	)		(2.2	)

Total long-term debt, less current portion	$	715.8		$	842.3

Summary of maximum commitments and net amounts available under the 2015 Credit Agreement and other lines of credit


	Weighted Average Interest Rate			Total Amount Committed by Lenders		Outstanding Borrowings		Outstanding Letters of Credit		Total Committed Amounts Available
2019 Credit Agreement		1.3	%	$	600.0	$	—	$	0.2	$	599.8
Bank guarantees and working capital line		0.0	%		120.2		—		120.2		—

Total revolving lines of credit				$	720.2	$	—	$	120.4	$	599.8

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 38 R28.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2021

Fair Value of Financial Instruments

Schedule of financial instruments measured at fair value on a recurring basis


March 31, 2021	Total		Quoted Prices in Active Markets Available (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Time deposits and money market funds	$	151.1	$	—	$	151.1	$	—
Short-term investments		50.0		—		50.0		—
Interest rate and cross currency swap agreements		7.1		—		7.1		—
Forward currency contracts		0.1		—		0.1		—
Fixed price commodity contracts		3.8		—		3.8		—
Debt securities available for sale		1.2		—		—		1.2

Total assets recorded at fair value	$	213.3	$	—	$	212.1	$	1.2

Liabilities:
Contingent consideration	$	3.3	$	—	$	—	$	3.3
Hybrid instrument liability		13.8		—		—		13.8
Interest rate and cross currency swap agreements		33.3		—		33.3		—
Embedded derivatives in purchase and delivery contracts		0.3		—		0.3		—
Forward currency contracts		1.3		—		1.3		—

Total liabilities recorded at fair value	$	52.0	$	—	$	34.9	$	17.1


December 31, 2020	Total		Quoted Prices in Active Markets Available (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Time deposits and money market funds	$	183.2	$	—	$	183.2	$	—
Short-term investments		50.0		—		50.0		—
Interest rate and cross currency swap agreements		7.6		—		7.6		—
Forward currency contracts		2.1		—		2.1		—
Embedded derivatives in purchase and delivery contracts		0.1		—		0.1		—
Fixed price commodity contracts		3.1		—		3.1		—
Debt securities available for sale		1.2		—		—		1.2

Total assets recorded at fair value	$	247.3	$	—	$	246.1	$	1.2

Liabilities:
Contingent consideration	$	4.3	$	—	$	—	$	4.3
Hybrid instrument liability		13.9		—		—		13.9
Interest rate and cross currency swap agreements		61.5		—		61.5		—
Forward currency contracts		0.4		—		0.4		—

Total liabilities recorded at fair value	$	80.1	$	—	$	61.9	$	18.2

Schedule of changes in contingent consideration liabilities

The following table sets forth the changes in contingent consideration liabilities (dollars in millions):


Balance at December 31, 2020	$	4.3
Current period adjustments		(0.5	)
Current period settlements		(0.4	)
Foreign currency effect		(0.1	)

Balance at March 31, 2021	$	3.3

Schedule of changes in hybrid instrument liability

The following table sets forth the changes in hybrid instrument liability (dollars in millions):


Balance at December 31, 2020	$	13.9
Current period adjustments		0.4
Foreign currency effect		(0.5	)

Balance at March 31, 2021	$	13.8

XML 39 R29.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities (Tables)

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities

Schedule of notional amounts outstanding under foreign currency contracts

The Company had the following notional amounts outstanding under foreign exchange contracts and cross-currency interest rate swap agreements (in millions):


	March 31, 2021					December 31, 2020
	Notional Amount in U.S. Dollars		Fair Value			Notional Amount in U.S. Dollars		Fair Value
Forward Currency Contracts (1):
Assets	$	10.0	$	0.1		$	175.8	$	2.1
Liabilities		121.3		(1.3	)		102.5		(0.4	)
Cross-Currency and Interest Rate Swap Agreements (2):
Liabilities		505.0		(26.2	)		505.0		(53.9	)

	$	636.3	$	(27.4	)	$	783.3	$	(52.2	)

(1)	Derivatives not designated as accounting hedges.

(2)	Derivatives designated as accounting hedges.

Schedule of fair value and balance sheet location of derivative instruments

The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets as follows (dollars in millions):


	March 31, 2021			December 31, 2020
Derivatives designated as hedging instruments
Interest rate cross-currency swap agreements
Other current assets	$	7.1		$	7.6
Other current liabilities		(9.3	)		(4.3	)
Other long-term liabilities		(24.0	)		(57.2	)

Total derivatives designated as hedging instruments		(26.2	)		(53.9	)

Derivatives not designated as hedging instruments
Forward currency contracts
Other current assets	$	0.1		$	2.1
Other current liabilities		(1.3	)		(0.4	)
Embedded derivatives in purchase and delivery contracts
Other current assets		—			0.1
Other current liabilities		(0.3	)		—
Fixed price commodity contracts
Other current assets		3.8			3.1

Total derivatives not designated as hedging instruments		2.3			4.9

Total derivatives	$	(23.9	)	$	(49.0	)

Schedule of impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments


		Three Months Ended March 31,
	Financial Statement Classification	2021			2020
Derivatives not designated as hedging instruments
Forward currency contracts	Interest and other income (expense), net	$	(5.0	)	$	(0.5	)
Embedded derivatives in purchase and delivery contracts	Interest and other income (expense), net		(0.4	)		0.6

		$	(5.4	)	$	0.1

Derivatives designated as Cash Flow hedging instruments
Interest rate cross-currency swap agreements
Interest incurred	Interest and other income (expense), net	$	(1.1	)	$	—
Unrealized gains (losses) on contracts	Accumulated other comprehensive income		9.9			(19.0	)

		$	8.8		$	(19.0	)

Derivatives designated as Net Investment hedging instruments
Interest rate cross-currency swap agreements
Interest earned	Interest and other income (expense), net	$	2.5		$	2.6
Unrealized gains on contracts	Accumulated other comprehensive income		17.8			29.9

		$	20.3		$	32.5

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959

+ Details

XML 40 R30.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Earnings Per Share

Computation of basic and diluted weighted average shares outstanding and net income per common share


	Three Months Ended March 31,
	2021		2020
Net income attributable to Bruker Corporation, as reported	$	56.7	$	10.5
Weighted average shares outstanding:
Weighted average shares outstanding-basic		151.8		154.2
Effect of dilutive securities:
Stock options and restricted stock awards and units		1.4		1.2

		153.2		155.4

Net income per common share attributable to Bruker Corporation shareholders:
Basic	$	0.37	$	0.07

Diluted	$	0.37	$	0.07

Schedule of common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive


	Three Months Ended March 31,
	2021		2020
Stock options		—		0.1
Unvested restricted stock units		—		—

XML 41 R31.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2021

Shareholders' Equity

Summary of comprehensive income (loss)


	Three Months Ended March 31,
	2021			2020
Consolidated net income	$	57.8		$	10.6
Foreign currency translation adjustments		(19.5	)		(13.0	)
Pension liability adjustments, net of tax		3.3			14.5

Net comprehensive income		41.6			12.1
Less: Comprehensive income (loss) attributable to noncontrolling interests		0.9			(0.1	)
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		—			(0.5	)

Comprehensive income attributable to Bruker Corporation	$	40.7		$	12.7

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income (loss), net of tax (dollars in millions):


	Foreign Currency Translation			Pension Liability Adjustment			Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2020	$	49.4		$	(45.7	)	$	3.7
Other comprehensive income (loss) before reclassifications		(19.1	)		2.6			(16.5	)
Realized loss on amounts reclassified from other comprehensive income (loss), net of tax		—			0.7			0.7

Net current period other comprehensive income (loss)		(19.1	)		3.3			(15.8	)

Balance at March 31, 2021	$	30.3		$	(42.4	)	$	(12.1	)

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Costs of product revenue	$	0.5	$	0.5
Selling, general and administrative		2.4		2.0
Research and development		0.5		0.5

Total stock-based compensation	$	3.4	$	3.0

XML 42 R32.htm IDEA: XBRL DOCUMENT

Other Charges, Net (Tables)

3 Months Ended

Mar. 31, 2021

Other Charges, Net

Schedule of components of other charges, net

The components of other charges, net were as follows (dollars in millions):


	Three Months Ended March 31,
	2021		2020
Information technology transformation costs	$	0.7	$	0.9
Professional fees incurred in connection with investigation matters		0.1		3.4
Restructuring charges		1.3		1.5
Acquisition-related charges		0.9		(1.1	)
Long-lived asset impairments		—		1.2
Other		—		0.3

Other charges, net	$	3.0	$	6.2

Summary of restructuring charges


	Three Months Ended March 31,
	2021		2020
Cost of revenues	$	1.1	$	0.8
Other charges, net		1.3		1.5

	$	2.4	$	2.3

Schedule of changes in restructuring reserves

The following table sets forth the changes in restructuring reserves (dollars in millions):


	Total			Severance			Exit Costs			Provisions for Excess Inventory
Balance at December 31, 2020	$	9.8		$	7.6		$	0.8		$	1.4
Restructuring charges		2.4			2.2			0.2			—
Cash payments		(5.2	)		(4.7	)		(0.5	)		—
Other, non-cash adjustments and foreign currency effect		(0.1	)		—			—			(0.1	)

Balance at March 31, 2021	$	6.9		$	5.1		$	0.5		$	1.3

XML 43 R33.htm IDEA: XBRL DOCUMENT

Business Segment Information (Tables)

3 Months Ended

Mar. 31, 2021

Business Segment Information

Schedule of revenue, operating income and total assets by reportable segment

Revenue and operating income by reportable segment are presented below (dollars in millions):


	Three Months Ended March 31,
	2021			2020
Revenue:
BSI Life Science	$	351.8		$	261.4
BSI NANO		154.4			120.1
BEST		52.4			46.2
Eliminations (a)		(3.9	)		(3.7	)

Total revenue	$	554.7		$	424.0

Operating Income (loss)
BSI Life Science	$	88.9		$	39.5
BSI NANO		12.3			(8.0	)
BEST		4.1			1.7
Corporate, eliminations and other (b)		(16.2	)		(16.8	)

Total operating income	$	89.1		$	16.4

(a)	Represents product and service revenue between reportable segments.

(b)	Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by reportable segment are as follows (dollars in millions):


	March 31, 2021			December 31, 2020
Assets:
BSI Life Science, BSI NANO & Corporate	$	2,947.8		$	2,964.5
BEST		92.3			88.7
Eliminations and other (a)		(5.2	)		(4.2	)

Total assets	$	3,034.9		$	3,049.0

(a)	Assets not allocated to the reportable segments and eliminations of intercompany transactions.

XML 44 R34.htm IDEA: XBRL DOCUMENT

Description of Business (Details)	3 Months Ended
Description of Business (Details)	Mar. 31, 2021 segment
Description of Business
Number of operating segments	4
Number of reportable segments	3

XML 45 R35.htm IDEA: XBRL DOCUMENT

Revenue - Disaggregation (Details) - USD ($) $ in Millions	3 Months Ended
Revenue - Disaggregation (Details) - USD ($) $ in Millions	Mar. 31, 2021	Mar. 31, 2020
Revenues disaggregated by Group
Total revenue	$ 554.7	$ 424.0
Revenue recognized at a point in time
Revenues disaggregated by Group
Total revenue	480.0	367.7
Revenue recognized over time
Revenues disaggregated by Group
Total revenue	74.7	56.3
United States
Revenues disaggregated by Group
Total revenue	119.0	109.4
Germany
Revenues disaggregated by Group
Total revenue	70.1	40.9
Rest of Europe
Revenues disaggregated by Group
Total revenue	149.8	104.0
Asia Pacific
Revenues disaggregated by Group
Total revenue	180.5	137.2
Other
Revenues disaggregated by Group
Total revenue	35.3	32.5
Bruker BioSpin
Revenues disaggregated by Group
Total revenue	159.4	120.9
Bruker CALID
Revenues disaggregated by Group
Total revenue	192.4	140.5
Bruker Nano
Revenues disaggregated by Group
Total revenue	154.4	120.1
BEST
Revenues disaggregated by Group
Total revenue	52.4	46.2
Eliminations
Revenues disaggregated by Group
Total revenue	$ (3.9)	$ (3.7)

XML 46 R36.htm IDEA: XBRL DOCUMENT

Revenue - Remaining Performance Obligations (Details) $ in Millions	Mar. 31, 2021 USD ($)
Remaining Performance Obligations
Amount of remaining performance obligations	$ 1,940.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Remaining Performance Obligations
Remaining performance obligation expected to be recognized in the given period (as a percent)	65.70%
Duration of expected recognition period for remaining performance obligation	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 \| Minimum
Remaining Performance Obligations
Duration of expected recognition period for remaining performance obligation	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 \| Maximum
Remaining Performance Obligations
Duration of expected recognition period for remaining performance obligation	3 years

XML 47 R37.htm IDEA: XBRL DOCUMENT

Revenue - Contract Balances (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Revenue
Contract assets	$ 48.8	$ 41.8
Contract liabilities	407.5	$ 399.4
Revenue recognition during the period	$ 121.4

XML 48 R38.htm IDEA: XBRL DOCUMENT

Acquisitions - Consideration transferred and reportable segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Cash Consideration	$ 4.0	$ 22.0
2021 Acquisitions
Business Acquisition [Line Items]
Consideration	8.5
Cash Consideration	8.5
Glycopath Inc. \| BSI Life Science
Business Acquisition [Line Items]
Consideration	2.0
Cash Consideration	2.0
IonPath Inc \| BSI Life Science
Business Acquisition [Line Items]
Consideration	2.0
Cash Consideration	2.0
Acuity Spatial Genomics, Inc. \| BSI NANO
Business Acquisition [Line Items]
Consideration	4.5
Cash Consideration	$ 4.5

XML 49 R39.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Inventories
Raw materials	$ 197.1	$ 198.8
Work-in-process	253.2	245.7
Finished goods	157.0	152.1
Demonstration units	93.4	95.7
Inventories	700.7	692.3
Inventory-in-transit	$ 59.6	$ 67.8

XML 50 R40.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Goodwill
Balance at the beginning of the period	$ 320.4
Current period additions/adjustments	(0.3)
Foreign currency impact	(6.8)
Balance at the end of the period	$ 313.3

XML 51 R41.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	$ 458.5		$ 473.6
Accumulated Amortization, intangible assets subject to amortization	(245.1)		(244.5)
Net Carrying Amount, intangible assets subject to amortization	213.4		229.1
Amortization expense related to intangible assets subject to amortization	8.9	$ 8.7
Technology
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	299.0		309.8
Accumulated Amortization, intangible assets subject to amortization	(192.3)		(194.6)
Net Carrying Amount, intangible assets subject to amortization	106.7		115.2
Customer relationships
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	144.4		148.3
Accumulated Amortization, intangible assets subject to amortization	(48.0)		(45.4)
Net Carrying Amount, intangible assets subject to amortization	96.4		102.9
Trade name
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	14.8		15.2
Accumulated Amortization, intangible assets subject to amortization	(4.7)		(4.4)
Net Carrying Amount, intangible assets subject to amortization	10.1		10.8
Other
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	0.3		0.3
Accumulated Amortization, intangible assets subject to amortization	(0.1)		(0.1)
Net Carrying Amount, intangible assets subject to amortization	$ 0.2		$ 0.2

XML 52 R42.htm IDEA: XBRL DOCUMENT

Debt - Components (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Debt
Unamortized debt issuance costs	$ (2.3)	$ (2.4)
Total debt	824.2	844.5
Current portion of long-term debt	(108.4)	(2.2)
Total long-term debt, less current portion	715.8	842.3
2012 Note Purchase Agreement
Debt
Debt, before unamortized debt issuance costs	205.0	205.0
2019 Note Purchase Agreement
Debt
Debt, before unamortized debt issuance costs	314.8	335.5
2019 Term Loan
Debt
Debt, before unamortized debt issuance costs	300.0	300.0
Capital lease obligations and other loans
Debt
Total debt	$ 6.7	$ 6.4

XML 53 R43.htm IDEA: XBRL DOCUMENT

Debt - Revolving Loan Arrangements (Details) $ in Millions	Mar. 31, 2021 USD ($)
Revolving lines of credit
Total Amount Committed by Lenders	$ 720.2
Outstanding Letters of Credit	120.4
Total Committed Amount Available	$ 599.8
2019 Credit Agreement \| US Dollar revolving loan
Revolving lines of credit
Weighted Average Interest Rate (as a percent)	1.30%
Total Amount Committed by Lenders	$ 600.0
Outstanding Letters of Credit	0.2
Total Committed Amount Available	$ 599.8
Bank guarantees and working capital line
Revolving lines of credit
Weighted Average Interest Rate (as a percent)	0.00%
Total Amount Committed by Lenders	$ 120.2
Outstanding Letters of Credit	$ 120.2

XML 54 R44.htm IDEA: XBRL DOCUMENT

Debt - Currency Swaps (Details) - USD ($) $ in Millions	3 Months Ended
Debt - Currency Swaps (Details) - USD ($) $ in Millions	Mar. 31, 2021	Mar. 31, 2020
Debt
Reduction of interest expense by cross-currency and interest swap agreements	$ 1.4	$ 2.6
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	27.7	$ 10.9
US to Swiss Franc
Debt
Notional Amount	150.0
US to Euro
Debt
Notional Amount	$ 355.0

XML 55 R45.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Hierarchy (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Significant Other Observable Inputs (Level 2)
Liabilities:
Fair value of long-term fixed interest rate debt	$ 527.7	$ 549.8
Recurring basis
Assets:
Time deposits and money market funds	151.1	183.2
Short-term investments	50.0	50.0
Interest rate and cross currency swap agreements	7.1	7.6
Forward currency contracts	0.1	2.1
Embedded derivatives in purchase and delivery contracts		0.1
Fixed price commodity contracts	3.8	3.1
Debt securities available for sale	1.2	1.2
Total assets recorded at fair value	213.3	247.3
Liabilities:
Contingent consideration	3.3	4.3
Hybrid instrument liability	13.8	13.9
Interest rate and cross currency swap agreements	33.3	61.5
Embedded derivatives in purchase and delivery contracts	0.3
Forward currency contracts	1.3	0.4
Total liabilities recorded at fair value	52.0	80.1
Recurring basis \| Significant Other Observable Inputs (Level 2)
Assets:
Time deposits and money market funds	151.1	183.2
Short-term investments	50.0	50.0
Interest rate and cross currency swap agreements	7.1	7.6
Forward currency contracts	0.1	2.1
Embedded derivatives in purchase and delivery contracts		0.1
Fixed price commodity contracts	3.8	3.1
Total assets recorded at fair value	212.1	246.1
Liabilities:
Interest rate and cross currency swap agreements	33.3	61.5
Embedded derivatives in purchase and delivery contracts	0.3
Forward currency contracts	1.3	0.4
Total liabilities recorded at fair value	34.9	61.9
Recurring basis \| Significant Unobservable Inputs (Level 3)
Assets:
Debt securities available for sale	1.2	1.2
Total assets recorded at fair value	1.2	1.2
Liabilities:
Contingent consideration	3.3	4.3
Hybrid instrument liability	13.8	13.9
Total liabilities recorded at fair value	$ 17.1	$ 18.2

XML 56 R46.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Mestrelab
Fair value of financial instruments
Remaining ownership percentage under options that can be exercised after 2022	49.00%
Contingent consideration
Changes in contingent consideration liabilities
Balance at December 31, 2020	$ 4.3
Current period adjustments	(0.5)
Current period settlements	(0.4)
Foreign currency effect	(0.1)
Balance at March 31, 2021	3.3
Hybrid instrument
Changes in contingent consideration liabilities
Balance at December 31, 2020	13.9
Current period adjustments	0.4
Foreign currency effect	(0.5)
Balance at March 31, 2021	$ 13.8

XML 57 R47.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities - Risk Management (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Derivative instruments and hedging activities
Fair value, net asset (liability)	$ (23.9)	$ (49.0)
Embedded derivatives in purchase and delivery contracts
Embedded derivatives in purchase and delivery contracts
Notional amount of derivative sale contracts	6.1	7.5
Notional amount of derivative purchase contracts	4.3	4.8
Forward currency and swap agreements
Derivative instruments and hedging activities
Notional Amount	636.3	783.3
Fair value, net asset (liability)	(27.4)	(52.2)
Forward currency contract
Derivative instruments and hedging activities
Notional amount, assets	10.0	175.8
Notional amount, liabilities	121.3	102.5
Not designated as accounting hedges
Assets	0.1	2.1
Liabilities	(1.3)	(0.4)
Fixed price commodity contracts
Derivative instruments and hedging activities
Notional Amount	5.8	8.8
Interest rate cross-currency swap agreements
Derivative instruments and hedging activities
Notional amount, liabilities	505.0	505.0
Designated as accounting hedges
Liabilities	$ (26.2)	$ (53.9)

XML 58 R48.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities - Balance Sheet (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	$ (23.9)	$ (49.0)
Forward currency and swap agreements
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	(27.4)	(52.2)
Embedded derivatives in purchase and delivery contracts \| Other current liabilities
Derivative instruments and hedging activities
Derivative Liability	(0.3)
Designated as hedging instrument
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	(26.2)	(53.9)
Designated as hedging instrument \| Other current assets
Derivative instruments and hedging activities
Derivative Asset	7.1	7.6
Designated as hedging instrument \| Other current liabilities
Derivative instruments and hedging activities
Derivative Liability	(9.3)	(4.3)
Designated as hedging instrument \| Other long-term liabilities
Derivative instruments and hedging activities
Derivative Liability	(24.0)	(57.2)
Not designated as hedging instruments
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	2.3	4.9
Not designated as hedging instruments \| Forward currency contract \| Other current assets
Derivative instruments and hedging activities
Derivative Asset	0.1	2.1
Not designated as hedging instruments \| Forward currency contract \| Other current liabilities
Derivative instruments and hedging activities
Derivative Liability	(1.3)	(0.4)
Not designated as hedging instruments \| Embedded derivatives in purchase and delivery contracts \| Other current assets
Derivative instruments and hedging activities
Derivative Asset		0.1
Not designated as hedging instruments \| Fixed price commodity contracts \| Other current assets
Derivative instruments and hedging activities
Derivative Asset	$ 3.8	$ 3.1

XML 59 R49.htm IDEA: XBRL DOCUMENT

Derivative Instruments and Hedging Activities - Income Statement (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Not designated as hedging instruments
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	$ (5.4)	$ 0.1
Not designated as hedging instruments \| Interest and other income (expense), net \| Forward currency contract
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	(5.0)	(0.5)
Not designated as hedging instruments \| Interest and other income (expense), net \| Embedded derivatives in purchase and delivery contracts
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	(0.4)	0.6
Designated as hedging instrument \| Cash Flow Hedging
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	8.8	(19.0)
Designated as hedging instrument \| Cash Flow Hedging \| Accumulated other comprehensive income \| Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	9.9	(19.0)
Designated as hedging instrument \| Cash Flow Hedging \| Interest and other income (expense), net \| Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	(1.1)
Designated as hedging instrument \| Net Investment Hedging
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	20.3	32.5
Designated as hedging instrument \| Net Investment Hedging \| Accumulated other comprehensive income \| Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	17.8	29.9
Designated as hedging instrument \| Net Investment Hedging \| Interest and other income (expense), net \| Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	$ 2.5	$ 2.6

XML 60 R50.htm IDEA: XBRL DOCUMENT

Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Provision for Income Taxes
Income tax expense (benefit)	$ 27.5	$ 2.9
Effective tax rates (as a percent)	32.20%	21.50%
Unrecognized tax benefits, excluding penalties and interest	$ 24.3		$ 22.7
Accrued interest and penalties related to uncertain tax positions	$ 1.9		$ 1.8
Statutory tax rate (as a percent)	21.00%
Change in tax rate - foreign jurisdictions (as a percent)	5.10%
Germany
Provision for Income Taxes
Statutory tax rate (as a percent)	30.00%
Switzerland
Provision for Income Taxes
Statutory tax rate (as a percent)	20.00%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 61 R51.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Computation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share
Net income attributable to Bruker Corporation, as reported	$ 56.7	$ 10.5
Weighted average shares outstanding:
Weighted average shares outstanding-basic	151.8	154.2
Effect of dilutive securities:
Stock options and restricted stock awards and units (in shares)	1.4	1.2
Weighted-average number of common shares used in computing diluted net income per common share	153.2	155.4
Net income per common share attributable to Bruker Corporation shareholders:
Basic (in dollars per share)	$ 0.37	$ 0.07
Diluted (in dollars per share)	$ 0.37	$ 0.07

XML 62 R52.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Anti-dilutive Stock Options (Details) shares in Millions	3 Months Ended
	Mar. 31, 2020 shares
Stock options
Anti-dilutive securities
Number of shares excluded from the computation of diluted earnings per share	0.1

XML 63 R53.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Share Repurchase and Dividends (Details) - May 2019 Repurchase Program - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	May 03, 2021	May 31, 2019
Shareholders' Equity
Amount approved for repurchase of common stock			$ 300.0
Common stock repurchased during the period (in shares)	530,729
Aggregate cost of common stock repurchased during the period	$ 32.8
Subsequent Event [member]
Shareholders' Equity
Remaining authorization amount for repurchase of common stock		$ 1.7

XML 64 R54.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Summary of comprehensive income (loss)
Consolidated net income	$ 57.8	$ 10.6
Foreign currency translation adjustments	(19.5)	(13.0)
Pension liability adjustments, net of tax	3.3	14.5
Net comprehensive income	41.6	12.1
Less: Comprehensive income (loss) attributable to noncontrolling interests	0.9	(0.1)
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		(0.5)
Comprehensive income attributable to Bruker Corporation	$ 40.7	$ 12.7

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 65 R55.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	$ 974.3
Balance at end of period	981.7
Accumulated Other Comprehensive Income (Loss)
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	3.7
Other comprehensive income (loss) before reclassifications	(16.5)
Realized loss on amounts reclassified from other comprehensive income (loss), net of tax	0.7
Net current period other comprehensive income (loss)	(15.8)
Balance at end of period	(12.1)
Foreign Currency Translation
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	49.4
Other comprehensive income (loss) before reclassifications	(19.1)
Net current period other comprehensive income (loss)	(19.1)
Balance at end of period	30.3
Pension Liability Adjustment
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	(45.7)
Other comprehensive income (loss) before reclassifications	2.6
Realized loss on amounts reclassified from other comprehensive income (loss), net of tax	0.7
Net current period other comprehensive income (loss)	3.3
Balance at end of period	$ (42.4)

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

XML 66 R56.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 3.4	$ 3.0
Additional information
Expected pre-tax stock-based compensation expense	$ 23.4
Weighted average remaining service period	2 years 3 months 18 days
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 0.5	0.5
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	2.4	2.0
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	0.5	0.5
Mestrelab
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 0.4	$ 0.3

XML 67 R57.htm IDEA: XBRL DOCUMENT

Other Charges, Net - Components of other charges (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Other Charges (Gain), Net
Information technology transformation costs	$ 0.7	$ 0.9
Professional fees incurred in connection with investigation matters	0.1	3.4
Restructuring charges	1.3	1.5
Acquisition-related charges	0.9	(1.1)
Long-lived asset impairments		1.2
Other		0.3
Other charges, net	$ 3.0	$ 6.2

XML 68 R58.htm IDEA: XBRL DOCUMENT

Other Charges, Net - Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring charges
Restructuring expenses	$ 2.4	$ 2.3
Cost of revenues
Restructuring charges
Restructuring expenses	1.1	0.8
Other charges, net
Restructuring charges
Restructuring expenses	$ 1.3	$ 1.5

XML 69 R59.htm IDEA: XBRL DOCUMENT

Other Charges, Net - Restructuring Reserves (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Changes in the restructuring reserves
Balance at the beginning of the period	$ 9.8
Restructuring charges	2.4	$ 2.3
Cash payments	(5.2)
Other, non-cash adjustments and foreign currency effect	(0.1)
Balance at the end of the period	6.9
Severance
Changes in the restructuring reserves
Balance at the beginning of the period	7.6
Restructuring charges	2.2
Cash payments	(4.7)
Balance at the end of the period	5.1
Exit Costs
Changes in the restructuring reserves
Balance at the beginning of the period	0.8
Restructuring charges	0.2
Cash payments	(0.5)
Balance at the end of the period	0.5
Provisions for Excess Inventory
Changes in the restructuring reserves
Balance at the beginning of the period	1.4
Other, non-cash adjustments and foreign currency effect	(0.1)
Balance at the end of the period	$ 1.3

XML 70 R60.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) $ in Millions	Mar. 05, 2021 USD ($)
Letters of Credit and Guarantees
Upfront payment	$ 4.0

XML 71 R61.htm IDEA: XBRL DOCUMENT

Business Segment Information (Details) $ in Millions	3 Months Ended
Business Segment Information (Details) $ in Millions	Mar. 31, 2021 USD ($) segment	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)
Business segment information
Number of reportable segments \| segment	3
Total revenue	$ 554.7	$ 424.0
Operating Income (loss)	89.1	16.4
Assets	3,034.9		$ 3,049.0
Eliminations
Business segment information
Total revenue	(3.9)	(3.7)
Corporate, eliminations and other
Business segment information
Operating Income (loss)	(16.2)	(16.8)
Assets	(5.2)		(4.2)
BSI Life Science \| Operating segments
Business segment information
Total revenue	351.8	261.4
Operating Income (loss)	88.9	39.5
Assets	2,947.8		2,964.5
BSI NANO \| Operating segments
Business segment information
Total revenue	154.4	120.1
Operating Income (loss)	12.3	(8.0)
BEST
Business segment information
Total revenue	52.4	46.2
BEST \| Operating segments
Business segment information
Total revenue	52.4	46.2
Operating Income (loss)	4.1	$ 1.7
Assets	$ 92.3		$ 88.7

EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
XH^,!1$^X% MU[&"&QYA]-;>I:#+R(-]Y..@%O">R08T_4L(O, _$<_D\^9>33C-4LBFQ6O6 M"%D#TRIA6A:F]0',(T;K_(&+!0FN4:+2@#M*6X4P?X50"J6^A?O[8CPZ'%-T M><"6$I$239^\I-Q[QWHW*;X9^HU6W]U4A7M_)FATRC-O:+5+6NU:6K]TC!(F M(J-:$YLBL$&XXZ'($,Y_$*&+2Z"LI)SCAZ?X)!E7*;-BC**_E N&U24\L=TI M9GD W6K4W4;WB%K[/7VO<76:6Z?DUJGE]CP#+2AQ$J7@EF(.:YY!M\3L?N4U M]4J87FUH/X51CZ4PRL2:ZU.RY0#MJB)M[[0@5Z77JT\(?NDZK1,N((4%P3I-;IT03+O2/E$BY4MZG.AJ47884Q='*4Y0/L+(?1^ M8AR4_PN&_P%02P,$% @ \9.G4J?JGL35!0 L!P !D !X;"]W;W)K M&ULK5EM;]LJ&/TK*-J'3;J+#3@OG=)(6WNK3=JT M:=UV/Q.;)&BVR062K-+]\1<VV2IS(UDN=F1#;ZGZOOLB M]%7292E816O)> T$75^.WL(W5QDV#9J('XP>9>\[,$-9I041+ MFBN3@NB/ [VB96DR:1S_MDE'79^F8?_[??:;9O!Z,"LBZ14O_V&%VEZ.YB-0 MT#79E^HK/[ZG[8 F)E_.2]G\!\Y2)2&99(G>0OAW0D""D#X1,088/@70"F"GN97 M\>;7-.^:I\/FB2Y&5Q'4500U^;) OENVJ=F:Y:16X+/:4@$^KR05![(JJ2[+ M;J\K\O(C/= 2H%>1_G#7'V[ZPX'^/C*R8B53C,HWD719ERZ+PF\F]' _H26O M-Z\5%158LU^TT!.E+ZA40!!%]7)?*=]\G7J8-CT8'C@L)V@VGBV20W]:/%'9 MQ7C>10W@3SKXDRC\KS3?"\'JC=F<3$8*,NTR3J/U?2LE5='2SKI,LRBV;YJ_ M=,UV7#*]!DA=@(K7]$YO1_%3$^YZ7Q?>Y7_*.NL5"D[@&#XHIR=JCL?(7\YY M!WD>7\Q;+M1I ;#ZH">^V=$^D*<\D_YLI@\01D,&\"XZ>!=1>!\&R]%4-!=< M2F#6 *WS.R"/9 ?(1E :!'[AU&WFU-87,_5#AZEESC2^T[@X$E%8L#FOE="Z MY.? U,&0.C@]0:@7- 3:HW@8!?IWM:)%H7=_004[$*.;TE#V;J\I74M@4_B" MEOJ^B(_BJNTI-(HA0,NX,$ZY-PTW[03+J>Z^JGC!U&/E1 X0W..>%JTO*(36 M\C7$4;37FC6!-#S5D#8@!RV(C3IH5P4D*:D7,';W=V]WMX#C04/ 5A%@7!*^ M<:45G30\J*U7SH59#$0S5J<57L29NQ@A'N.'F#UAV:P7-D1MA0!.SJ&+T.H MG$;+<*77DQ86S2-F:4FF=P,Q5M([]JEGY3@C=X.RX+BMR,"XRKR_6PEFE/K> M@(&RK<2=%ZE'-SP[P1MU$4<_-UV,2BUI]9NU!2.)X$!6/V!<0$Z M'S6^@Z[(I*'5@*S(H'.*#'+U SJE] 2EXRP U(H,BHO,B61*NVF?P#1MZH&S M>$B-R%6>>3I.+_I_@3'TG']=8?6%ARXHL\Z/X&>#W36N;*.I:XS%#B%9+4%Q+SD%\R)4/U[EZ@P+6 M%5F-07&->2*KN.+A6E=/4-"Z(BLP*"XP9[2NR%60H'5%5D!07$">85V1*Q2N M8'N# FBQ51,<5Y-G.D'L.99 Y"P!7U@V#:*VTH+A.9P@MCR/XSQ_CMV+/6<+ MU[9XHL*V!?<>&<6/(&>T+=@]<@1M"[;*@Q]Y"O4D@L$>(7%+Z08%;0NV6H/C M6O,GMJ5-/5@"6<]4M[C=*+T$ EX%6P7"<06*>Y7O-0_Y%!Q]:&DE!,_^T*=@ MR_(XSO+/.U%CE]#=$_4C04/ EO5QG/6?RZ,NJ7L0QX.M\V?I69XR6U+. MXG[_*:?IS/7N+E5Z@H*GZ>IC.7KSVG:7]48$MGEM6S.*O_"1>U MJ?M/XZ'K)GU19=WB L !D !X;"]W;W)K&ULK5;;;MLX$/V5 M@= %6F!KB;(3.X5MH$DV:($-$"1H^TQ+(XM;BO22=)S\_0XE6=*V%IL ?;%( MB7/FS(7'LSQH\]V6B Z>*JGL*BJ=VWV(8YN56'$[T3M4]*70IN*.MF8;VYU! MGM=&E8S3)#F/*RY4M%[6[^[,>JGW3@J%=P;LOJJX>;Y$J0^KB$7'%_=B6SK_ M(EXO=WR+#^B^[.X,[>(.)1<5*BNT H/%*OK(/ERRA3>H3WP5>+"#-?A0-EI_ M]YO/^2I*/".4F#D/P>GQB%NGM]^(1M0&<>+]/2UK]P:,\F$61[ZW35&A.#2JCFR9_:1 P, M4C9BD+8&:SH*,[]%?7JHNZ(-"8TNQ@QV: MC.#I6L*>\FU [WRY+;B2.\BX@@T"/M$I83$'7C@Z0XE,3Q4V['YV,4F2/P)Q MG'=QG >!!CV:#7LT #WOH.?!0ER5G("M[^!LQ O(MN<%AHJRZ#PN@L%<:%^'$]FTR7\>,)"A<=A8MP/O?&^#"I%X2F M&N?_D!J=:+J&0(,U'Q!XGTS.3C-@22].R6LX6'1.XBB'%NP'$K,1$@.%9$$2 MI/ZD[53ZFDSV#%@4])]RD@$[Q8"-,$A[!NE+NX%D*RL[W3K)(?V)PW2L%U@O M:RRL:ZW(]](3:'+6"QP+*]SONUBLESL6%IS77JT6;IA/-IU]ECKU8YU[0V3^K'%5B\0.'># ,56BV]V&RL_-L-4?[R928G2ECH>)!9DFDSFU JF&?.:C=.[>K3::$># M6KTL:31&XP_0]T)K=]QX!]VPO?X/4$L#!!0 ( /&3IU+ZF[&F+00 !$1 M 9 >&PO=V]R:W-H965T,=T*^J!5C&KUF::XFSDKK]5?/4_&*952Y8LURN+,0,J,:3N724VO):%(D M9:E'?'_H993GSG1<7'N4T['8Z)3G[%$BM>^'*ES05O M.E[3)7MF^N?Z4<*95U=)>,9RQ46.)%M,G%O\]8X,34(1\3=G.]4Z1F8J MS,E],G%\@XBE+-:F!(6?+;MC:6HJ 8Y_JZ)./:9);!_OJW\O)@^3F5/%[D3Z M#T_T:N*,')2P!=VD^DGL?K!J0J&I%XM4%=]H5\7Z#HHW2HNL2@8$&<_+7_I: M$=%*P(,3":1*(.!IAF,"^N('TK(9$3D!ZH M=%& KQ#Q">Y)O[.GSUA_A'$@FB*:B0WT@%BT,"!%4W9JN%*L MLGK4DF'HXB.INC&1&_9+%=6PH_\!NZ;-"CWJP!JXP1'TOIA1/_11#7UD[PDA M=U0F8(A2LCQ^*[15.[I&="E9X40V86_J86X^I=6QW[BO?YXFMX4FO6;I=Q^7 M8-AAO2?\Y0T'HOM)GO4N5>E"/U+:UDI;%&*_6/:!QW:<12>ZE'<&#(./P9S M_Y!T>*BPAET?[)XPGYQR0]RX.!Y:=02X8("*+W.J81FA(&$<&^!&0:.D M7;W&=K'==V]/B]6U2K^S$O0$D5;0(:C&4+'=4?]\1YI1MS-[E.F)\EM=?HBM M<6%\8V]?_@IZK"6/S6J492(!GSEK!2>-\1+_4YJ8-$9*[$9ZAM63KA^VV[(D MO2=HY([\]N?$TT%:K[QV [W/-9-,:22A-5 LA5+7M9F>O^Z2QE/)YW@J:3R5 M?-!3WS$KTC76T ^/M;$''4)M?)78WW1G_]FD2&.&Q/Y.^XX?5-F'&XQA:Z6N MYM\3%K;W(24ZK[5?-7\6P(X/)%8H90O(\]T(^)#E_KL\T6)=;&'G0L.&N#A< M,0IOKR8 [B^$T/L3LRNN_P69_@)02P,$% @ \9.G4I A$Y-5! 4A8 M !D !X;"]W;W)K&ULO5C9;N,V%/T50IB'!&@D MD?0ZL UD:3$#3-I@@FF?:8FVB9%$EZ3C!.C'EY1I4;)E66X-Y2'6TC= MR9:+GW)%J0+O:9+)J;=2:OTY"&2THBF1/E_33+]9<)$2I6_%,I!K04F<*Z5) M@,)P$*2$9=YLDC][$;,)WZB$9?1% +E)4R(^'FC"MU,/>OL'W]ERIK'^D7HNZ"P$K.49I+Q# BZF'KW\/,C'AB%7.)/1K>R= U,*G/.?YJ; MK_'4"TU$-*&1,B:(_GFCCS1)C"4=Q]_6J%?X-(KEZ[WUW_+D=3)S(NDC3_YB ML5I-O9$'8KH@FT1]Y]LOU";4-_8BGLC\/]A:V= #T48JGEIE'4'*LMTO>;>% M*"G W@D%9!506P5L%7">Z"ZR/*TGHLAL(O@6"".MK9F+O#:YMLZ&90;&5R7T M6Z;UU.R)"O9&3"G!UTPJL=$0*0E(%H,O-%ZR; GN3:698E2"._! $I)%%+SF M:^SFB2K"$GFKW_QX?0(WGV[!)\ R\,R21*,D)X'201I7060#>M@%A$X$]$R$ M#S#\!: 0P1KUQV;U)QH5ZF%5/="E*>J#BOJ@W!X^7Q]V4)^5K0\IZM/@#Q?^ M<.ZO=][?O914N[KYQLB<);F#V[IZ[@P.HC']6#,"RB'39&^VLZIW%,8\U=^["EZ<#U1D0KS6]Y MG6*:Z.?B T0\4T)72X)_P!]J184%3X'$I=A0PU$1U:@3S,:%OW%;S/98?=0! M-3Z&(/1Q/0(P=!P:GO$NV3(C2J- 9)&@2[PA05@B:MA)2:&C/HBNW0C68K43 M!J4U;CF\1JQ?YJQJQ(X\X3GV; ;B:-63/*^F:CDRA+UN\'&\"/L7X5,+2/^H MTD,?'L)1)S0X 8:C47B.1R\$HQT%0<>,<-@-(H[UX.@J-&3-5-;_V,=A^>\( MI!J=WDGN3;3[^]J>V%>2(%C43;2LD=*,<'8CWQZW+]QWD:!8-N@'/\2IJ/G*VV7>LB3(0 MX=&^4R.$2D+5\!P)HV82OCY:+0G/<2X:=_-1Z2@6GSNAMB,\:Z;"9?"HR^JD MPM+G3C5(Q\JXF97; G>M3YZS38@=5^..Q@2E.<%E@X*Z48DU<:H)JYX==^-F M[F[=7^Q=OUX+%E$-0IKR6"^Z_P6'(VS &ULQ5A=;YL\%/XK5K2+5MH FWQ62:0V MW;1>=*I6[=VU"TZP!CBSG::;]N/?8T,P(0G=NHKUH@%SOI_C\X"G6R&_J80Q MC9ZR-%>S7J+U^L+W592PC"I/K%D.3Y9"9E3#K5SY:BT9C:U2EOHD"(9^1GG> MFT_MVIV<3\5&ISQG=Q*I3991^>.*I6([Z^'>;N$S7R7:+/CSZ9JNV#W37]9W M$N[\RDK,,Y8K+G(DV7+6N\07"S(Q"E;B/\ZVJG:-3"H/0GPS-S?QK!>8B%C* M(FU,4/AY9 N6IL82Q/&]--JK?!K%^O7.^@>;/"3S0!5;B/0KCW4RZXU[*&9+ MNDGU9[']R,J$!L9>)%)E_Z-M*1OT4+116F2E,D20\;SXI4]E(6H*8.>X BD5 M2%.A?T(A+!5"FV@1F4WKFFHZGTJQ1=)(@S5S86MCM2$;GAL8[[6$IQST]/R: M2?Y(32G13:ZTW !$6B&:Q^@CBU<\7Z%+4VFN.5/H'0A%(F/H7E/-C"@ZNV:: M\E2=P\,O]]?H[,TY>H-XCFYYF@)0:NIKB--X\Z,RIJLB)G(BIA#=BEPG"KW/ M8Q;OZ_N07Y4DV25Y15H-WE+IH1"_120@^$@\B]]7#UK"":N:A]9>_X2]3T)# MIRF^RJ&(,:(*)66IN8.@Q4^_\M.W?L+GL>4-;'<.:85MB[]!Y6_0FM=-M@9[ M"#9G#O.'%YTBEFB3PX!)^4_(=06#I8@@%4HUO198%DZ&UHF90H_S=P.O/_4? MZX@="@4>KF3VPA]6X0__'A;T"[: 9I(I;=,0.F%RE^L9>X+QJMCY6UN!7P@F MS9;*&#:RE"R/?J (&EM"D5JJ/:K"'76"[KCR-^X"W<+)8 _=!K:%R*@N$GB# MX^!.JN@G78/[/GM@,0PHL+M#0IG!M][(* %FL29BEL*Z=,BW08$#-[6#3L#' M-9[ 7FF V]S=1Z0";WB\ S!Q*9#6%*Z?P1\P75"5H _P;K-CO[;:N7F/ MPV[00$=(Y9<#NUO 0Z6+N,HDVV2:U> ML9FA$/"ZFYCW4(N&+4QMVTN0M46))%3%#6ZUI6M$5Y*QY]@9.[[!PV[:PE$& M'G72%J.#MIAXDV8CC/Z@$1P)X786>F$C_,%8?\U6<.R$)YVT G$,0H(N6J'T MLC?/\:DW,>+8AK2SS6_ _ G"OLF!<[5=>'Y>$T<4A'2#AF,(TOY)\%IHA =H MD, +&SOSB%1(3KU@$<;3T(K45F+Q-&X7O,",#SI1!Z=V,<5*>C M\_\!4$L#!!0 ( /&3IU(+C_0#:0, -,+ 9 >&PO=V]R:W-H965T M?8!J*T$[5X?D- 8VV>3W+;> M'+NS'5KX];MV0MJRU+!I^]+&CL_Q.?TENJ'7@(8LBFYT.-@:I7$\B$K*1# 9N;DK-1G)RG FX$H1 M794E5?<7P.5Z'"3!X\1GME@:.Q%-1BNZ@&LP-ZLKA:.H92E8"4(S*8B"^3@X M3\YF2=\"W(JO#-9ZYYE8*[=2_K"#3\4XB*TBX) ;2T'Q[PZFP+EE0AT_&]*@ MW=,"=Y\?V=\[\VCFEFJ82OZ-%68Y#DX"4L"<5MQ\ENN/T!AR G/)M?LEZWKM M8!"0O-)&E@T8%91,U/]TTP1B!X \W8"T :1/ ;T#@*P!9"\%]!I ST6FMN+B M,*.&3D9*KHFRJY'-/KA@.C3:9\+F_=HH?,L09R972MXQET0\0^23R&4)Y O= M@"9',S"4<7U,WI*;ZQDY>G5,7A$FR"7C'!%Z%!E48'FBO-GMHMXM/;!;1BZE M,$M-WHD"BGU\A,I;^>FC_(O42WA)54BRY U)XS3IT#-].3SN@,_\\!GDA^![ M;K(V&9GCR_XX&1[R7DO><^2] ^0-G:$; ALL&QK(T2T(F#-SW)7)FFW@V&SU MN)NDP[ _BNYVP]NQ*#QMU^SI[+#WL/?";#\WLXY%:3CL3LZP]3'T^CC/\$Y\U/B>8F]Y^6TU7;J)9HNJ5@ ::+GM+VU10&O,4&^5XKI@KF+ M\R7?AG^K?IAX)2?Q]BJ)O4P? "]B<>_CVKF6DG]?"I-T2Y_^^]P_PYG%SR0_ MV=X#2>:7MV;F 13'K\O'MRW]2>\_1'-;L1-_F?R[:#Y3>@]&,]KI=DI0"]IV%_N"!<-OB\,<*>-PB%I5W4'6 M R-7KJ>ZE08[-/>XQ*X;E%V [^=2FL>!W:#MXR>_ %!+ P04 " #QDZ=2 MC+GQ\X # ";"@ &0 'AL+W=OW?=TC)BN+*6F\> M8I&:RSF'P]',#U*]ZIQ2 [\*+O3"RXTI'X) ISDMB/9E206^V4E5$(-+M0]T MJ2C)G%/!@S@,)T%!F/"6<[?WK)9S61G.!'U6H*NB(.KWBG)Y6'B1=]SXP?:Y ML1O!FU.Z]A]/D;_XL@CF2W1="WY M3Y:9?.'-/,CHCE3<_)"'K[0A-+;Q4LFU^P^'QC;T(*VTD47CC @*)NI?\JL1 MHN. R#T\9Y(QLF[#%N MC,*W#/W,\C-1@HF]AF>J8),31>$.UK(H*T./U!#&]0WNOVP>X?KJ!JX@ M &UM-3 !+X(9?=O9>&*#/A$E ])= MQ&$<]>-:7NX<#<))6_,3%2RX6?R#HJ TZ MH5,ZVE*J5RQWL+1.-MQ*4Y%;C6 ML\XU<;EL2WA;CB?^=!Z\=57[VR@*_7%K]('&N*4Q'M3FI[N - /R1A4VE&-] M82O2AH@,=7L84&O2IID,JG5!FCML$RSM$Z<./>WR'D?^[$2=/JN1'_?+,VUQ M3X=+9[?#1@AR!QGCE6V%H&E:*688U4/"S-H$LT%A-D:FKR!+6R4:4 DL$XWE ME%JQM'M)#D1E];O*]@"XQMM>ZW?3)]?L;R'\T8E8?39GI+IOF=Q?=,1WQR,6 M5;'%:X#:X2TIY!$S5!JI(874M3\\^5I;W!3O=ZI$SZY;']'[GA-/.C1JJGU6 MXXX@'\A&X7M##P,FG"W7>$"?WDM.?T6H73\,-?=$;,^!U[/(C]L2F _X$^O@A]G]5_H0\Z MG_F"JKV;?C2><"5,_0UL=]L)ZY.;*T[V5W;RYAZ;,,OW)[A?>=TAR%# M?XI-6M634+TPLG3#Q%8:'$W<8X[3(U76 -_OI#3'A4W0SJ/+/U!+ P04 M" #QDZ=2LW8&+#P" #Z! &0 'AL+W=OS;)A%CX([4G0/]]QS:D MK%2X)!Y[WILWXQD7!V-WK@5 =E12NWG2(G8/:>JJ%A1W(].!II/&6,613+M- M76>!UP&D9)IGV<=4<:&3L@A[*UL6ID3).SANO8MNB MWTC+HN-;6 /^Z%:6K'1@J84"[831S$(S3Q['#XN9]P\./P4)YD7!!(J] R),AI >>+D^LW\.N5,N&^[@R,K=%4._:]\U5T[-TS(!?2O6?.>SLF-%L**?UAD2)) M\L1I=0J_B.'S*^$G;&DTMHZ]Z!KJM_B44AGRR<_Y+/*;A$MN1VPR_L#R+,^B MPANLDZ%*D\ ZO<(:2V!B"6[P30>^:>";7.%[6V '56\%BIM29P/U[*;4;[W: MT%6:YGP_<*QD3\5EC36*80NL,JKKD8>I(+^@@\[AW H=X0/X?_<9H]^'Z'[B M]V4V&A?I_E)R>M&/"NPV3)VCN+W&V)K#[C#8C[&?_[G'5X'N&(-GPP<8GKOR+U!+ P04 " #Q MDZ=2?9D#@_(" C" &0 'AL+W=O][ Y92ESFQBUU9R-A&Y3E@**TE4SCF5ISM(Q''J=)WS MPII%L38+[FR2T0@VH!^RE<296[&$C$.JF$B)A/W4N>W>+,;&WAI\97!4M3$Q MGFR%>#23+^'4\8P@2&"G#0/%UP'FD"2&"&4\E9Q.=:0!UL=G]D_6=_1E2Q7, M1?*-A3J>.B.'A+"G>:+7XO@92G_ZAF\G$F6?Y%C:>@[9Y4H+7H)1 6=I\:;/ M91QJ .1I!O@EP'\)""X @A(0_"N@5P)Z-C*%*S8."ZKI;"+%D4ACC6QF8(-I MT>@^2\VU;[3$788X/=O$5$(LDA"D>D_NGW*F3^0CLH:39?T1'RO.ZY;KZ2().6X^[!9D*MWU^0=82E9LB3!RU83 M5Z-T(\#=E3+O"IG^!9D!68I4QXK>W$BZI[)"@^P&E M^]T&/?/7X"?B!1?1B]?1Q=G=<8LO076'@:4+WG"'+;2]BK9G:7L7:&^YR%-- M:)9)<8"08(W!#[VZ8[$G.\$Y?KN8I+O'IB@4_"/+;^K/819XWL0]-(CJ5Z+Z MK:+FM2-K:D(2YI*E$=$QD PD$R&YPHQ3)C3JNBGABG/Z-7']P!OZXV9]@TK? MH#UH420AHAHP.$J_#%*[XB:5Q6F#>@C]SJA9X[#2.&S5N,FW"IYRP,N]/YCG M=PY\"_)'2]*,*N[1_\S%<44[;I6\!M/"3+AHKF,AV4]:M(TB1]^P74$L#!!0 ( /&3 MIU)LX>'+2 , )P) 9 >&PO=V]R:W-H965T^HK82+4Q#@@F!V#Z[S;7Q<.QBNQ3^_Y#E5[U/@"2%)=UP\R"WWZ%TJ&OM+237[I=L2]G0(XN--C(OE9$@9Z+XIV]E M(&H*:*==(2X5XJ9"YX!"4BHDSM&"S+EU10V=C)3<$F6ET9H=N-@X;?2&"7N, MCT;A5X9Z9O*84069Y"DH_952?G9"9SS(K,'M10E(M+ M0N22+'8BR\K(ZX1I3:/"EXDZ-<=VH/L5=/\H] ^D:LNW-L;^WOZ=J';2!>2^ M4!3[43ODH((<'(6\!:TO&@5GYUH0:HQB\XVA7C(JV'EU? _>Z4@!6S1=G; P;8Z-FQC/Y V4?C9%,*_ ME)$6[B;P5&V>0:&/:BV5N[VMA3_<*R&=T.\WCJ!%"C.KW_ CJ/6Y'-3*M7^- M*;X1IN@-U6KUQ+ATC;6Q/K5/#]<_/\T4[Q:L_"LF-.&P1),(BE5$%4^!8F+D MVG73N338F]TPP^<3*"N WY=2FH^)W:!ZD$W^ %!+ P04 " #QDZ=2?MT, MB^4# "E$ &0 'AL+W=ODXV:??(:5(-FRQ#F 4 MN8EUFN$W,^1/3B9;I7^8G#&+'@LAS33*K5U_B&.3YJR@IJ/63,*;I=(%M7"K M5[%9:T8S;U2(F"3)("XHE]%LXI_=ZME$;:S@DMUJ9#9%0?73G FUG48X>GYP MQU>Y=0_BV61-5^R>V6_K6PUW<>TEXP63ABN)-%M.HTO\84[ZSL!_\9VSK=FY M1BZ4A5(_W,VG;!HECH@)EEKG@L+/ [MB0CA/P/&SMG[W_ZX"&8 M!37L2HE_>&;S:32*4,:6="/LG=K^Q:J /&"JA/%_T;;Z-HE0NC%6%94Q$!1< MEK_TL4K$C@'!+0:D,B">NQS(4UY32V<3K;9(NZ_!F[OPH7IK@./25>7>:GC+ MP<[.[G.J6:Y$QK3Y WW\N>'V";U'EVFZ*3:"6I:A+S9G&EVI LJ>NWH\,/1) MIJI@Z.*S,N8MNKAFEG(!5V\0E^B&"P$9-Y/8 J$;)TXKFGE)0UIHNNA&29L; M]%%F+-NWCR&R.CSR'-Z4-U!7?P.D83@;_?7Z.+-VX#;;IVUKG?;;16B)(#H)<UTQSE1VK1.EOX/VYM?LP&P][G>XD?CB"T:\Q^J=B M,)F% 4I/PUV $>X,CP,,:H!!$.!%$S>0]V$]WO"5S(11330Z\TP8'12BVU:& M<0TQ#D)\:8T670BO&0L&6PH#84\%-88O>4IMFVB,#P#?XT&G?QP1)XWT)4'( M.T8%_P]JXXB0VR(*M7&E:Z#@Y5*K(E"]*I[V(E:ZEQS$D+0E&>^(-PY&\#>, MF6ZTA@E7U??7I$?I\)$,]SNC%C[2\)&SR4'E:I^!=' +0R/5N!MD@,T;MF:) MKGR>TB?T55-IA)]M@>6&&^7%O5 MGU<(JL'VY\BX=8XT(HZ'OV<=#5_$UT@Z/EG3?[V.CLAYTK:OXT;0<5C1;ZN3 M^&=.%URX4^)E]B^<3^&$;D,'M4:-2?)*EA%I])6$]?7ERX@<4=)>OTWI2:.D M)*RDYUU'Y%!K26?0PM@H+0DK[>_<3RN4D_93TD@Y"9^BSZ4#U3#[1ZJ6)4@: M42?G.UQ7K@9[\Y _++L/)O/RP8>6BU8 M(08)M@13* 80Z+(G+F^L6OL^=*$L=+7^,F<4&D_W ;Q?*F6?;]P ]7\F9O\# M4$L#!!0 ( /&3IU)=QL!FE@, #8- 9 >&PO=V]R:W-H965TS:3I.(/2A'OR2V///HF1G-X_%D+]63S@$,>2ZXT-,@-V;S M-0QUFD-!=4=N0."3E50%-7BKUJ'>**"9[@["@3 2SB5N[5[.)W!K. M!-PKHK=%0=7A&KC<3X,H>%EX8.O*KEV MOV1?V@[' 4FWVLBB-T3!AR_AH%#YEZ&=FCSE5D$N>@=(?R>W/+3,' M$,^??A,/A FR!WC',N@)Z%!%A8K3*L=K\L= MXPL[)N1."I-KP'OJ.J0)/I"XFX&S^'WWKH=. M4F0KV:4,\1ZETB9&3Z5&V4M@B=*UV)-'!(5@%VLZ33FX2[=CI+FU'; MIK8X(MBO"?:]&9MG&;.$*,>352K3";TCX$$-//!&;D]Q:C!L5+@K0Y^)OI * M N5Y/Y>2P4E*XG9.CH@-:V)#+[$?3EV0!-V!0K5$0;22R\2::% [E@+9@&(R M.T?(#QV3 U"E24**LLVB$,#JFV=+MR$\3WWQX7KZ0-0@\0YQ0@<CJB*XCT,L454.:27-T9N MW)R[E :G9G>9XX<-*&N SU=2FI<;NT']J33[!5!+ P04 " #QDZ=2Y#I] MIQP# #9" &0 'AL+W=O0:',KO:"V$BU[05IV$8C=9Y-,$PO'+K;3PM_OV$E#6T*6ES:V9\Z< M,\[,9+J5ZDGG (:\%%SHF9<;L[[P?9WD4%#=EVL0>+*2JJ &ERKS]5H!39U3 MP?TH"(9^09GPYE.W=ZOF4UD:S@3<*J++HJ#J=0%<;F=>Z.TV[EB6&[OASZ=K MFL$]F(?UK<*5WZ"DK "AF11$P6KF7887RS"P#L[B#X.MWGLF5LJCE$]V<9W. MO, R @Z)L1 4_S:P!,XM$O)XKD&])J9UW'_>H7]SXE',(]6PE/PO2TT^\\8> M26%%2V[NY/8'U(+.+5XBN7:_9%O;!AY)2FUD43LC@X*)ZI^^U(G8H M=HB.'08?.,2U0^R$5LR[J_(R9=3 M\H4P06X8YW@Q>NH;Y&71_:3FL*@X1!]PB,F-%";7Y*M((3WT]U%/(RK:B5I$ MG8 W5/5)')Z1*(C"%C[+S[L''73B)L>QPXL_DV-R\AV+Z]2EN@-[T& /'/;@ M ^QK496R+0D#22XDE]DK,8H*_7:22&U:+Z8"'SIP6_&;>= ?3?W-?K+:;":- MS0'K\X;U>2?K6R57H&TKH)RL +/"1%(J!:E]DQ(I1%WE6V9RW-J -BRKM* D M ZI5315T=, T/%+SWB;N#]K5#!LUPTXU=\A.E8DI%1/9KE#:^ W?Q0[[\1&_ M-IOS=GZCAM^HD]]E\EPRS6SV>@HX-9CF#I:CEBQ.CEB^M^F%>ZD^H#EN:(X[ M:?Z4(NMQ;.HIH5IC(V+%FC)5V#[45L3CEDQ%[10F#85))P57J6VQ)BTYB=MC MA<%;ZPW^'VUW$V=$'#>$NG=6(./]-_;H-FJ3_1(=ODN%OSP 9JOF?D_4$L#!!0 ( /&3IU)),BNPC0( M +,' 9 >&PO=V]R:W-H965TQ)G ML@T7K[("4.BMIDQ.@DJIU6T8RJ*"&LL>7P'3.PLN:JST5"Q#N1* 2PNJ:9A$ MT3"L,6%!GMFUN<@SWBA*&,P%DDU=8_$^!TLC@S 1OPFL)$[8V2DO'#^:B8_RDD0F8R M0J$,!=:O-?G^[1Y<45ND"$H0=" MJ?X@,@N5SL>PAD5[]M2=G9PX.T4/G*E*HJ^LA'(?'VH=7DRR%3--.@D?L.BA M-+Y&293$1_*9?1X>=:23>F]3RY>>X-NWL7 >=_#V/6_?\O8_Q0MO^DK+0V)G ME^,96AYSH==YTNMGX7K7DV,QJ8_92W#@$QQT)CCC4B&^T-=\#:SIU#STE,.S M>CGRO*,S>>EX1CL^Q;WXP,O_8Z+>^+B78Y_@N#-!=T&+[05EH#I4WWC2F[.Z M&4UT0, '@/ 9 >&PO M=V]R:W-H965T7IFWB!UND.&<.AS/'G,51JF\Z!C#D M(4N%7@YB8W8??5^',61<>W(' M]LI,JXP:':^GJG@$?.*$M]%@03/^.)&*P6 M;NY&K19R;])$P(TB>I]E7#U>0"J/RP$=/$W<)MO8V E_M=CQ+=R!^;*[43CR M2Y0HR4#H1 JB8+,9KI[@XW&LCL$8&62)R'_Y0Q&(F@'BM!NPPH ]-QAU M& P+@Z';:,[,;>N2&[Y:*'DDRJY&-/O@8N.L<3>)L,=X9Q2^3=#.K/XU,2BR MCKG:@CXC_V#BG)-;T$;M0[-7B=C:$:@#:/+^$@Q/4OT!EWRYNR3OWWT@[T@B MR'62IG@F>N$;I&2!_;!P?Y&[9QWNA^1:"A-K!%1A8&R0,-.9]/;"J"&R/GU'I M9^3\C#K\7/"4BQ (-\[//6P3(:P/N7$3.U")C-K.)\>=.%Q;\X?5W)L%]0^& M\=!";5Q2&_=2.TVF,,^T-B8YS+3&A'FCTG=^>N,&6^8-V_E-2GZ37GYKKF.R MXX^H3::5UZ3!ZWSLL7:GT]+IM->I*[LS(J0X#ZU_'GW%6G<4"!<107U& 1*H M $J!"!$;#8H?&WTIDUZ@==Q9K.2WNQ7T@F0T4\3:=;@,?'F[33F)8UY+XT[ M.("R1'HJA :5T@5O6HNTIJGTC:JQ *Y'<>I-VJ-(6<6'O4X)%CBG-=B1ZK32 M0#K\LPHK[$]R>.1-._Q6FDA_211?E,4%9)W*N*N::"6!M%\#KQX20]92/]_^ M*5RE6'3RMIEK".0E2[1?F%Z>28WY2CHS.1*CVB_(/T\ MD^=M:CQN]\LJZ6+!JV=R 7D:@2XFE;2Q?FF[4?*0V#N\MO]1Y.HA!*W)9W' MB$CUV'>#J^2*L3=-;U8I$^M7IM]/;]:4+%J[K9SRJ12+]2O6*UX+6%/(NN\% MK%(RUJ]DOY6)S5L;;=S:_%H/DP&6M6WM- GE7IC\^E_.ENWC)]&PO=V]R M:W-H965T)")T4>][:VR,V)I-"XM>!. M2G'[OD)INF4R32X;+^+84-A@1=[R(^Z0]NW6^HB-+)50J)TP&BS6R^3S]&DU M"_DQX:? SEVM(51R,.8U!-^K99(&0RBQI,# _>^,:Y0R$'D;OP?.9)0,P.OU MA?U+K-W7MS%_,$RI,C MHP:P=Z"$[O_\;>C#%2";W@!D R"+OGNAZ'+#B1>Y-1W8D.W9PB*6&M'>G-#A M4G9D_:GP."K61BE!OLOD@.L*UD:3T$?4I4 ']QLD+J1[@#L0&IZ%E+Z5+F?D MI0,!*P>952^3W9!YYG8"Z>(#9&DVW>\V<'_W\#<+\\9']]GH/HNTLQNT/Y ( MK0-3P]IB)2C6\/7$+=>$Z/XC,1LE9E%B?D-BW];6]P1:_AZZ]*_2>X+'2! > MP;F8Y^Q\K?%@G8?G[Z@$P;[^Q@R$] 7#;^R:$- M"?Z\-H8N01B#\1$7?P!02P,$% @ \9.G4@^6GI=D! 5Q, !D !X M;"]W;W)K&ULM5A;C]HX%/XK%NK#5&J3V$X@&0'2 M +/:D7:FH]+N/F?@ %&3F+7-T)7VQZ]S(0ZYF,ZV\ ").9?/W_'YXGA\9/R; MV %(]#V)4S$9[*3.Q"%)0O[/#&)VG SPX#3P.=KN9#9@3\?[< M+ MD%_WSUS=V564=91 *B*6(@Z;R> .WRYH[I!;_!G!4=2N43:5%\:^933>8E%#!G\5_16NXF M W^ UK )#['\S(Z_0SDA+XNW8K'(O]&QL/7H *T.0K*D=%8(DB@M?L/O)1$U M!^+W.)#2@30=<(\#+1WHCSJXI8.;,U-,)>=A$: M?I1F=5]*KOZ-E)^_0.12EZC.)8 M#8NQ+57FS-]>E5EF11;2DX6B1Y;*G4#WZ1K6Y_ZV0ES!)B?8,V(,^!AR"U'\ M 1&'X*_+!;IY]UX4,^A -__Q8$X9K"/*PAQE :L+4H"NC(7[L);1\UQK5&4MBEU8^34KE[C=R(85 MLJ$1V:<]<,5XNE7ML6()H)N8"=&U2&9%H%$MNQ]83E#_-/"V/?#0Z@$\J@"/ MC(#OA #9V:BC5C;J4-=J@%J,6B12QPVZ0?D5*-$ZCZ.E(+E*U<8EFY0A0NN MT1G8T=+H_-QZ+/WK9'ZD32KGW5:C;BYQ3;BQ$=V<<=6PH80/"&K$HC!=(R9W MP$T<$)V%7(5D+6^8_JK6*B.=$:E:A33Y[C;S>PC72HG-4MG?4Z7C64:OB6O1 M9>76K,YA:='$9M6<+1_0']$&T'(50;H")=J:TY.2FTJE11 /K[(6M&AALVI= M;K@.]?)PK;3E"FB;D2'NTU2L]0N;!>PM:]5O/P=\*W!J']Q$W7:A@>7U@-8J MB8/_NVR#-DV!.VK2N>BT&[I]T(@66&(6V&SI/MT]?7KKDB5:) F^QI(E6A$ M^;DE6_J?/=[5IL5M%+_+C#@6[J%8RROY9?)*VKJ)B46;0&EKV_>Q1UJ)EE9B MEM;9_?*+J1Q:#(EWE7IK#23FG>#E>K>W2DWLJWD=K/QK!1(1UKI#J?%Z_SVQTJ9BS>!NQ^] M/SH:G QNWUT<(L*>Z'>.R1,4H7HPTO,G;?.Q?3KJL,WJ9%PH MV2AN_%'O>ZV*GJ &HJNZ$5U X=C9L _RZ;X]ZE'3R+-ZCX MG3*?5G8[LIE#L[ KS0J^;N;KHA. L4<2]=Y-EK$)F\!I$OLR?#]MC9.=OV3K;.&L ; M1$:^P=N*Z(,&LQ47ALMVMN1YSN2# \[2&SJS+Y%[_'9]S@JZ$N:F S/2C[^R MG*_*M%MU!8EH5_7C+["]*.E>7VPL+G.V9OFTG>K%K!D&=F"CMA5' M,!^'^1' L#B8 LS'>6%Q_J?]C-#]. S3-O(B(]1GA/HX+Q\R;3Y8'+]/:B__ M3M,TCI,$R^ATZE4PQ?*6)/#ULV':P .+ Y'^+-=XM?$.>;P/L)H^UB'83O%. MQ':*YQH0?][ (TW]U<;B@ =6!:QW(+X_#O24WR>.H:J8-NP)QI$TQ1#H17^/ M)@F2G00^_OI@3TD/F'#PXC\+M.17VOZQ, M?@%02P,$% @ \9.G4I>*NQS $P( L !?3T\$MP> M:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5; M&GC3Y?YVX$G1H2)8%II%R=.B':5_'YGUR1(E4T\CD6](ZM.#L3_OC?G)'BNEW72P\WY_ M/ARZ8BZ'AR,;8BGO8M=NAVUO!2[<3PE=JF(Q&DV'%I1Y\_G2LZ]H. MXQWC1>&ET5 8"NZD>' OQ\,N.T@G[Z62_FDZ:+:5&+!*:EG)7Z*<#D8#YG;F MX9NQ\I?1GJMU88U2T\&X/7 GK)?%J^)U@+SE]ZXI\?S^A@/(=# 9084;:9UO MSFCJY\!X$'!RNU=[ANJ@;L81K?1Q.'XVP;QW/Z7,)K- M1A9B88JZ$MJW<;1"!4#M=G+O!DSS2DP'T->B"+PF7/ M)1RPJ[)AI./Y<3G[L5C=+A=L?G6Y6%ZNVZWUU??58G:[C" 3!#(Y(>0_2029 M(I#I*2'3"#)#(+-30F819(Y YJ>$S"/("0(Y.27D)()\CT"^IX5<"%=8N0_E MS&S8E]I)+9R+X#X@P65&86GOHD!G81<-V(<(_(\B/".1':LB# MT'6GLQYAO?6(%F=6_%O#19ORF DU"+%"5AI"Y$'FHH.$^6),+(ROQI0/4BG& M=8%\;$8KC@TK([KFH1.HH+J;DN M)%<0/.=M7<68F!G&Q&I8""L//.1V1S(XWS6/^9LHMS$FYH8QL1R@(PL7A5X7 M_@ZDA:D$N^6/W1:"B6%,;(8EMQJZ7,>N(1U=[[CM='&8%<;$6FA@=D:5PKH_ MV!+Z._\4LV$R&!/;X,KO(%QS(-P*]Q>[%''[33 Q),1BF)NJDOZE-!8^.X/!HQ+NSY@+DT5" M+(O8_+UPF#T28GM$*4 O&Z:,A%@9>"[ 8DQ,&0FQ,D(RT!L[S!()L270K* S M\$XP923$RD"S@BXF9H^$V!ZOG=OWP%-,(RFQ1OKDVPN):20EULAK"_!L'GP,2;F MGI38/9V$IV%U$KJE]L%[&V-B[DF)W=-)?=IFT^V&,..DQ,9!Q&IO=)-A]#WP#/-.1NR=9T1HXD8=0O_SW7#-9M9" M2$45M^T,\T[V/\Q\A4C6UL((]8FM'_C^C6BBBR6GG!3KOI>8=S)B[^"8\:). MAGDG(Q_A8%EZ)YJ8=S+R-1,,LQ--S#O92<<\\2)9AADH(S;0VS.A37./%QPQ M ^7$!NH9FK4=?>W#R3$F9J"D>1[YZ!;V(+ MY9B%;8< MLU!.;*&>R8,XI8LQ,0OEQ!;JQ;P1H:,O?!V/?G+,0CFQA5#,S@ CQRR4$UL( M71UA9_$7)9B%)L06PF>-%C$F9J%)^UW;\6.V4FR@UO(2+N&@O."JN+8L_+3K M]%D>UM0VM5)S*+O2,&0HC]_&';_K^_P;4$L#!!0 ( /&3IU+U29+, 0( M %XD : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VDMNHT 4A>&M M6"P@Y?LB22O.J">91MD @'O0DJC-"!>+RB\$G!#P\ MYT,W[?M3V>V'LO@X'DYEU>RF:?B54EGO\K$K-_V03^5\WX]"I-JAVD$*3U@PR"K'Z00Y#7#PH( MBOI!+02U]8-N(>BV?M =!-W5#[J'H/OZ0;)$&9<$23.L";06Y%H(O!8$6PC$ M%B1;",P61%L(U!9D6PC<%H1;".06I%L([!;$6PCT5M1;"?16U%L)]-;9PS:! MWHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>AGH;@=Z&>AN! MWH9Z&X'>-GM90J"WH=Y&H+>AWD:@MZ'>1J"WH=Y&H+>AWD:@MZ'>1J"WH]Y. MH+>CWDZ@MZ/>3J"WH]Y.H+?/7G83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW M$^@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VH=Q#H';./E01Z!^H=!'H'ZAT$>@?J M'01Z!^H=!'JWJ'=+H'>+>K<_J7>9/@^Y7'N^UGC]GZ1Z.I^;KY>_++]VSF[" M!><$OQ,]_@502P,$% @ \9.G4M9,P)+@ 0 XR, !, !;0V]N=&5N M=%]4>7!E&ULS=K+3L,P$ 707XFR18WK5WF(L@&VT 4_8)()C9K$EFV@ M_#U."I5 I:(J$G?3J+4]=^*1SJJ7#V^.0K;NVC[,\V6,[H*Q4"ZI,Z&PCOJT M4EO?F9B^^B?F3+DR3\3$=#ICI>TC]7$2AQKYU>4-U>:YC=GM.OT<&MO/^^I8R^4@HTLEQ3U@V+IRD#3G;F3"L_!SP<>[^ MA;QO*LH6QL<[TZ5=;-VR$-]:"L7^$CMZM'7=E%39\KE+1XK@/)DJ+(EBUQ:; MHB?[DV.Z8=I\\J/SQS+[ M/.A;@8V/X^_XZXRW]0_L0X#T(4'Z4"!]:) ^9B!]G(+T M<0;2QSE('WR*T@B*J!R%5(YB*D=!E:.HRE%8Y2BNNCM:L_CA^?16>:_C.?C?_MN7H'4$L! M A0#% @ \9.G4@=!36*! L0 ! ( ! &1O M8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " #QDZ=2$8MN9N\ K @ $0 M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " #Q MDZ=2F5R<(Q & "<)P $P @ '- 0 >&PO=&AE;64O=&AE M;64Q+GAM;%!+ 0(4 Q0 ( /&3IU(4X1U.&04 $,5 8 M " @0X( !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ \9.G4OK]V>X7 P -@H !@ M ("! !0 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ \9.G4N/3QLJ( @ U@4 !@ ("!)B4 'AL M+W=O 8 " @>0G !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4A1# MQP,A P 1P< !@ ("!U#< 'AL+W=O&UL4$L! A0#% @ M\9.G4@#T+[X8 P " < !D ("!#$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4OP_UQKK!0 NPX !D M ("!4U\ 'AL+W=O\VH# >" &0 @(%U90 >&PO=V]R:W-H M965T&UL4$L! M A0#% @ \9.G4NI%UY_? P \ @ !D ("!LV\ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G M4K^C"AE7 P D@< !D ("!2G\ 'AL+W=O&PO=V]R:W-H965T*% !X;"]W;W)K M&UL4$L! A0#% @ \9.G4J=5JCMP P ^ < M !D ("!@X@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4C15J.Z*!0 =Q !D M ("!9I4 'AL+W=O&PO=V]R:W-H965T M !X;"]W;W)K&UL4$L! A0# M% @ \9.G4G,A!FD ! _0D !D ("!):, 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4@K^ M5GIE! #A4 !D ("!A*T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4MW^"<@S P #0P !D M ("!U;< 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ \9.G4O/6SZPX! M10 !D ("! ML\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ \9.G4J?&OZ7L @ (P@ !D ("!]\L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4OJ;L:8M M! $1$ !D ("!TM@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \9.G4@N/] -I P TPL !D M ("!2>8 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ \9.G4GV9 X/R @ (P@ !D ("!$_ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M\9.G4EW&P&:6 P -@T !D ("!U_H 'AL+W=O&UL4$L! A0#% @ \9.G4H'J![71 P M> \ !D ("!NP0! 'AL+W=O&PO=V]R:W-H965T0* 0!X;"]W;W)K&UL4$L! A0#% @ \9.G4AV7,UD7 P 9A$ T M ( !?P\! 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ \9.G4O5)DLP! @ 7B0 !H M ( !T1@! 'AL+U]R96QS+W=O<&5S72YX;6Q02P4& $4 10#:$@ &QT! end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 212 330 1 false 82 0 false 7 false false R1.htm 1001 - Document - Cover Page Sheet http://bruker.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) Sheet http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 1005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY Sheet http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY Statements 5 false false R6.htm 1006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical) Sheet http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 1007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 1008 - Disclosure - Description of Business Sheet http://bruker.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 1009 - Disclosure - Recent Accounting Pronouncements Sheet http://bruker.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 9 false false R10.htm 1010 - Disclosure - Revenue Sheet http://bruker.com/role/Revenue Revenue Notes 10 false false R11.htm 1011 - Disclosure - Acquisitions Sheet http://bruker.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 1012 - Disclosure - Inventories Sheet http://bruker.com/role/Inventories Inventories Notes 12 false false R13.htm 1013 - Disclosure - Goodwill and Intangible Assets Sheet http://bruker.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 1014 - Disclosure - Debt Sheet http://bruker.com/role/Debt Debt Notes 14 false false R15.htm 1015 - Disclosure - Fair Value of Financial Instruments Sheet http://bruker.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 15 false false R16.htm 1016 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://bruker.com/role/DerivativeInstrumentsAndHedgingActivities Derivative Instruments and Hedging Activities Notes 16 false false R17.htm 1017 - Disclosure - Provision for Income Taxes Sheet http://bruker.com/role/ProvisionForIncomeTaxes Provision for Income Taxes Notes 17 false false R18.htm 1018 - Disclosure - Earnings Per Share Sheet http://bruker.com/role/EarningsPerShare Earnings Per Share Notes 18 false false R19.htm 1019 - Disclosure - Shareholders' Equity Sheet http://bruker.com/role/ShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 1020 - Disclosure - Other Charges, Net Sheet http://bruker.com/role/OtherChargesNet Other Charges, Net Notes 20 false false R21.htm 1021 - Disclosure - Commitments and Contingencies Sheet http://bruker.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 1022 - Disclosure - Business Segment Information Sheet http://bruker.com/role/BusinessSegmentInformation Business Segment Information Notes 22 false false R23.htm 1023 - Disclosure - Revenue (Tables) Sheet http://bruker.com/role/RevenueTables Revenue (Tables) Tables http://bruker.com/role/Revenue 23 false false R24.htm 1024 - Disclosure - Acquisitions (Tables) Sheet http://bruker.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://bruker.com/role/Acquisitions 24 false false R25.htm 1025 - Disclosure - Inventories (Tables) Sheet http://bruker.com/role/InventoriesTables Inventories (Tables) Tables http://bruker.com/role/Inventories 25 false false R26.htm 1026 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://bruker.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://bruker.com/role/GoodwillAndIntangibleAssets 26 false false R27.htm 1027 - Disclosure - Debt (Tables) Sheet http://bruker.com/role/DebtTables Debt (Tables) Tables http://bruker.com/role/Debt 27 false false R28.htm 1028 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://bruker.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://bruker.com/role/FairValueOfFinancialInstruments 28 false false R29.htm 1029 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://bruker.com/role/DerivativeInstrumentsAndHedgingActivities 29 false false R30.htm 1030 - Disclosure - Earnings Per Share (Tables) Sheet http://bruker.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://bruker.com/role/EarningsPerShare 30 false false R31.htm 1031 - Disclosure - Shareholders' Equity (Tables) Sheet http://bruker.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://bruker.com/role/ShareholdersEquity 31 false false R32.htm 1032 - Disclosure - Other Charges, Net (Tables) Sheet http://bruker.com/role/OtherChargesNetTables Other Charges, Net (Tables) Tables http://bruker.com/role/OtherChargesNet 32 false false R33.htm 1033 - Disclosure - Business Segment Information (Tables) Sheet http://bruker.com/role/BusinessSegmentInformationTables Business Segment Information (Tables) Tables http://bruker.com/role/BusinessSegmentInformation 33 false false R34.htm 1034 - Disclosure - Description of Business (Details) Sheet http://bruker.com/role/DescriptionOfBusinessDetails Description of Business (Details) Details http://bruker.com/role/DescriptionOfBusiness 34 false false R35.htm 1035 - Disclosure - Revenue - Disaggregation (Details) Sheet http://bruker.com/role/RevenueDisaggregationDetails Revenue - Disaggregation (Details) Details 35 false false R36.htm 1036 - Disclosure - Revenue - Remaining Performance Obligations (Details) Sheet http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails Revenue - Remaining Performance Obligations (Details) Details 36 false false R37.htm 1037 - Disclosure - Revenue - Contract Balances (Details) Sheet http://bruker.com/role/RevenueContractBalancesDetails Revenue - Contract Balances (Details) Details 37 false false R38.htm 1038 - Disclosure - Acquisitions - Consideration transferred and reportable segment (Details) Sheet http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails Acquisitions - Consideration transferred and reportable segment (Details) Details 38 false false R39.htm 1039 - Disclosure - Inventories (Details) Sheet http://bruker.com/role/InventoriesDetails Inventories (Details) Details http://bruker.com/role/InventoriesTables 39 false false R40.htm 1040 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) Sheet http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails Goodwill and Intangible Assets - Goodwill (Details) Details 40 false false R41.htm 1041 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 41 false false R42.htm 1042 - Disclosure - Debt - Components (Details) Sheet http://bruker.com/role/DebtComponentsDetails Debt - Components (Details) Details 42 false false R43.htm 1043 - Disclosure - Debt - Revolving Loan Arrangements (Details) Sheet http://bruker.com/role/DebtRevolvingLoanArrangementsDetails Debt - Revolving Loan Arrangements (Details) Details 43 false false R44.htm 1044 - Disclosure - Debt - Currency Swaps (Details) Sheet http://bruker.com/role/DebtCurrencySwapsDetails Debt - Currency Swaps (Details) Details 44 false false R45.htm 1045 - Disclosure - Fair Value of Financial Instruments - Hierarchy (Details) Sheet http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails Fair Value of Financial Instruments - Hierarchy (Details) Details 45 false false R46.htm 1046 - Disclosure - Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details) Sheet http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details) Details 46 false false R47.htm 1047 - Disclosure - Derivative Instruments and Hedging Activities - Risk Management (Details) Sheet http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails Derivative Instruments and Hedging Activities - Risk Management (Details) Details 47 false false R48.htm 1048 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet (Details) Sheet http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails Derivative Instruments and Hedging Activities - Balance Sheet (Details) Details 48 false false R49.htm 1049 - Disclosure - Derivative Instruments and Hedging Activities - Income Statement (Details) Sheet http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails Derivative Instruments and Hedging Activities - Income Statement (Details) Details 49 false false R50.htm 1050 - Disclosure - Provision for Income Taxes (Details) Sheet http://bruker.com/role/ProvisionForIncomeTaxesDetails Provision for Income Taxes (Details) Details http://bruker.com/role/ProvisionForIncomeTaxes 50 false false R51.htm 1051 - Disclosure - Earnings Per Share - Computation (Details) Sheet http://bruker.com/role/EarningsPerShareComputationDetails Earnings Per Share - Computation (Details) Details 51 false false R52.htm 1052 - Disclosure - Earnings Per Share - Anti-dilutive Stock Options (Details) Sheet http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails Earnings Per Share - Anti-dilutive Stock Options (Details) Details 52 false false R53.htm 1053 - Disclosure - Shareholders' Equity - Share Repurchase and Dividends (Details) Sheet http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails Shareholders' Equity - Share Repurchase and Dividends (Details) Details 53 false false R54.htm 1054 - Disclosure - Shareholders' Equity - Comprehensive Income (Loss) (Details) Sheet http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails Shareholders' Equity - Comprehensive Income (Loss) (Details) Details 54 false false R55.htm 1055 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details) Details 55 false false R56.htm 1056 - Disclosure - Shareholders' Equity - Expense (Details) Sheet http://bruker.com/role/ShareholdersEquityExpenseDetails Shareholders' Equity - Expense (Details) Details 56 false false R57.htm 1057 - Disclosure - Other Charges, Net - Components of other charges (Details) Sheet http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails Other Charges, Net - Components of other charges (Details) Details 57 false false R58.htm 1058 - Disclosure - Other Charges, Net - Restructuring Plans (Details) Sheet http://bruker.com/role/OtherChargesNetRestructuringPlansDetails Other Charges, Net - Restructuring Plans (Details) Details 58 false false R59.htm 1059 - Disclosure - Other Charges, Net - Restructuring Reserves (Details) Sheet http://bruker.com/role/OtherChargesNetRestructuringReservesDetails Other Charges, Net - Restructuring Reserves (Details) Details 59 false false R60.htm 1060 - Disclosure - Commitments and Contingencies (Details) Sheet http://bruker.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://bruker.com/role/CommitmentsAndContingencies 60 false false R61.htm 1061 - Disclosure - Business Segment Information (Details) Sheet http://bruker.com/role/BusinessSegmentInformationDetails Business Segment Information (Details) Details http://bruker.com/role/BusinessSegmentInformationTables 61 false false All Reports Book All Reports d112071d10q.htm brkr-20210331.xsd brkr-20210331_cal.xml brkr-20210331_def.xml brkr-20210331_lab.xml brkr-20210331_pre.xml d112071dex311.htm d112071dex312.htm d112071dex321.htm http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d112071d10q.htm": { "axisCustom": 0, "axisStandard": 25, "contextCount": 212, "dts": { "calculationLink": { "local": [ "brkr-20210331_cal.xml" ] }, "definitionLink": { "local": [ "brkr-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "d112071d10q.htm" ] }, "labelLink": { "local": [ "brkr-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "brkr-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "brkr-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 484, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 1, "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 7 }, "keyCustom": 17, "keyStandard": 313, "memberCustom": 28, "memberStandard": 54, "nsprefix": "brkr", "nsuri": "http://bruker.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://bruker.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Revenue", "role": "http://bruker.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Acquisitions", "role": "http://bruker.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Inventories", "role": "http://bruker.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Goodwill and Intangible Assets", "role": "http://bruker.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Debt", "role": "http://bruker.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Fair Value of Financial Instruments", "role": "http://bruker.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Derivative Instruments and Hedging Activities", "role": "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Provision for Income Taxes", "role": "http://bruker.com/role/ProvisionForIncomeTaxes", "shortName": "Provision for Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Earnings Per Share", "role": "http://bruker.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Shareholders' Equity", "role": "http://bruker.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Other Charges, Net", "role": "http://bruker.com/role/OtherChargesNet", "shortName": "Other Charges, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Commitments and Contingencies", "role": "http://bruker.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Business Segment Information", "role": "http://bruker.com/role/BusinessSegmentInformation", "shortName": "Business Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Revenue (Tables)", "role": "http://bruker.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_AcquisitionsIn2021MemberusgaapBusinessAcquisitionAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Acquisitions (Tables)", "role": "http://bruker.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_AcquisitionsIn2021MemberusgaapBusinessAcquisitionAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Inventories (Tables)", "role": "http://bruker.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://bruker.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Debt (Tables)", "role": "http://bruker.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://bruker.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Earnings Per Share (Tables)", "role": "http://bruker.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Shareholders' Equity (Tables)", "role": "http://bruker.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "brkr:ScheduleOfOtherNonrecurringExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Other Charges, Net (Tables)", "role": "http://bruker.com/role/OtherChargesNetTables", "shortName": "Other Charges, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "brkr:ScheduleOfOtherNonrecurringExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Business Segment Information (Tables)", "role": "http://bruker.com/role/BusinessSegmentInformationTables", "shortName": "Business Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Description of Business (Details)", "role": "http://bruker.com/role/DescriptionOfBusinessDetails", "shortName": "Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_segment", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Revenue - Disaggregation (Details)", "role": "http://bruker.com/role/RevenueDisaggregationDetails", "shortName": "Revenue - Disaggregation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Revenue - Remaining Performance Obligations (Details)", "role": "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails", "shortName": "Revenue - Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Revenue - Contract Balances (Details)", "role": "http://bruker.com/role/RevenueContractBalancesDetails", "shortName": "Revenue - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Acquisitions - Consideration transferred and reportable segment (Details)", "role": "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "shortName": "Acquisitions - Consideration transferred and reportable segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_AcquisitionsIn2021MemberusgaapBusinessAcquisitionAxis", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Inventories (Details)", "role": "http://bruker.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)", "role": "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)", "role": "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)", "role": "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Debt - Components (Details)", "role": "http://bruker.com/role/DebtComponentsDetails", "shortName": "Debt - Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Debt - Revolving Loan Arrangements (Details)", "role": "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails", "shortName": "Debt - Revolving Loan Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "brkr:CrossCurrencySwapInterestEffect", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Debt - Currency Swaps (Details)", "role": "http://bruker.com/role/DebtCurrencySwapsDetails", "shortName": "Debt - Currency Swaps (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "brkr:CrossCurrencySwapInterestEffect", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Fair Value of Financial Instruments - Hierarchy (Details)", "role": "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails", "shortName": "Fair Value of Financial Instruments - Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_MestrelabResearchS.lMemberusgaapBusinessAcquisitionAxis", "decimals": "INF", "first": true, "lang": null, "name": "brkr:VotingEquityInterestIncludedInOptionsProvidedToShareholdersPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details)", "role": "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails", "shortName": "Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_MestrelabResearchS.lMemberusgaapBusinessAcquisitionAxis", "decimals": "INF", "first": true, "lang": null, "name": "brkr:VotingEquityInterestIncludedInOptionsProvidedToShareholdersPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Derivative Instruments and Hedging Activities - Risk Management (Details)", "role": "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails", "shortName": "Derivative Instruments and Hedging Activities - Risk Management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis", "decimals": "-5", "lang": null, "name": "brkr:NotionalAmountOfDerivativeSaleContracts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Derivative Instruments and Hedging Activities - Balance Sheet (Details)", "role": "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "shortName": "Derivative Instruments and Hedging Activities - Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn03_31_2021_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis", "decimals": "-5", "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Derivative Instruments and Hedging Activities - Income Statement (Details)", "role": "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "shortName": "Derivative Instruments and Hedging Activities - Income Statement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY", "role": "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Provision for Income Taxes (Details)", "role": "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "shortName": "Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Earnings Per Share - Computation (Details)", "role": "http://bruker.com/role/EarningsPerShareComputationDetails", "shortName": "Earnings Per Share - Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Earnings Per Share - Anti-dilutive Stock Options (Details)", "role": "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails", "shortName": "Earnings Per Share - Anti-dilutive Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn05_31_2019_May2019RepurchaseProgramMemberusgaapShareRepurchaseProgramAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Shareholders' Equity - Share Repurchase and Dividends (Details)", "role": "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails", "shortName": "Shareholders' Equity - Share Repurchase and Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn05_31_2019_May2019RepurchaseProgramMemberusgaapShareRepurchaseProgramAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Shareholders' Equity - Comprehensive Income (Loss) (Details)", "role": "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails", "shortName": "Shareholders' Equity - Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Shareholders' Equity - Expense (Details)", "role": "http://bruker.com/role/ShareholdersEquityExpenseDetails", "shortName": "Shareholders' Equity - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "brkr:ScheduleOfOtherNonrecurringExpenseTableTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InformationTechnologyAndDataProcessing", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Other Charges, Net - Components of other charges (Details)", "role": "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails", "shortName": "Other Charges, Net - Components of other charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "brkr:ScheduleOfOtherNonrecurringExpenseTableTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InformationTechnologyAndDataProcessing", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Other Charges, Net - Restructuring Plans (Details)", "role": "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "shortName": "Other Charges, Net - Restructuring Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_CostOfSalesMemberusgaapIncomeStatementLocationAxis", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1059 - Disclosure - Other Charges, Net - Restructuring Reserves (Details)", "role": "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails", "shortName": "Other Charges, Net - Restructuring Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical)", "role": "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P03_05_2021To03_05_2021", "decimals": "-5", "first": true, "lang": null, "name": "brkr:UpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1060 - Disclosure - Commitments and Contingencies (Details)", "role": "http://bruker.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P03_05_2021To03_05_2021", "decimals": "-5", "first": true, "lang": null, "name": "brkr:UpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "div", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "Unit_segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1061 - Disclosure - Business Segment Information (Details)", "role": "http://bruker.com/role/BusinessSegmentInformationDetails", "shortName": "Business Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021_CorporateReconcilingItemsAndEliminationsMembersrtConsolidationItemsAxis", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Description of Business", "role": "http://bruker.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Recent Accounting Pronouncements", "role": "http://bruker.com/role/RecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d112071d10q.htm", "contextRef": "P01_01_2021To03_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 82, "tag": { "brkr_AcquisitionsIn2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisitions In 2021.", "label": "Acquisitions In 2021 [Member]", "terseLabel": "2021 Acquisitions" } } }, "localname": "AcquisitionsIn2021Member", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/AcquisitionsTables" ], "xbrltype": "domainItemType" }, "brkr_AcuitySpatialGenomicsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acuity Spatial Genomics Inc [Member]", "terseLabel": "Acuity Spatial Genomics, Inc." } } }, "localname": "AcuitySpatialGenomicsIncMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "brkr_BankGuaranteesAndWorkingCapitalLineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Bank guarantees and working capital line.", "label": "Bank Guarantees And Working Capital Line [Member]", "terseLabel": "Bank guarantees and working capital line" } } }, "localname": "BankGuaranteesAndWorkingCapitalLineMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "domainItemType" }, "brkr_BrukerBioSpinGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to the Bruker BioSpin Group operating segment of the entity.", "label": "Bruker Bio Spin Group [Member]", "terseLabel": "Bruker BioSpin" } } }, "localname": "BrukerBioSpinGroupMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "brkr_BrukerCalidGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to the Bruker CALID Group (Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection) operating segment of the entity.", "label": "Bruker Calid Group [Member]", "terseLabel": "Bruker CALID" } } }, "localname": "BrukerCalidGroupMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "brkr_BrukerNanoGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to the Bruker Nano Group operating segment of the entity.", "label": "Bruker Nano Group [Member]", "terseLabel": "Bruker Nano" } } }, "localname": "BrukerNanoGroupMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "brkr_BsiNanoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to the BSI NANO Group operating segment of the entity.", "label": "Bsi Nano [Member]", "terseLabel": "BSI NANO" } } }, "localname": "BsiNanoMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/BusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "brkr_CapitalLeaseObligationsAndOtherLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to capital lease obligation and other loans.", "label": "Capital Lease Obligations And Other Loan [Member]", "terseLabel": "Capital lease obligations and other loans" } } }, "localname": "CapitalLeaseObligationsAndOtherLoanMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "domainItemType" }, "brkr_ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest": { "auth_ref": [], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 16.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to redeemable noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Loss Net Of Tax Attributable To Non redeemable Non controlling Interest", "verboseLabel": "Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest" } } }, "localname": "ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "brkr_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Comprehensive income loss net of tax including portion attributable to noncontrolling interest and redeemable noncontrolling interest.", "label": "Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest", "terseLabel": "Net comprehensive income" } } }, "localname": "ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "brkr_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "domainItemType" }, "brkr_CorporateReconcilingItemsAndEliminationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate-level activity, eliminations and other items used in reconciling reportable segments' amounts to consolidated amount.", "label": "Corporate Reconciling Items And Eliminations [Member]", "terseLabel": "Corporate, eliminations and other" } } }, "localname": "CorporateReconcilingItemsAndEliminationsMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "brkr_CrossCurrencyAndInterestRateSwapAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to cross-currency and interest rate swap agreements.", "label": "Cross Currency And Interest Rate Swap Agreements [Member]", "terseLabel": "Interest rate and cross currency swap agreements" } } }, "localname": "CrossCurrencyAndInterestRateSwapAgreementsMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "brkr_CrossCurrencyInterestRateContractUSDollarsToSwissFrancMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates of U.S. dollars and Swiss Franc.", "label": "Cross Currency Interest Rate Contract U S Dollars To Swiss Franc [Member]", "terseLabel": "US to Swiss Franc" } } }, "localname": "CrossCurrencyInterestRateContractUSDollarsToSwissFrancMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "brkr_CrossCurrencyInterestRateContractUsDollarsToEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates of U.S. dollars and Euro.", "label": "Cross Currency Interest Rate Contract US Dollars To Euro [Member]", "terseLabel": "US to Euro" } } }, "localname": "CrossCurrencyInterestRateContractUsDollarsToEuroMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "brkr_CrossCurrencySwapInterestEffect": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense effect of cross-currency swap.", "label": "Cross Currency Swap Interest Effect", "terseLabel": "Reduction of interest expense by cross-currency and interest swap agreements" } } }, "localname": "CrossCurrencySwapInterestEffect", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails" ], "xbrltype": "monetaryItemType" }, "brkr_EnergyAndSuperconTechnologiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to the Bruker Energy and Supercon Technologies (BEST) reporting segment of the entity.", "label": "Energy And Supercon Technologies [Member]", "terseLabel": "BEST" } } }, "localname": "EnergyAndSuperconTechnologiesMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "brkr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTranslationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign currency translation adjustments related to financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Translation Adjustments", "terseLabel": "Foreign currency effect" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTranslationAdjustments", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "brkr_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of intangibles assets excluding goodwill, in total and by major class, including the gross carrying amount and accumulated amortization for amortizable intangible assets.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "brkr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible assets" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "brkr_GermanyAndSwitzerlandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Germany and Switzerland.", "label": "Germany And Switzerland [Member]", "terseLabel": "Germany and Switzerland" } } }, "localname": "GermanyAndSwitzerlandMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "brkr_GlycopathIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Glycopath Inc [Member]", "terseLabel": "Glycopath Inc." } } }, "localname": "GlycopathIncMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "brkr_HainLifescienceGmbhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Hain lifescience gmbh.", "label": "Hain Lifescience Gmbh [Member]", "terseLabel": "Hain" } } }, "localname": "HainLifescienceGmbhMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "brkr_HybridInstrumentLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability related to hybrid instrument liability.", "label": "Hybrid Instrument Liability Fair Value Disclosure", "terseLabel": "Hybrid instrument liability" } } }, "localname": "HybridInstrumentLiabilityFairValueDisclosure", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "brkr_InterestAcquiredInSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest acquired in Hain LifeScience GmbH.", "label": "Interest Acquired In Subsidiary", "verboseLabel": "Acquired 80% interest in Hain LifeScience GmbH" } } }, "localname": "InterestAcquiredInSubsidiary", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "brkr_IonPathIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ion Path Inc [Member]", "terseLabel": "IonPath Inc" } } }, "localname": "IonPathIncMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "brkr_May2019RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A share repurchase program approved by the entity's Board of Directors in May 2019.", "label": "May2019 Repurchase Program [Member]", "terseLabel": "May 2019 Repurchase Program" } } }, "localname": "May2019RepurchaseProgramMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "domainItemType" }, "brkr_MestrelabResearchS.lMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Mestrelab Research, S.L.", "label": "Mestrelab Research S.l [Member]", "terseLabel": "Mestrelab" } } }, "localname": "MestrelabResearchS.lMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "brkr_NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss) including Attributable to Redeemable Noncontrolling Interest, Total", "label": "Net Income (Loss), Including Portion Attributable to Redeemable Noncontrolling Interest", "negatedLabel": "Consolidated net income" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "brkr_NotePurchaseAgreement2012Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing member information pertaining to 2012 Note Purchase Agreement.", "label": "Note Purchase Agreement2012 [Member]", "terseLabel": "2012 Note Purchase Agreement" } } }, "localname": "NotePurchaseAgreement2012Member", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "domainItemType" }, "brkr_NotePurchaseAgreement2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing member information pertaining to 2019 Note Purchase Agreement.", "label": "Note Purchase Agreement2019 [Member]", "terseLabel": "2019 Note Purchase Agreement" } } }, "localname": "NotePurchaseAgreement2019Member", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "domainItemType" }, "brkr_NotionalAmountOfDerivativePurchaseContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate notional amount of derivatives to purchase the underlying asset.", "label": "Notional Amount of Derivative Purchase Contracts", "terseLabel": "Notional amount of derivative purchase contracts" } } }, "localname": "NotionalAmountOfDerivativePurchaseContracts", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "brkr_NotionalAmountOfDerivativeSaleContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate notional amount of derivatives to deliver the underlying asset.", "label": "Notional Amount of Derivative Sale Contracts", "terseLabel": "Notional amount of derivative sale contracts" } } }, "localname": "NotionalAmountOfDerivativeSaleContracts", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "brkr_OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss), excluding redeemable noncontrolling interest.", "label": "Other Comprehensive Income (Loss), Net of Tax, Excluding Redeemable Noncontrolling Interest", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "brkr_OtherCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other countries or geographical areas not specifically identified.", "label": "Other Country [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountryMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "brkr_OtherMiscellaneousNonrecurringExpense": { "auth_ref": [], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonrecurringIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other miscellaneous nonrecurring expense.", "label": "Other Miscellaneous Nonrecurring Expense", "terseLabel": "Other" } } }, "localname": "OtherMiscellaneousNonrecurringExpense", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "brkr_OtherShareholdersEquity": { "auth_ref": [], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of all other stockholder's equity not separately identified, including additional paid-in capital and the cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Other Shareholders Equity", "terseLabel": "Other shareholders' equity" } } }, "localname": "OtherShareholdersEquity", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "brkr_ProvisionsForExcessInventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Write-down of excess inventory associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Provisions For Excess Inventory [Member]", "terseLabel": "Provisions for Excess Inventory" } } }, "localname": "ProvisionsForExcessInventoryMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "domainItemType" }, "brkr_RedeemableNoncontrollingInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing information pertaining to Redeemable Noncontrolling Interest.", "label": "Redeemable Noncontrolling Interest [Member]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "localname": "RedeemableNoncontrollingInterestMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "brkr_RestOfEuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe, excluding countries specifically identified.", "label": "Rest Of Europe [Member]", "terseLabel": "Rest of Europe" } } }, "localname": "RestOfEuropeMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "brkr_RestructuringChargesExcludingCostOfSales": { "auth_ref": [], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonrecurringIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations.", "label": "Restructuring Charges, Excluding Cost of Sales", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringChargesExcludingCostOfSales", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "brkr_RevolvingCreditAgreement2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing member information pertaining to 2019 Revolving Credit Agreement.", "label": "Revolving Credit Agreement2019 [Member]", "terseLabel": "2019 Credit Agreement" } } }, "localname": "RevolvingCreditAgreement2019Member", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "domainItemType" }, "brkr_ScheduleOfOtherNonrecurringExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the expenses charged against earnings for events that are infrequent in occurrence or unusual in nature.", "label": "Schedule of Other Nonrecurring Expense [Table Text Block]", "terseLabel": "Schedule of components of other charges, net" } } }, "localname": "ScheduleOfOtherNonrecurringExpenseTableTextBlock", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/OtherChargesNetTables" ], "xbrltype": "textBlockItemType" }, "brkr_ScientificInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to the Bruker Scientific Instruments (BSI) reporting segment of the entity.", "label": "Scientific Instruments [Member]", "terseLabel": "BSI Life Science" } } }, "localname": "ScientificInstrumentsMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/BusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "brkr_ShortTermInvestmentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of short term investments accounted for under equity method.", "label": "Short term investments fair value disclosure", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestmentsFairValueDisclosure", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "brkr_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing member information pertaining to 2019 Term Loan Agreement.", "label": "Term Loan Agreement [Member]", "terseLabel": "2019 Term Loan" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "domainItemType" }, "brkr_UpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment.", "label": "Upfront Payment", "terseLabel": "Upfront payment" } } }, "localname": "UpfrontPayment", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "brkr_VotingEquityInterestIncludedInOptionsProvidedToShareholdersPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of shares remaining that were included in the options provided to the non-controlling shareholders.", "label": "Voting Equity Interest Included in Options Provided to Shareholders Percentage", "terseLabel": "Remaining ownership percentage under options that can be exercised after 2022" } } }, "localname": "VotingEquityInterestIncludedInOptionsProvidedToShareholdersPercentage", "nsuri": "http://bruker.com/20210331", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "percentItemType" }, "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "Switzerland" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "verboseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://bruker.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r169", "r171", "r175" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r169", "r171", "r175" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r304", "r306", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r508", "r511" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r304", "r306", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r508", "r511" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r177", "r278", "r282", "r461", "r507", "r509" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r177", "r278", "r282", "r461", "r507", "r509" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r294", "r304", "r306", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r508", "r511" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/CommitmentsAndContingenciesDetails", "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r294", "r304", "r306", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r508", "r511" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/CommitmentsAndContingenciesDetails", "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r178", "r179", "r278", "r283", "r510", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r178", "r179", "r278", "r283", "r510", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Summary of the components of accumulated other comprehensive income, net of tax" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r19", "r183", "r184" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r51", "r57", "r58", "r383" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension Liability Adjustment" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r54", "r56", "r57", "r495", "r519", "r523" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r444" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r53", "r57", "r58", "r105", "r106", "r107", "r383", "r514", "r515" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r50", "r57", "r58", "r383", "r438", "r439", "r440", "r441", "r444" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r105", "r106", "r107", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r110", "r111", "r112", "r114", "r189", "r190", "r191", "r192", "r195", "r196", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r340", "r341", "r342", "r343", "r463", "r464", "r465", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile consolidated net income to cash flows from operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r307", "r309", "r328", "r329" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r309", "r315", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r94", "r207", "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense related to intangible assets subject to amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Number of shares excluded from the computation of diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r159", "r166", "r173", "r188", "r378", "r384", "r434", "r473", "r492" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r45", "r100", "r188", "r378", "r384", "r434" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r421" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets recorded at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r186", "r187", "r197", "r480" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 7.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities available for sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r310", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r400", "r406" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/AcquisitionsTables", "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r303", "r305", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/AcquisitionsTables", "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/AcquisitionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "verboseLabel": "Interest acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r358" ], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonrecurringIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related charges" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r367", "r368", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r366", "r369", "r371" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisitions" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r96" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r91", "r96", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r91", "r436" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r38", "r237", "r481", "r499" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r234", "r235", "r236", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommodityContractMember": { "auth_ref": [ "r295", "r412" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices.", "label": "Commodity Contract [Member]", "terseLabel": "Fixed price commodity contracts" } } }, "localname": "CommodityContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends declared (per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r18" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.01 par value 260,000,000 shares authorized, 174,132,743 and 174,045,610 shares issued and 151,543,485 and 151,987,081 shares outstanding at March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r70", "r486", "r503" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income attributable to Bruker Corporation", "totalLabel": "Comprehensive income attributable to Bruker Corporation" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r61", "r63", "r69", "r375", "r388", "r485", "r502" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 14.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r264", "r266", "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r264", "r265", "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r264", "r265", "r279" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Customer advances" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognition during the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r74", "r100", "r188", "r434" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 7.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Total cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Interest rate cross-currency swap agreements" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r15", "r16", "r474", "r475", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails", "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r247", "r475", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Debt, before unamortized debt issuance costs" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails", "http://bruker.com/role/DebtCurrencySwapsDetails", "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails", "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r36", "r102", "r254", "r257", "r258", "r259", "r446", "r447", "r449", "r489" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails", "http://bruker.com/role/DebtCurrencySwapsDetails", "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted Average Interest Rate (as a percent)" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r31", "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r101", "r339", "r349", "r350", "r351" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r94", "r154" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r391", "r392", "r394" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional amount, assets" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r46", "r47", "r433" ], "calculation": { "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet", "weight": 1.0 }, "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "verboseLabel": "Interest rate and cross currency swap agreements" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r389" ], "calculation": { "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Fair value, net asset (liability)", "totalLabel": "Derivative Assets (Liabilities)" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Impact on net income of unrealized gains and losses" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r401", "r404", "r409", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r398", "r401", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAtFairValueNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments in Hedges, at Fair Value, Net [Abstract]", "terseLabel": "Designated as accounting hedges" } } }, "localname": "DerivativeInstrumentsInHedgesAtFairValueNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "negatedTerseLabel": "Liabilities" } } }, "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments Not Designated as Hedging Instruments [Abstract]", "terseLabel": "Not designated as accounting hedges" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "terseLabel": "Assets" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "negatedLabel": "Liabilities" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r46", "r47", "r433" ], "calculation": { "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet", "weight": -1.0 }, "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "verboseLabel": "Interest rate and cross currency swap agreements" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r391", "r392", "r394" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Notional amount, liabilities" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative instruments and hedging activities" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r392", "r394" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "verboseLabel": "Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r390", "r393", "r394", "r398", "r399", "r407", "r409", "r416", "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenues disaggregated by Group" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r278", "r282", "r283", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of revenues disaggregated by Group, end customer geographical location and timing of recognition" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared to common stockholders" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticLineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, inside the reporting entity's home country.", "label": "Domestic Line of Credit [Member]", "terseLabel": "US Dollar revolving loan" } } }, "localname": "DomesticLineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "terseLabel": "Net income per common share attributable to Bruker Corporation shareholders:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r71", "r115", "r116", "r117", "r118", "r119", "r126", "r129", "r132", "r133", "r134", "r138", "r139", "r487", "r504" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income per common share attributable to Bruker Corporation shareholders:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r71", "r115", "r116", "r117", "r118", "r119", "r129", "r132", "r133", "r134", "r138", "r139", "r487", "r504" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r135", "r136", "r137", "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r436" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rates (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r333", "r352" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r333", "r352" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Change in tax rate - foreign jurisdictions (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset": { "auth_ref": [ "r403" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as an asset.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Asset", "terseLabel": "Embedded derivatives in purchase and delivery contracts" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r403" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivatives in purchase and delivery contracts" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]", "terseLabel": "Embedded derivatives in purchase and delivery contracts" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument embedded in host contract.", "label": "Embedded Derivative Financial Instruments [Member]", "terseLabel": "Embedded derivatives in purchase and delivery contracts" } } }, "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Additional information" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Expected pre-tax stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining service period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r105", "r106", "r107", "r111", "r120", "r122", "r141", "r192", "r253", "r260", "r322", "r323", "r324", "r342", "r343", "r437", "r438", "r439", "r440", "r441", "r444", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Exit Costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r421", "r422", "r423", "r431" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r422", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r429", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r421", "r422", "r424", "r425", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r295", "r296", "r301", "r302", "r422", "r452" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r422", "r453" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Changes in contingent consideration liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r426", "r431" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r426", "r431" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in contingent consideration liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Current period adjustments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r428" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Current period settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at March 31, 2021", "periodStartLabel": "Balance at December 31, 2020" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r429", "r432" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r426", "r430" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in hybrid instrument liability" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r212" ], "calculation": { "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization, intangible assets subject to amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r208", "r209", "r212", "r214", "r462", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r212", "r469" ], "calculation": { "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount, intangible assets subject to amortization" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r208", "r211" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r212", "r462" ], "calculation": { "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount, intangible assets subject to amortization" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "verboseLabel": "Forward currency contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward currency contracts" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r295", "r411" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Forward currency and swap agreements" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Forward currency contract" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r200", "r201", "r472" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "negatedLabel": "Current period additions/adjustments" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Foreign currency impact" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r72", "r100", "r159", "r165", "r169", "r172", "r175", "r188", "r434" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r398", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HybridInstrumentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents hybrid instruments that have embedded credit derivatives (for example, a credit-linked note).", "label": "Hybrid Instrument [Member]", "terseLabel": "Hybrid instrument" } } }, "localname": "HybridInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsContingentConsiderationAndHybridInstrumentLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r94", "r216", "r218" ], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonrecurringIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "verboseLabel": "Long-lived asset impairments" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r66", "r159", "r165", "r169", "r172", "r175", "r470", "r482", "r488", "r505" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes and noncontrolling interest in consolidated subsidiaries" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails", "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r334", "r337", "r338", "r347", "r353", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Provision for Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r121", "r122", "r157", "r332", "r348", "r354", "r506" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Provision for Income Taxes" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Customer advances" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other changes in operating assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InformationTechnologyAndDataProcessing": { "auth_ref": [ "r76" ], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonrecurringIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses incurred in the period for information technology and data processing products and services.", "label": "Information Technology and Data Processing", "terseLabel": "Information technology transformation costs" } } }, "localname": "InformationTechnologyAndDataProcessing", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r206", "r210" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest and other income (expense), net" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r169", "r171", "r175" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r24", "r198" ], "calculation": { "http://bruker.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r43" ], "calculation": { "http://bruker.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r26", "r198" ], "calculation": { "http://bruker.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r25", "r198" ], "calculation": { "http://bruker.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r421" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Time deposits and money market funds" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "calculation": { "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails": { "order": 1.0, "parentTag": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Outstanding Letters of Credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r100", "r188", "r434", "r477", "r497" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35", "r100", "r188", "r379", "r384", "r385", "r434" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r421" ], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities recorded at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Abstract]", "terseLabel": "Revolving lines of credit" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r33" ], "calculation": { "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "totalLabel": "Total Amount Committed by Lenders" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r33" ], "calculation": { "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails": { "order": 2.0, "parentTag": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "verboseLabel": "Total Committed Amount Available" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtRevolvingLoanArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r248", "r475", "r493" ], "calculation": { "http://bruker.com/role/DebtComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://bruker.com/role/DebtComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current, Total", "negatedLabel": "Current portion of long-term debt", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value of long-term fixed interest rate debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://bruker.com/role/DebtComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtComponentsDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Letters of Credit and Guarantees" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r42", "r100", "r188", "r434", "r476", "r496" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest in consolidated subsidiaries" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r260", "r376", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "terseLabel": "Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r91", "r92", "r95" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r59", "r62", "r67", "r95", "r100", "r110", "r115", "r116", "r117", "r118", "r121", "r122", "r130", "r159", "r165", "r169", "r172", "r175", "r188", "r434", "r483", "r500" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to Bruker Corporation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r62", "r121", "r122", "r381", "r387" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "verboseLabel": "Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r115", "r116", "r117", "r118", "r126", "r127", "r131", "r134", "r159", "r165", "r169", "r172", "r175" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income attributable to Bruker Corporation, as reported" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r108", "r109", "r112", "r113", "r123", "r124", "r125", "r193", "r194", "r289", "r290", "r291", "r292", "r325", "r344", "r345", "r346", "r466", "r467", "r468", "r518", "r519", "r520", "r521", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable": { "auth_ref": [ "r73" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 15.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) attributable to other nonredeemable noncontrolling equity holder.", "label": "Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Nonredeemable", "terseLabel": "Less: Comprehensive income (loss) attributable to noncontrolling interests", "verboseLabel": "Less: Comprehensive income (loss) attributable to noncontrolling interests" } } }, "localname": "NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r105", "r106", "r107", "r260", "r373" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests in Consolidated Subsidiaries" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest and other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk.", "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]", "terseLabel": "Not designated as hedging instruments" } } }, "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails", "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r159", "r165", "r169", "r172", "r175" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income (loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r164", "r165", "r166", "r167", "r169", "r175" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r57", "r65", "r437", "r439", "r444" ], "calculation": { "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r49", "r55", "r435", "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "verboseLabel": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtCurrencySwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r63", "r65", "r68", "r253", "r437", "r442", "r444", "r484", "r501" ], "calculation": { "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Net current period other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r52", "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "terseLabel": "Pension liability adjustments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included.", "label": "Other Comprehensive Income (Loss) [Member]", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r400", "r418" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other charges, net" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInventoryDemo": { "auth_ref": [ "r43" ], "calculation": { "http://bruker.com/role/InventoriesDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of merchandise, goods, commodities, or supplies to which the entity holds the title and uses for the specific purpose of showing the benefits and features of the entity's products to existing or potential customers.", "label": "Other Inventory, Demo, Gross", "terseLabel": "Demonstration units" } } }, "localname": "OtherInventoryDemo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryInTransit": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.", "label": "Other Inventory, in Transit, Gross", "terseLabel": "Inventory-in-transit" } } }, "localname": "OtherInventoryInTransit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r34" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash expenses, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonrecurringExpense": { "auth_ref": [ "r78" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 11.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature.", "label": "Other Nonrecurring Expense", "terseLabel": "Other charges, net" } } }, "localname": "OtherNonrecurringExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonrecurringIncomeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature.", "label": "Other Nonrecurring (Income) Expense", "totalLabel": "Other charges, net" } } }, "localname": "OtherNonrecurringIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonrecurringIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonrecurring (Income) Expense [Abstract]", "verboseLabel": "Other Charges, Net" } } }, "localname": "OtherNonrecurringIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetTables" ], "xbrltype": "stringItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Shareholders' Equity Attributable to Bruker Corporation" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "negatedLabel": "Net proceeds from cross-currency swap agreements" } } }, "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r85" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r89", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r85" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Payment of dividends to common stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r80" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired", "verboseLabel": "Cash Consideration" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r88" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedLabel": "Cash payments to noncontrolling interest" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r310", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriceRiskDerivativeAssetsAtFairValue": { "auth_ref": [], "calculation": { "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of price risk derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets on the balance sheet.", "label": "Price Risk Derivative Assets, at Fair Value", "terseLabel": "Fixed price commodity contracts" } } }, "localname": "PriceRiskDerivativeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r84", "r103" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving lines of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherDebt": { "auth_ref": [ "r84" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from debt classified as other.", "label": "Proceeds from Other Debt", "terseLabel": "Proceeds from other debt" } } }, "localname": "ProceedsFromOtherDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "verboseLabel": "Proceeds from sales of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r524", "r525" ], "calculation": { "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonrecurringIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "verboseLabel": "Professional fees incurred in connection with investigation matters" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetComponentsOfOtherChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r59", "r62", "r90", "r100", "r110", "r121", "r122", "r159", "r165", "r169", "r172", "r175", "r188", "r375", "r380", "r382", "r387", "r388", "r434", "r488" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Consolidated net income", "totalLabel": "Consolidated net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r217", "r498" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r57", "r58", "r65", "r437", "r441", "r444" ], "calculation": { "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Realized loss on amounts reclassified from other comprehensive income (loss), net of tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r86" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "negatedLabel": "Repayment of other debt" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r330", "r536" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 10.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r10", "r96", "r97", "r471", "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "periodEndLabel": "Restricted cash period ending balance", "periodStartLabel": "Restricted cash period beginning balance" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Charges (Gain), Net", "terseLabel": "Other Charges, Net" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Other Charges, Net" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r94", "r221", "r226", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges", "verboseLabel": "Restructuring expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r222", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Changes in the restructuring reserves" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": { "auth_ref": [ "r222", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).", "label": "Restructuring Reserve, Translation and Other Adjustment", "terseLabel": "Other, non-cash adjustments and foreign currency effect" } } }, "localname": "RestructuringReserveTranslationAndOtherAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r106", "r107", "r111", "r120", "r122", "r192", "r322", "r323", "r324", "r342", "r343", "r514", "r516" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r150", "r151", "r164", "r170", "r171", "r177", "r178", "r181", "r277", "r278", "r461" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 6.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/RevenueDisaggregationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r276", "r281", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Amount of remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Remaining Performance Obligations" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Duration of expected recognition period for remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Remaining performance obligation expected to be recognized in the given period (as a percent)" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r57", "r442", "r444" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of the components of accumulated other comprehensive income (loss), net of tax" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareAntiDilutiveStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/AcquisitionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of comprehensive income (loss)" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r36", "r102", "r254", "r257", "r258", "r259", "r446", "r447", "r449", "r489" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Components of debt obligations" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of fair value and balance sheet location of derivative instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r390", "r393", "r394", "r398", "r399", "r407", "r409", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of notional amounts outstanding under foreign currency contracts" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of basic and diluted weighted average shares outstanding and net income per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r309", "r314", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "verboseLabel": "Schedule of the impact of stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial instruments measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r208", "r211" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes in the carrying amount of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r33", "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Summary of maximum commitments and net amounts available under the 2015 Credit Agreement and other lines of credit" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r408", "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Schedule of impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of components and fair value allocation of the consideration transferred in connection with acquisitions" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r224", "r225", "r229" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r224", "r225", "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of restructuring charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r222", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of changes in restructuring reserves" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r159", "r162", "r168", "r204" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r159", "r162", "r168", "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Schedule of revenue, operating income and total assets by reportable segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r310", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r39", "r98", "r142", "r143", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r146", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r175", "r181", "r507" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r146", "r148", "r149", "r159", "r163", "r169", "r173", "r174", "r175", "r176", "r177", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Business segment information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/BusinessSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r93" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r308", "r311" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r14", "r478", "r479", "r491" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r146", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r175", "r181", "r204", "r220", "r223", "r232", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/AcquisitionsConsiderationTransferredAndReportableSegmentDetails", "http://bruker.com/role/BusinessSegmentInformationDetails", "http://bruker.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r41", "r105", "r106", "r107", "r111", "r120", "r122", "r141", "r192", "r253", "r260", "r322", "r323", "r324", "r342", "r343", "r437", "r438", "r439", "r440", "r441", "r444", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r141", "r461" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r253", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "RSU vested (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r253", "r260", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Stock options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r253", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "RSU vested" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r41", "r253", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Amount approved for repurchase of common stock" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorization amount for repurchase of common stock" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r17", "r18", "r253", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Shares purchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r17", "r18", "r253", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Shares purchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r100", "r185", "r188", "r434" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders' equity attributable to Bruker Corporation" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r100", "r105", "r106", "r107", "r111", "r120", "r188", "r192", "r260", "r322", "r323", "r324", "r342", "r343", "r373", "r374", "r386", "r434", "r437", "r438", "r444", "r515", "r516" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r99", "r260", "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails", "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityExpenseDetails", "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r278", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r278", "r287" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]", "terseLabel": "Revenue recognized at a point in time" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]", "terseLabel": "Revenue recognized over time" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/RevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r40", "r261" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r40", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r18", "r253", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "verboseLabel": "Common stock repurchased during the period (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r40", "r261", "r262" ], "calculation": { "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 22,589,258 and 22,058,529 shares at March 31, 2021 and December 31, 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r253", "r260", "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Aggregate cost of common stock repurchased during the period" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ShareholdersEquityShareRepurchaseAndDividendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r110", "r111", "r112", "r114", "r189", "r190", "r191", "r192", "r195", "r196", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r340", "r341", "r342", "r343", "r463", "r464", "r465", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestAndShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/OtherChargesNetRestructuringPlansDetails", "http://bruker.com/role/OtherChargesNetRestructuringReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r331", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits, excluding penalties and interest" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties related to uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/ProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r134" ], "calculation": { "http://bruker.com/role/EarningsPerShareComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Stock options and restricted stock awards and units (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r128", "r134" ], "calculation": { "http://bruker.com/role/EarningsPerShareComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average number of common shares used in computing diluted net income per common share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding:", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r126", "r134" ], "calculation": { "http://bruker.com/role/EarningsPerShareComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding-basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://bruker.com/role/EarningsPerShareComputationDetails", "http://bruker.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r372": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e526-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r537": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r539": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r540": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r541": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r542": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 79 0001193125-21-155172-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-155172-xbrl.zip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